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Abstract 
 
 
Parkinson’s disease (PD), a neurodegenerative movement disorder characterized by resting 
tremors, bradykinesia, postural instability and rigidity, is due to a selective loss of dopaminergic 
neurons in the substantia nigra. Non-motoric symptoms include autonomic, cognitive and 
psychiatric problems. PD has been suggested to result from environmental factors, genetic 
factors or a combination of the two. Evidence has mounted over the last 13 years supporting the 
involvement of a significant genetic component. Mutations in the parkin, PINK1, DJ-1, 
ATP13A2, SNCA, and LRRK2 genes have been conclusively associated with PD.  
 
The aim of the present study was to establish the first study on the genetic etiology of PD in 
South African patients. Patients from the various South African ethnic groups with 
predominantly early-onset PD and/or a positive family history were recruited. Varying numbers 
of study participants (ranging from 88-205) were used for the different sections of this study 
depending on their availability at the time of the experiments and the specific clinical criteria 
applied. Mutation screening was conducted using High-resolution melt (HRM) analysis, DNA 
sequencing and multiplex ligation-dependent probe amplification (MLPA). 
 
HRM analysis and sequencing of the known PD genes identified the following mutations: parkin 
(T113fsX163), PINK1 (Y258X), and LRRK2 (G2019S and R1441C). Using haplotype analyses, 
the five South African LRRK2 G2019S-positive patients were found to share a common ancestor 
with other G2019S haplotype 1-associated families reported worldwide.  
 
Two commercially available MLPA kits, SALSA P051 and P052, were used to assess the study 
participants for exon dosage mutations. Exonic deletions and insertions in parkin were identified 
in five patients. In addition, a family with a whole-gene triplication mutation of SNCA was 
identified. This is the 4th family worldwide to have this specific mutation which leads to a severe 
phenotype with autonomic dysfunction and early-onset dementia. 
 
The CAESAR (CAndidatE Search And Rank) bioinformatic program was used to select novel 
candidate genes for PD. CAESAR produced a ranked list containing known PD causing genes as 
well as novel candidates. The MAPT and SNCAIP genes were selected from the list of ten 
highest scoring genes. HRM analysis identified novel sequence variants in both genes with 
unknown functional significance that warrants further study. 
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A novel 16bp deletion (g.-6_+10del) in the promoter region of DJ-1 was identified in one PD 
patient. The functional significance of this variant was investigated using a Dual-Luciferase 
Reporter assay. The variant was found to significantly reduce luciferase activity in two separate 
cell lines, HEK293 and BE(2)-M17 neuroblastoma cells, both with and without oxidative stress 
(p<0.0001), and we proposed that the 16bp sequence might be important in transcriptional 
regulation of DJ-1. In addition, the activity of three transcription factors (AhR, ARNT and HIF-
1) with binding sites within the deletion sequence may be influenced by the variant.  
 
In conclusion, mutation screening resulted in the identification of mutations in six patients in 
parkin, six patients in LRRK2, one patient in PINK1 and one patient in SNCA. In addition, a 
number of novel sequence variants were identified with unknown functional significance. 
Investigating the genetic basis of PD in the unique South African ethnic groups has shown that 
the known PD associated genes play minor roles in causing the disease in this population which 
indicates the possible involvement of other as yet unidentified PD genes. Innovative 
bioinformatic and wet bench experimental strategies are therefore urgently needed to identify 
new candidate genes for PD.  
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Opsomming 
 
 
Parkinson se siekte (PS), ‘n neurodegeneratiewe bewegings-siekte, gekarakteriseer deur rustende 
spiersametrekkings, bradykinesia, posturale onstabiliteit en rigiditeit, onstaan as gevolg van 
geselekteerde verlies van dopaminergiese neurone in die substantia nigra. Nie-motoriese 
simptome sluit in outonome, kognitiewe en psigiatriese afwykings. Dit is voorgestel dat PS 
ontwikkel as gevolg van omgewings- en genetiese faktore of ‘n kombinasie van die twee. Daar 
was ‘n toename in bewyse vir die verantwoordelikheid van die genetiese komponent oor die 
afgelope 13 jaar. Mutasies in die parkin, PINK1, DJ-1, ATP13A2, SNCA, en LRRK2 gene word 
met PS geassosieer.  
 
Die doel van hierdie studie was om vir die eerste keer die genetiese etiologie van PS in Suid- 
Afrikaanse pasiënte te ondersoek. Pasiënte van die verskillende Suid-Afrikaanse etniese groepe, 
met hoofsaaklik vroeë-aanvang PS en/of ‘n positiewe familie-geskiedenis, was gebruik. 
Wisselende getalle van studie-deelnemers (van 88-205) was gebruik vir die verskillende dele van 
die studie, afhangende van hul beskikbaarheid op die tyd van die eksperimente en die spesifieke 
kliniese kriteria wat van toepassing was. Mutasie-analiese was uitgevoer deur middel van Hoë-
resolusie smelting (HRS)-analiese, DNS volgorde-bepaling en multipleks ligasie-afhanklike 
‘probe’ amplifikasie (MLPA).     
 
HRS-analiese en DNS volgorde-bepaling van die bekende PS gene het die volgende mutasies 
deïdentifiseer: parkin (T113fsX163), PINK1 (Y258X), en LRRK2 (G2019S en R1441C). 
Haplotiepe-analiese het gevind dat vyf Suid-Afrikaanse LRRK2 G2019S patiente ‘n 
gemeenskaplike voorvader deel met ander wêreldwyd gerapporteerde LRRK2 haplotiepe 1-
geassosieerde families.  
 
Twee kommersieel beskikbare MLPA ‘kits’, SALSA P051 en P052, was gebruik om die 
deelnemers te toets vir exon-dosis mutaties. Exon-delesies en invoegings in parkin was gevind in 
vyf patiente. ‘n Familie met ‘n volle geen triplikasie van SNCA was gevind. Dit is die 4de familie 
wêreldwyd wat die spesifieke mutasie het en dit lei tot ‘n erge fenotiepe met outonomiese 
afwykings en vroeë-aanvang dementia.  
 
Die ‘CAESAR (CAndidatE Search And Rank)’ bioinformatiese program was gebruik om nuwe 
kandidaat PS gene te selekteer. Die program het ‘n lys kandidaat gene, wat beide bekende 
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geassosieerde en nuwe bevat, opgelewer. Die MAPT en SNCAIP gene was gekies uit tien gene 
met die hoogste tellings. HRS analiese het nuwe DNS volgorde variante in beide gene gevind. 
Die funksies van die variante is tans onbekend en moet verder ondersoek word. 
 
‘n Onbekende 16bp delesie (g.-6_+10del) in die promotor area van DJ-1 was gevind in een PS 
patient. ‘n Dubbel-lusiferase rapporteerder eksperiment was uitgevoer om die funksie van die 
variant te ondersoek. Die variant het die lusiferase-aktiwiteit aansienlik verlaag in twee 
afsonderlike sel lyne, HEK293 en BE(2)-M17 neuroblastoma selle, met en sonder oksidatiewe 
spanning (p<0.0001). Dit was voorgestel dat die 16bp volgorde dalk belangrik kan wees vir 
transkripsionele regulasie van DJ-1. Die variant mag dalk ook die aktiwiteit van drie transkripsie 
faktore (AhR, ARNT and HIF-1) met bindings plekke in die delesie- volgorde, beïnvloed. 
 
Ter afsluiting, mutasie analiese het gelei tot die identifikasie van mutasies in ses patiente in 
parkin, ses patiente in LRRK2, een patient in PINK1 en een patient in SNCA. ‘n Aantal nuwe 
variante was gevind met ombekende funksies. Ondersoek van die genetiese basis van PS in die 
uniek Suid-Afrikaanse etniese groepe het gevind dat die bekende PS gene nie ‘n groot rol speel 
in die ontwikkeling van die siekte in die populasie nie. Dit is moontlik dat ander onbekende PS 
gene hier verantwoordelik is vir die siekte. Dit is dus belangrik om innoverende bioinformatiese 
en eksperimentele strategieë toe te pas om nuwe kandidaat-gene, vir PS, te identifiseer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
  
Table of Contents 
 
Page  
                  
Acknowledgments          viii                         
List of Abbreviations          ix                   
List of Figures                      xi                            
List of Tables            xii                           
Chapter 1: Introduction                                                                        1                             
 
Chapter 2: Molecular analysis of the parkin gene in South African patients   51                          
                  diagnosed with Parkinson’s disease       
 
Chapter 3: Analysis of exon dosage using MLPA in South African Parkinson's   64 
                  disease patients  
 
Chapter 4: LRRK2 G2019S mutation: frequency and haplotype data in    80 
                  South African Parkinson's disease patients 
 
Chapter 5: Assessing the prevalence of PINK1 genetic variants in South African  93 
                  patients diagnosed with early- and late-onset Parkinson's disease 
 
Chapter 6: Identification of Parkinson’s disease candidate genes using CAESAR  106  
                  and screening in South African Parkinson’s disease patients  
 
Chapter 7: Additional unpublished results       124 
 
Chapter 8: Identification of a novel functional deletion variant     128 
                  in the 5’-UTR of the DJ-1 gene 
 
Chapter 9: Conclusion         147 
 
Appendix           168 
            
            
      
viii 
 
  
Acknowledgments 
 
I would like to express my sincere gratitude to the following people and organizations that 
contributed to the completion of my PhD degree: 
 
• Dr. Soraya Bardien and Prof. Jonathan Carr, for your guidance and support during this 
project. Thank you for everything that I have learned from you and for giving me the 
opportunity to conduct this study with your guidance;  
 
• My parents, for all your support, encouragement and prayers throughout my university 
studies. Thank you for being there for me. It would not have been possible without you;  
 
• My family and friends, for your encouragement throughout this project; 
 
• Ekow Oppon, for your love and support through everything. You inspired me and your 
encouragement helped me to keep on going. Thank you. Medaase, Mido Wu; 
 
• Coworkers in the laboratory, for all your support and practical help throughout this 
project. Thank you for everything my friends; 
 
• Dr Suzanne Lesage and Prof Alexis Brice for accommodating me in your laboratory in 
Paris, France. Celine Dupuits, for teaching me and making me feel welcome. Merci 
Beaucoup; 
 
• The Oppenheimer Memorial Trust, Movement Disorder Society and Dean’s Travel Fund 
(Stellenbosch Univeristy) for travel grants to attend the Movement Disorder congress and 
to spend two months on a research visit to Paris, France;  
 
• Prof Paul van Helden, for providing financial support; 
 
 
 
 “Ask the Lord to bless your plans and you will be successful in carrying them out”     
Prov. 16:3 
ix 
 
  
List of Abbreviations 
 
AAO:   Age at onset 
AD:   Alzheimer’s disease  
ad:   Autosomal dominant 
Ampr:   Ampicillin resistance   
ALP:   Autophagy-lysosome pathway 
ALS:   Amyotrophic lateral sclerosis 
ANK:   Ankyrin repeat 
ar:   Autosomal recessive 
ARM:   Armadillo  
ATP13A2: ATPase type 13A2 
BCL2L1:  Bcl-2-like protein 1 
C106:   Cysteine residue 106 
CAESAR:  Candidate search and rank program 
CBS:   Corticobasal syndrome 
CDCrel-1:  Cell division control-related protein-1 
COMT:  Catechol-O-methyl transferase 
COR:   C-terminal of Roc 
DAT:   Dopamine transporter 
DBS:   Deep brain stimulation 
DJ-1:   Oncogene DJ-1 
dsDNA:  Double stranded DNA 
EO:   Early-onset 
ETC:   Electron transport chain 
FBXO7:  F-box only protein 7 
FTDP:  Frontotemporal dementia with parkinsonism 
GBA:   β glucocerebrosidase 
GD:   Gaucher’s disease 
GIGYF2:  GRB10 interacting GYF protein 2 
GWAS:  Genome-wide association studies 
HD:   Huntington’s disease 
HEK293:  Human embryonic kidney 
HRM:   High-resolution melt 
HTRA2:  HtrA serine peptidase 2 
IBR:   In-between-RING 
KRS:   Kufor-Rakeb syndrome 
LBs:   Lewy bodies 
L-DOPA:  Levodopa 
LO:   Late-onset 
LRR:   Leucine rich repeat 
LRRK2:  Leucine-rich repeat kinase 2 
MAO-B:  Monoamine-oxidase-B 
MAPKKK:  Mitogen-activated protein kinase kinase kinase 
MAPT:  Microtubule-associated protein tau 
MCS:   Multiple cloning site 
MLPA:  Multiplex ligation-dependent probe amplification 
MPDP+:  1-methyl-4-phenyl-2,3-dihydropyridinium  
MPP+:   1-methyl-4-phenyl-pyridinium  
MPTP:  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MTS:   Mitochondrial-targeting domain 
x 
 
  
NAC:   Non-amyloid-β component 
O:   Ocular signs 
OMIM:  Online mendelian inheritance in man 
PARK2:  Parkin 
PCR:   Polymerase chain reaction 
PD:   Parkinson’s disease  
PET:  Positron Emission Tomography 
PGC-1α:  Peroxisome proliferator-activated receptor-gamma coactivator -1, alpha 
PINK1:  PTEN-induced kinase 1 
PLA2G6:  Phospholipase A2, group VI 
PolyPhen:  Polymorphism Phenotyping 
PSP:   Progressive supranuclear palsy 
RanBP2:  RAN binding protein 2 
REM:   Rapid eye movement 
RING:   Really Interesting New Gene 
RNAi:   RNA interference 
Roc:   Ras of complex proteins 
ROS:   Reactive oxygen species 
RPH:   Relative peak height 
SANBI:  South African National Bioinformatics Institute 
SCA2:  Spinocerebellar ataxia type2 
SIFT:   Sorting Intolerant From Tolerant 
SNCA:  α-synuclein  
SNCAIP:  Synphilin-1 
SNCB:  β-synuclein 
SNpc:   Substantia nigra pars compacta 
SNPeffect:  Single Nucleotide Polymorphism effect 
SNPs3D:  Single Nucleotide Polymorphisms 3D 
SSCP:   Single strand conformation polymorphism 
ssDNA:  Single stranded DNA 
TH:   Tyrosine hydroxylase 
TM:   Transmembrane 
Ubl:   Ubiquitin-like 
UCHL1:  Ubiquitin carboxyl-terminal esterase L1 
UPS:   Ubiquitin proteasome system 
UTR:   Untranslated region 
XRE:   Xenobiotic Response Elements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
  
List of Figures 
 
 
Chapter 1                                                                                                                   Page 
Figure 1.1 Photograph of Dr. James Parkinson (1755-1825)     2 
Figure 1.2 Illustration of the location of the substantia nigra in the brain     5 
Figure 1.3 Microscopic images of the pathology of the substantia nigra     6 
Figure 1.4 The nigrostriatal system in Parkinson’s disease      6 
Figure 1.5 Representation of the parkin protein and expression profile    11 
Figure 1.6 Representation of the PINK1 protein and expression profile    13 
Figure 1.7 Representation of the DJ-1 protein and expression profile    14 
Figure 1.8 Illustration of the ATP13A2 transmembrane protein and expression profile  16 
Figure 1.9 Representation of the α-synuclein protein and expression profile   18 
Figure 1.10 Representation of the LRRK2 protein and expression profile    19 
Figure 1.11 Illustration of the SNCAIP gene and expression profile     21 
Figure 1.12 Representation of the MAPT protein and expression profile    22 
Figure 1.13 Illustration of MPTP metabolism        24 
Figure 1.14 Molecular pathways involved in PD pathogenesis      26 
Figure 1.15 Numbers of PD patients from each of the different South African    33 
                    sub-population groups 
Figure 1.16 Flowchart showing the outline of the present study      35 
Figure 1.17 Illustration of the High-resolution melt technique      36 
Figure 1.18 Illustration of the MLPA method        37 
Figure 1.19 Restriction map and multiple cloning site (MCS)      38 
                    of the pGL4.10[luc2] vector 
 
Chapter 2 
Figure 1 High-resolution melt analysis         59 
 
Chapter 3 
Fig. 1a MLPA analysis results of an individual with a heterozygous duplication of   71 
            parkin exon 2 (ratioԜ=Ԝ1.5) and heterozygous deletion of parkin exon 9 (ratioԜ=Ԝ0.6)  
Fig. 1b MLPA results of an individual with a whole-gene triplication of α-synuclein   71 
Fig. 1c MLPA results of an individual with an Y258X point mutation in PINK1 exon 3   71 
            which prevented binding of the probe for this exon (ratioԜ=Ԝ0.0) 
Fig. 2 Chromatogram illustrating the Y258X point mutation in PINK1 exon 3 that was shown  73 
          to co-segregate with PD in an Indian family 
Fig. 3 Sequence alignment (using ClustalW) of PINK1 amino acid sequences of human   73 
          (NP_115785.1), chimp (XP_001164912.1), mouse (NP_081156.2),  
          and rat (XP_216565.2) 
 
Chapter 4 
Fig. 1 High-resolution melt (HRM) analysis of the G2019S mutation illustrating that the  85 
           mutation can be distinguished from the wild-type allele 
Fig. 2 Pedigrees of the South African families (family A, B, C and D) with the   86 
          G2019S mutation 
 
Chapter 5 
Fig. 1 Difference graphs produced by the high-resolution melt technique illustrating   100 
          that sequence variants can be distinguished from wild-type alleles 
Fig. 2 Sequence alignment (using ClustalW) of PINK1 amino acid sequences of human    100 
          (NP_115785.1), chimp (ENSPTRP00000000500), mouse (NP_081156.2), 
          rat (XP_216565.2), cow (NP_001093171.1), chicken (XP_423139.2), and zebrafish   
          (NP_001008628.1) 
 
xii 
 
  
Chapter 6 
Figure 1 Comparative protein alignments (using ClustalW) of selected regions of MAPT   115 
               and SNCAIP across different species to determine whether they are  
               evolutionarily-conserved 
 
Chapter 7 
Figure 7.1 Pedigree of the patient with the homozygous G2019S mutation   125
   
Chapter 8 
Figure 1 Nucleotide sequence of the promoter region of the human DJ-1 gene     137 
               (GenBank Accession number AB045294) showing the positions of significant sites 
Figure 2 The DJ-1 16 bp deletion variant exhibited significantly reduced transcription levels  138 
               compared to the wild-type (P < 0.0001) in two different cell lines 
Figure 3 H2O2 dose-dependent up-regulation of DJ-1 promoter activity     140 
Figure 4 Comparative multi-species analysis using rVISTA of the DJ-1 promoter region   141 
               of approximately 2000 bp + 5'-UTR. 
 
Chapter 9 
Figure 9.1 Number of individuals from the different South African sub-population  149
      groups in which pathogenic mutations were found 
 
List of Tables 
 
Chapter 1 
Table 1.1 Genes involved in Parkinson’s disease       9 
Table 1.2 Genetic categorization of 250 South African PD patients from which    31 
                DNA has been archived  
 
Chapter 2 
Table 1 Mutations identified in the parkin gene in the South African group of PD patients  57 
Table 2 Parkin polymorphisms identified in the present study in both PD patients and controls 58 
 
Chapter 3 
Table 1 Mutations identified using MLPA kits P051 and P052      70 
 
Chapter 5 
Table 1A Known and putative mutations identified in PINK1 in South African PD patients  99 
Table 1B Polymorphisms identified in PINK1 in South African PD patients    99 
 
Chapter 6 
Table 1 Missense sequence variants identified in MAPT and SNCAIP in South African   113 
             PD patients 
Table 2 Synonymous and intronic sequence variants identified in MAPT and SNCAIP in   114 
              South African PD patients 
Supplementary Table 1. Ranked list of PD candidate genes selected by the CAESAR program 123 
 
Chapter 7 
Table 7.1 Pathogenic mutations and novel sequence variants identified     126
     in LRRK2 in South African PD patients 
 
Chapter 9 
Table 9.1 Known and putative mutations identified in the present study     149 
 
1 
 
Chapter 1  
Introduction   
Page 
1.1 Introduction           2                               
                                                 
1.2 The epidemiology of Parkinson’s disease        3                                
 1.2.1 Age at onset of PD         3                                
 1.2.2 Gender variance          3                                
 1.2.3 Geographical and ethnic variability in PD prevalence              4                                
 
1.3 Pathological characteristics         5
                
1.4 Clinical characteristics              7                                
 1.4.1 Motor symptoms           7                                
 1.4.2 Non-motor symptoms              8                                
 
1.5 Genetic involvement in PD pathogenesis                         8                                
1.5.1 Genes involved in autosomal recessive PD               10                              
           1.5.1.1  Parkin                                              10                             
1.5.1.2  PINK1                        12                             
1.5.1.3  DJ-1                            13                              
1.5.1.4  ATP13A2                                                    14                              
1.5.2 Genes involved in autosomal dominant PD        16                              
          1.5.2.1  SNCA          16 
 1.5.2.2  LRRK2          18 
 1.5.3 Other genes associated with PD        20 
                      1.5.3.1  SNCAIP         20 
  1.5.3.2  MAPT          21 
1.5.4 PD susceptibility alleles        22 
 
1.6 Molecular pathways implicated in PD pathogenesis      23 
1.6.1 Mitochondrial dysfunction and oxidative stress      23 
1.6.2 The ubiquitin proteasome system and the autophagy-lysosomal pathway   25 
 
1.7 Current therapeutic approaches for PD        28 
1.7.1 Levodopa (L-DOPA)         28 
1.7.2 Dopamine agonists         28 
1.7.3 MAO-B inhibitors         29 
1.7.4 COMT inhibitors          29 
1.7.5 Deep brain stimulation (DBS)       29 
1.7.6 Experimental therapeutic approaches      30
        
1.8 PD molecular research in South Africa         31 
1.8.1 The present study          32 
1.8.2 The experimental approaches used       34 
1.8.3 Outline of the dissertation         39 
 
1.9 Reference list           40 
 
 
 
 
 
2 
 
1.1 Introduction  
 
Parkinson’s disease (PD) (OMIM#168600) is a debilitating neurodegenerative disorder, which is 
currently without cure, and significantly impairs the sufferer’s motor skills. Neuropsychiatric 
disturbances, such as cognition, mood and behavior problems, are also associated with PD in 
addition to the abnormality of movement. PD is the second most common neurodegenerative 
disorder after Alzheimer’s disease (AD), and is characterized by the progressive and selective 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc).  
 
PD was first described in 1817 by the English physician Dr. James Parkinson (figure 1.1) as 
Paralysis Agitans in his essay entitled “An essay on the shaking palsy”. About 60 years after the 
publication of the essay, the French neurologist Dr. Jean Martin Charcot was the first to truly 
recognize the importance of Parkinson’s work and decided to name the disease after the English 
physician.   
                 
Figure 1.1 Photograph of Dr. James Parkinson (1755-1825) 
   
 
The molecular pathways leading to onset of PD are unclear, but it is generally accepted that it 
may result from environmental factors (including exposure to neurotoxins), genetic factors 
(mutations in specific PD linked genes) or a combination of the two. The pathways involved in 
PD pathogenesis are proposed to include mitochondrial dysfunction, oxidative damage, 
abnormal protein accumulation and protein phosphorylation, all of which potentially affect 
dopaminergic neuronal function and survival (Thomas & Beal 2007; Cookson & Bandmann 
2010). The discovery of genes involved in familial forms of PD has strengthened the role of 
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genetic factors in development of the disease. Discovery of these genes has made it possible to 
investigate the pathological mechanisms that lead to disease development. In addition, they have 
identified possible targets for the development of neuroprotective therapies.  
 
1.2 The epidemiology of Parkinson’s disease 
 
1.2.1 Age at onset of PD 
 
It has been found that increasing age is one of the strongest risk factors for developing PD 
(Marion 2001; Siderowf 2001). Since PD affects mainly individuals of older age, it has been 
shown to be more common in developed countries where life expectancy is greater. PD has been 
found to affect 1-2% of the population over the age of 65 years and increases to 5% in 
individuals 85 years and older (de Rijk et al. 2000; Fahn 2003). However, the age at onset of the 
disorder is widely variable and ranges from juvenile to very late in life. Individuals with an age 
at onset (AAO) before 20 years are considered to have juvenile-onset PD. Early-onset PD has 
been variably defined across studies as age at onset <40-50 years (Lucking & Brice 2000; 
Periquet et al. 2003; Mata et al. 2004) and individuals developing PD after 50 years of age are 
referred to as late-onset PD (Pankratz & Foroud 2007). 
 
1.2.2 Gender variance  
 
PD is more prevalent among men (19.0 per 100 000) than among women (9.9 per 100 000) (Van 
Den Eeden et al. 2003) and epidemiological and clinical data suggest that estrogen has 
neuroprotective properties against PD in women (Dluzen & McDermott 2000; Shulman 2007; 
Gillies & McArthur 2010). The potential mechanisms by which estrogen may act as a 
neuroprotectant include antioxidative functions, inhibition of the monoamine oxidase enzyme, 
activation of neurotrophins, and by increasing the blood flow to facilitate the clearance of 
potential neurotoxins from the brain (Dluzen & McDermott 2000). Furthermore, women are 
exposed to different environmental and occupational risk factors, which might influence their 
susceptibility to develop PD. There might also be gender specific genetic influences leading to 
fewer women being diagnosed with PD.   
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1.2.3 Geographical and ethnic variability in PD prevalence  
 
PD occurs worldwide, but fewer cases are reported in Africa than in Europe or North America 
(Okubadejo et al. 2006). This could be due to genetic and environmental diversity, and different 
population strata. The prevalence of PD in Africa is lowest in individuals from western (Ghana, 
Liberia, Nigeria) and eastern (Ethiopia, Kenya, Somalia, Tanzania, Uganda) African countries 
(Okubadejo et al. 2006). In these countries less than 4% of the population are 60 years of age or 
older and the life expectancy is usually less than 57 years (Okubadejo et al. 2006). However, 
Africa is experiencing a demographic transition which will result in the population becoming 
older by the year 2015. Diseases mostly affecting the elderly, such as PD, could therefore 
become more common in these countries (Heligman et al., 2000).  
 
The estimated prevalence rate of PD varies globally from 7 per 100 000 to 657 per 100 000 
individuals per year (Tekle-Haimanot et al. 1990; Zhang & Roman 1993; Melcon et al. 1997). 
The prevalence rate for Africa ranges from 7 to 43 per 100 000 individuals per year (Ashok et al. 
1986; Tekle-Haimanot et al. 1990) (Attia et al., 1993). The prevalence rate for Europe has been 
found to be between 100 and 200 per 100 000 individuals (von Campenhausen S. et al. 2005), 
which is similar to prevalence rates reported for North Africa (Ashok et al. 1986) (Attia et al., 
1993). The prevalence rate for China has been reported to be about 1700 per 1000 000 
individuals, although this figure is for AAO ≥ 65 years, so is not really comparable (Zhang et al. 
2005b).   
 
Given the above, it is not surprising that the incidence of PD varies between different ethnic 
groups. The highest incidence has been reported to be among Hispanics (16.6 per 100 000), 
followed by non-Hispanic Whites (13.6 per 100 000), Asians (11.3 per 100 000), and Blacks 
(10.2 per 100 000) (Van Den Eeden et al. 2003). PD might be less common in Black and Asian 
people than in those of European origin, however, incidence reports have been conflicting and 
may be due to differences in case-ascertainment methods between studies (Alves et al. 2008).  
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1.3 Pathological characteristics  
 
PD is characterized pathologically by progressive and profound loss of neuromelanin containing 
dopaminergic neurons in the SNpc situated in the midbrain (figure 1.2). The dopaminergic 
neurons have high levels of melanin and therefore give the substantia nigra (Latin for ‘black 
substance’) a unique appearance (figure 1.3 a and b). Widespread neurodegeneration in the 
central nervous system also occurs, with the SNpc being involved after involvement of more 
caudal regions of the brainstem and the olfactory bulb (Lang & Lozano 1998). Symptoms of PD 
appear when about 70-80% of dopaminergic neurons have been lost. The loss of these neurons 
leads to decreases in the levels of the neurotransmitter dopamine at the nerve terminals in the 
striatum and causes dysregulation of the motor circuits (nigrostriatal system) that project 
throughout the basal gangli (figure 1.4) (Gibb & Lees 1991; Lang & Lozano 1998). The 
consequences of the cell loss are impaired coordination of movement as well as autonomic, 
cognitive and psychiatric problems.  
 
Another pathological characteristic is intra-cytoplasmic proteinaceous inclusions known as Lewy 
bodies (LBs) that occur in the surviving neurons of the SNpc and other brain regions (figure 1.3 
c). The LBs are enriched in filamentous α-synuclein as well as other proteins that are in most 
cases highly ubiquitinated. The presence of LBs is a requirement for the definitive diagnosis of 
PD. However, LBs  have been reported to be absent in a few cases with parkin or LRRK2-
associated disease that have undergone autopsy  (Hayashi et al. 2000; Zimprich et al. 2004) 
 
 
 
Figure 1.2 Illustration of the location of the substantia nigra in the brain. A transverse/horizontal 
section through the midbrain shows the position of the substantia nigra (taken from  
http://health.allrefer.com/health/parkinsons-disease-substantia-nigra-and-parkinsons-disease.html) 
 
 
 
Substantia nigra 
6 
 
                          
 
Figure 1.3 Microscopic images of the pathology of the substantia nigra. a) Normal (above) and 
abnormal (below) pigmentation of the neurons of the substantia nigra. Absence of pigmentation is 
indicative of dopaminergic cell death. b) Microscopic section of the substantia nigra showing normal 
(above) and abnormal (below) distribution of neuromelanin containing neurons. c) Microscopic image of 
the intra-cytoplasmic proteinaceous inclusions known as Lewy bodies (indicated by an arrow) (adapted 
from (Shulman 2007).  
 
 
 
 
Figure 1.4 The nigrostriatal system in Parkinson’s disease. a) Normal pathway showing dopaminergic 
nerve fibers (thick red line) extending from the substantia nigra (SNpc) to the striatum (i.e. putamen and 
caudate nucleus). Arrows indicate the nerve cell bodies in the SNpc. b) Abnormal pathway showing fewer 
nerve fibers extending from the SNpc to the putamen (dashed line) than to the caudate nucleus (thin red 
line). Arrows indicate the loss of cell bodies and depigmentation in the SNpc (taken from (Dauer & 
Przedborski 2003).  
 
 
a) b) c) 
b) Parkinson’s disease  a) Normal  
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1.4 Clinical characteristics  
 
1.4.1 Motor symptoms  
 
PD patients develop severe motor disabilities about 4-6 years after being diagnosed with the 
disease. The four most common motor symptoms include resting tremor, rigidity, bradykinesia 
and postural instability.  
 
Resting tremor 
Resting tremor is in most cases the first neurological sign of PD, and is the one that motivates 
patients to visit a physician for a diagnosis. Tremors in PD patients do not impair daily activities 
of living to a large extent, since they predominantly occur when the individual is at rest and 
decreases during voluntary movement. Tremor normally occurs in the hand or foot on one side 
of the body and will involve the other side as the disease progresses (Siderowf 2001).  
 
Rigidity 
Rigidity (i.e. stiffness or inflexibility) is described as increased resistance to passive movements 
of a patient’s limbs. Rigidity may cause pain and cramping and decreases the range of motion of 
the patient (Siderowf 2001). 
 
Bradykinesia 
Bradykinesia (brady-, ‘slow’, kinisi, ‘motion’) is characterized by slowness of movement. 
Bradykinesia, hypokinesia (reduction in movement amplitude) and akinesia (absence of normal 
unconscious movement) can result in paucity of normal facial expression, decreased volume of 
the voice, drooling, decreased size and speed of handwriting, and decreased stride length during 
walking (Dauer & Przedborski 2003). 
 
Postural instability 
Some patients lose normal postural reflexes that lead to falls which in some cases might be 
sufficiently severe to cause them to be confined to a wheelchair. A common symptom of PD is 
freezing, which is the inability to initiate a voluntary movement such as walking. 
 
The quality of life of the PD patient is significantly impaired by these symptoms due to the fact 
that it takes longer to perform everyday tasks such as eating and getting dressed.  Furthermore, 
several non-motor symptoms also occur and include constipation, olfactory dysfunction, 
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depression, anxiety, and Rapid Eye Movement (REM) sleep behavior disorder (Parkinson’s 
Disease Foundation; http://www.pdf.org/en/symptoms).  
 
1.4.2 Non-motor symptoms 
 
PD patients develop cognitive abnormalities in which they become passive or withdrawn. They 
often develop depression with dementia occurring more frequently in older patients. It has been 
reported that 20-30% of PD patients develop dementia with 65% having this abnormality by the 
age of 85 years (Siderowf 2001). Psychiatric disturbances have been observed in 30% of PD 
cases. Patients may also experience hallucinations which are usually visual with delusions, and 
may also suffer from agitation or aggression. Some individuals become paranoid towards 
partners or other family members (Naimark et al. 1996). Sensory symptoms such as numbness, 
aching, tingling and muscle soreness have been observed (Snider et al. 1976). Constipation often 
occurs and may worsen with medication. Urinary incontinence, sexual dysfunction, excessive 
sweating, and sleep disturbances have also been observed with daytime drowsiness and insomnia  
(Partinen 1997; Davie 2008).    
 
1.5 Genetic involvement in PD pathogenesis   
 
Environmental factors were initially thought to be the predominant cause of PD. Some of these 
factors include exposure to pesticides and herbicides (e.g. dieldrin, paraquat and rotenone), 
neurotoxins (e.g. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP), rural living and well-
water drinking, heavy metals (e.g. iron and manganese), and head trauma (Elbaz & Tranchant 
2007). In the last 13 years, there has been a substantial increase in the evidence for the 
involvement of a genetic component and mutations have been found in six different genes in 
cases of autosomal recessive (ar) and dominant (ad) PD (Lesage & Brice 2009). Recessive forms 
of PD arise from mutations in the parkin (PARK2), PTEN-induced kinase 1 (PINK1), oncogene 
DJ-1 (DJ-1) and ATPase type 13A2 (ATP13A2) genes. The dominant forms of PD arise from 
mutations in the α-synuclein (SNCA) and leucine-rich repeat kinase 2 (LRRK2) genes. A 
summary of the various PD genes is shown in Table 1.1. To date, most PD-causing mutations 
(>150) have been found in parkin (Parkinson’s disease Mutation Database, 
http://grenada.lumc.nl/LOVD2/TPI/home.php). 
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              Table 1.1 Genes involved in Parkinson’s disease  
Locus Gene Chromosome Form of PD Inheritance AAO (yrs) Mutations 
PD associated genes with conclusive evidence 
PARK1/  
PARK 4 SNCA 4q21 EOPD ad 20-85 
A30P, E46K, A53T, genomic 
duplications/triplications 
PARK2 Parkin 6q25.2-27 Juvenile and EOPD ar 16-72 Point mutations, exonic rearrangements 
PARK6 PINK1 1p35-36 EOPD ar 20-40 Point mutations, rare large deletions 
PARK7 DJ-1 1p36 EOPD ar 20-40  Point mutations and large deletions 
PARK8 LRRK2 12p11.2 LOPD ad 32-79 7 pathogenic mutations, including the common G2019S 
PARK9 ATP13A2 1p36 Juvenile ar Kufor-Rakeb syndrome and parkinsonism ar 11-16  Point mutations 
PD associated genes of unknown relevance/ inconclusive evidence 
PARK3 unknown 2p13 LOPD ad 60s Not identified 
PARK5 UCHL1 4p14 LOPD ad  55-58 One mutation in a single PD sibling pair 
PARK10 unknown 1p32 unclear ad 50-60 Not identified 
PARK11 GIGYF2 2q36-q37 LOPD ad 33-68 Seven missense variants 
PARK12 unknown Xq unclear unclear - Not identified 
PARK13 Omi/HTRA2 2p13 unclear unclear 49-77 Two missense variants 
PARK14 PLA2G6 22q13.1 
Juvenile ar levodopa-
responsive dystonia-
parkinsonism 
ar 18-26 Two missense variants 
PARK15 FBXO7 22q12-q13 EO ar parkinsonism-pyramidal syndrome ar 10-19 Three point mutations 
PARK16 unknown 1q32 unclear unclear - Not identified 
Not assigned SNCAIP 5q23.1-q23.3 LOPD unclear 63-69 R621C, various SNPs with association 
Not assigned  MAPT 17q21.1 FTDP, O, CBS ad 25-76 Haplotype H1, various SNPs with association 
Not assigned SCA2 12q24.1 EOPD ad 45-59 Low-range interrupted CAG expansions in SCA2 
Not assigned GBA 1q21 EOPD ar 40-50 Point mutations 
AAO: age at onset; ad: autosomal dominant; ar: autosomal recessive; ATP13A2: ATPase type 13A2; CBS: corticobasal syndrome; EOPD: early-onset PD; FBXO7: F-box only protein 7; FTDP: frontotemporal 
dementia with parkinsonism; GBA:β glucocerebrosidase; GD: Gaucher’s disease; GIGYF2: GRB10 interacting GYF protein 2; LOPD: late-onset PD; LRRK2: Leucine-rich repeat kinase 2; MAPT: 
microtubule-associated protein tau; O: ocular signs; HTRA2: HtrA serine peptidase 2; PD: Parkinson’s disease; PINK1:  PTEN-induced kinase 1; PLA2G6: phospholipase A2, group VI; SCA2: Spinocerebellar 
ataxia type2; SNCA: α-synuclein; SNCAIP: synphilin-1; UCHL1: ubiquitin carboxyl-terminal esterase L1 ( Adapted from (Lesage & Brice 2009) and (Wider et al. 2010a). 
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1.5.1 Genes involved in autosomal recessive PD  
1.5.1.1  Parkin  
 
Parkin (OMIM 600116; chromosome 6q25) comprises 12 exons and encodes a 465 amino acid 
protein. The protein contains an N-terminal ubiquitin-like (Ubl) domain, a central RING (Really 
Interesting New Gene) domain (R0) and a C-terminal RING domain consisting of two RING 
finger motifs (R1 and R2) separated by an In-between-RING (IBR) domain (figure 1.5). The 
Parkin gene was first associated with PD in 1998 when exonic deletion mutations were 
identified in Japanese families with autosomal recessive juvenile Parkinsonism (Kitada et al. 
1998). Since then, more than 150 different mutations have been identified including numerous 
point mutations and exonic rearrangements such as duplications and deletions (Periquet et al. 
2003; Sun et al. 2006; Shadrina et al. 2007). Mutations in this gene have been found to be a 
common cause of early-onset Parkinsonism. However, mutations have also been found in cases 
of late-onset PD (>50-60 years of age) (Foroud et al. 2003; Sun et al. 2006). The mutations are 
not restricted to any of the functional domains of parkin and occur throughout the entire gene. 
Approximately half of the reported mutations fall in the category of exonic deletions or 
duplications (Hedrich et al. 2004). Individuals with Parkin mutations are reported to have slower 
disease progression, symmetrical onset, and in some cases, early-onset dystonia and levodopa 
responsiveness (Lohmann et al. 2003).  
 
Single heterozygous Parkin mutations have been identified at higher frequencies than 
homozygous or compound heterozygous mutations. It has been proposed that heterozygous 
Parkin mutations could contribute to the development of PD by functioning as susceptibility 
factors. Heterozygous Parkin mutations have been shown to lead to later onset of PD (Foroud et 
al. 2003). Furthermore,  fluorine-18-labelled dopa Positron Emission Tomography (PET) studies 
have found that dysfunction of dopaminergic neurons also occurred in individuals heterozygous 
for Parkin mutations, however the dysfunction was less severe than in homozygous individuals 
(Hilker et al. 2001). A possible mechanism by which heterozygous mutations might cause PD is 
haploinsufficiency where expression of a reduced amount of wild-type protein is insufficient to 
maintain normal function. It has also been suggested that some heterozygous mutations are more 
pathogenic than others because of a more severe consequence on structure and function of the 
protein (Klein & Lohmann-Hedrich 2007).  
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Parkin functions as an E3-type, E2 enzyme-dependent ubiquitin ligase and plays a role in the 
ubiquitin proteasome system (UPS) by ubiquitination of target proteins for degradation (Shimura 
et al. 2000). The UPS is the predominant proteolytic system for degradation of cytosolic, 
secretory, and membrane proteins (Hershko & Ciechanover 1998). Abnormalities in the UPS 
have been linked to neurodegenerative disorders such as PD, AD, Huntington’s disease (HD), 
Prion diseases, familial Amyotrophic lateral sclerosis (ALS), and polyglutamine expansion 
disorders (Ciechanover & Brundin 2003). It has been observed that inactivation of parkin leads 
to reduction in UPS mediated degradation of target proteins, and that the accumulated proteins 
result in selective toxicity to dopaminergic neurons (Shimura et al. 2000; Yang et al. 2003; 
Sriram et al. 2005). Mutations in Parkin have been reported to cause alterations in the cellular 
localization, solubility, binding and ubiquitination properties of the parkin protein (Cookson et 
al. 2003; Gu et al. 2003; Sriram et al. 2005). Some mutations lead to compartmentalisation of 
parkin away from its normal cytoplasmic distribution as well as the site of enzymatic activity 
(Sriram et al. 2005).  
 
Furthermore, several putative substrates of parkin have been identified including Sept5/CDCrel-
1 (cell division control-related protein-1) (Zhang et al. 2000), synaptotagmin XI (Huynh et al. 
2003) and RanBP2 (RAN binding protein 2) (Um et al. 2006). The accumulation of one or 
several of these substrates is suggested to contribute to the selective death of dopaminergic 
neurons. 
 
 
 
Figure 1.5 Schematic representation of the parkin protein and expression profile. a) Functionally 
important sites of parkin which contains the following domains: ubiquitin-like domain (Ubl), RING 
finger domains (R0-R2) and an In-between-RING domain (IBR) (taken from (Cookson & Bandmann 
2010). b) Northern blot analysis of parkin in various human tissues showing ubiquitous expression (taken 
from (Kitada et al. 1998).  
a) 
b) 
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1.5.1.2  PINK1 
 
PINK1 (OMIM 605909; chromosome 1p35-37) has 8 exons and encodes a highly conserved 581 
amino acid protein that contains a mitochondrial-targeting domain (MTS), a putative 
transmembrane region (TM) and a conserved serine/threonine kinase domain (figure 1.6). The 
PINK1 protein, which is ubiquitously expressed in the human brain, has been shown to localize 
to the mitochondrion (Valente et al. 2004a; Gandhi et al. 2006).  Mutations were first identified 
in 2004 in families of Italian and Spanish origin (Valente et al. 2004a) and have been found to be 
the second most common cause after the parkin gene of autosomal recessive early-onset PD. The 
frequency of PINK1 mutations ranges from 1 to 7% in patients of different ethnicities (Rogaeva 
et al. 2004; Bonifati et al. 2005; Klein et al. 2005). Most PINK1 mutations are located in the 
kinase domain and functional studies have shown that these mutations result in reduction in the 
enzymatic activity of PINK1 (Beilina et al. 2005; Sim et al. 2006). Little is known about the 
function of PINK1, but it is suggested to play a neuroprotective role against mitochondrial 
dysfunction and proteasomal-induced apoptosis (Valente et al. 2004a; Petit et al. 2005). PD 
patients with PINK1 mutations have been reported to have atypical clinical features, such as 
psychiatric disturbances, dystonia at onset and sleep benefit (Valente et al. 2004b; Ephraty et al. 
2007).  
 
The involvement of PINK1 in PD points towards two important factors. Firstly, this finding 
produced the first evidence that a kinase signaling pathway might be important in the 
pathogenesis of dopaminergic nigral cell death. Secondly, PINK1 established a molecular link 
between the mitochondria and neurodegeneration in PD (Valente et al. 2004a; Abou-Sleiman et 
al. 2006). It has been shown that mitochondrial dysfunction plays an important role in the 
pathogenesis of PD (Onyango 2008) which will be discussed in Section 1.6.1. Interestingly, an 
interaction has been identified between parkin and PINK1, and it has been reported that they 
function together in the same pathway in maintaining mitochondrial integrity and function, with 
PINK1 functioning upstream of parkin (Park et al. 2006; Um et al. 2009).  
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Figure 1.6 Schematic representation of the PINK1 protein and expression profile. a) The protein 
contains a mitochondrial-targeting domain (MTS), putative transmembrane region (TM) and a 
serine/threonine kinase domain (taken from (Cookson & Bandmann 2010). b) Northern blot analysis of 
PINK1 in various human tissues (taken from (Unoki & Nakamura 2001). 
 
1.5.1.3  DJ-1 
 
DJ-1 (OMIM 602533; chromosome 1p38) consists of 7 exons and encodes a highly conserved 
protein of 189 amino acids that belongs to the DJ-1/Thi/PfpI protein super family (figure 1.7a) 
(Nagakubo et al. 1997; Huai et al. 2003; Kahle et al. 2009). It is ubiquitously expressed in a 
variety of mammalian tissues including the brain (figure 1.7b; (Nagakubo et al. 1997). This gene 
was initially reported to be involved in oncogenesis and male rat infertility; however, it was later 
shown that DJ-1 is associated with autosomal recessive early-onset PD, although such mutations 
are extremely rare (Nagakubo et al. 1997; Wagenfeld et al. 1998; Bonifati et al. 2003). 
Mutations include exon deletions, truncations, and homozygous and heterozygous point 
mutations, and have been shown to result predominantly in loss of function of the protein 
(Bonifati et al. 2003; Bonifati et al. 2004). Studies have shown that DJ-1 translocates to the 
mitochondria, where it is is proposed to play a role in protecting neurons from oxidative stress 
and protecting against mitochondrial damage (Canet-Aviles et al. 2004; Zhang et al. 2005a; Lev 
et al. 2008). Mitochondrial dysfunction leads to generation of reactive oxygen species (ROS), 
which causes damage to various cellular components.  
a) 
b) 
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Figure 1.7 Schematic representation of the DJ-1 protein and expression profile. a) DJ-1 has only one 
domain called the DJ-1/Pfp I domain. The protein contains a critical Cysteine residue (C106) that can be 
modified in the presence of reactive oxygen species (ROS) to form a sulfinic acid (taken from (Moore et 
al. 2005). b) Northern blot analysis of DJ-1 in various human tissues (taken from (Nagakubo et al. 1997).  
 
 
1.5.1.4  ATP13A2 
  
ATP13A2 (OMIM 610513; chromosome 1p36) comprises 29 exons and encodes a large protein 
of 1,180 amino acids that contains 10 transmembrane domains which are located in lysosomal 
membranes (figure 1.8a) (Ramirez et al. 2006). Two motifs, TGES and DKTGTLT, are also 
found within the protein. ATP13A2 belongs to the P-type superfamily of ATPases that is 
involved in the transport of inorganic cations and other substrates across cell membranes 
(Schultheis et al. 2004). This protein is ubiquitously expressed and is also expressed throughout 
the brain (figure 1.8b), with highest levels in the SNpc, and is reported to be up-regulated in 
patients with late-onset PD (Ramirez et al. 2006). The involvement of this gene in PD was first 
discovered in 2006 with the identification of mutations in Jordanian and Chilean families with 
Kufor-Rakeb syndrome (KRS), which is a form of recessively inherited atypical parkinsonism  
(Ramirez et al. 2006). KRS has more widespread neurodegeneration, including dementia, and is 
clinically distinct from PD. Affected members of the Jordanian family harbored a homozygous 
22 base pair duplication mutation (1632_1653dup22), which resulted in a frameshift and a 
a) 
b) 
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premature stop codon. Affected members of the Chilean family had a one base pair deletion in 
exon 26 (1019GfsX1021) that was inherited from the mother, and a splice site mutation 
(c.1305+5G>A) that was inherited from the father. The splice site mutation caused in-frame 
skipping of exon 13 which led to the removal of 111 nucleotides. These mutations were 
suggested to result in retention and proteasomal degradation of ATP13A2 in the endoplasmic 
reticulum as opposed to being inserted into the lysosomal membranes (Ramirez et al. 2006). 
Two additional mutations, F182L (Ning et al. 2008) and G504R (Di Fonzo et al. 2007), have 
also been reported. Interestingly, a genetic interaction has recently been reported in a study by 
Gitler and colleagues where the yeast homologue of human ATP13A2 was found to interact with 
α-synuclein in yeast and subsequently suppress α-synuclein toxicity (Gitler et al. 2009).  
 
The role played by ATP13A2 in PD is however still questionable. A study conducted by 
Vilarino-Guell and colleagues identified 37 novel variants of which none segregated with the 
disease within kindreds (Vilarino-Guell et al. 2009). Case-control association studies gave 
negative results and ATP13A2 mRNA expression was not increased in PD brains compared to 
controls (Vilarino-Guell et al. 2009). They concluded that genetic variability in ATP13A2 is 
unlikely to cause or influence the development of PD. 
 
 
 
 
a) 
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Figure 1.8 Illustration of the ATP13A2 transmembrane protein and expression profile. a) The 
protein contains 10 transmembrane domains (M1-10), a TGES motif and a DKTGTLT motif. The 
positions of frameshift mutations are indicated by red stars. The position of the in-frame deletion is shown 
by red shading. b)  Northern blot analysis of ATP13A2 in various human tissues (taken from (Ramirez et 
al. 2006).   
 
 
1.5.2 Genes involved in autosomal dominant PD  
1.5.2.1  SNCA  
 
α-Synuclein (SNCA) (OMIM 163890; chromosome 4q21) has 6 exons and encodes a 140 amino 
acid protein consisting of an N-terminal amphipathic region, a non-amyloid-B component 
(NAC) domain in the middle region, and an acidic C-terminal region (figure 1.9) (Jo et al. 2000). 
The protein is abundantly expressed throughout the brain with the highest levels reported in 
deeper layers of the cerebral neocortex, the hippocampus and the SNpc (Solano et al. 2000). α-
Synuclein is a presynaptic protein and has been proposed to function in synaptic vesicle 
recycling, storage and compartmentalization of neurotransmitters and associates with vesicles 
and membrane structures (Abeliovich et al. 2000; Yavich et al. 2004). Of great importance, the 
protein has been found to be a major component of Lewy bodies and Lewy neurites in PD as 
well as other α-synucleinopathies (Spillantini et al. 1997).   
 
The involvement of the α-synuclein gene in PD was first reported in 1997 with the identification 
of an A53T substitution mutation in a large kindred with autosomal dominant PD  
(Polymeropoulos et al. 1997). Another two rare point mutations have also been found and 
include A30P (Kruger et al. 1998) and E46K (Zarranz et al. 2004). A30P, E46K and A53T 
mutant proteins have been shown to display an increased propensity for self-aggregation and 
oligomerization into protofibrils in comparison to wild-type proteins (Conway et al. 1998). 
Whole-gene multiplications (duplications or triplications) have also been identified in the α-
synuclein gene and lead to over-expression of the protein. Duplication mutations of this gene 
give rise to a classical PD phenotype, whereas those affected with triplication mutations have 
b) 
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earlier onset, faster disease progression, marked dementia and frequent dysautonomia (Singleton 
et al. 2003; Chartier-Harlin et al. 2004; Ibanez et al. 2004; Ross et al. 2008a). Therefore, the 
higher the expression levels of α-synuclein, the more malignant the PD phenotype, which 
suggests that there is more widespread neurodegeneration in patients with higher levels of α-
synuclein expression. This form of mutation is rare and less than five families worldwide have 
been reported to have an α-synuclein triplication, whereas duplication mutations have been 
reported in at least twelve families. Both recombination and duplication mechanisms have been 
shown to lead to α-synuclein multiplication (Ross et al. 2008a).   
 
A susceptibility factor (REP1, D4S3481) for PD was identified in the promoter region of α-
synuclein. REP1 is a dinucleotide repeat sequence that promotes normal gene expression 
(Touchman et al. 2001). It was found that REP1 allele length variability is associated with an 
increased risk for PD (Maraganore et al. 2006). A 263bp allele was associated with an increased 
risk for PD, while a 259bp allele was associated with a reduced risk for PD. 
 
One of the mechanisms for the toxic effect of overexpression of wild-type or mutant α-synuclein 
has been proposed to be inhibition of the function of the proteasome in the UPS (Tanaka et al. 
2001). In studies using Drosophila, it was shown that high levels of α-synuclein lead to abnormal 
protein aggregation and neurotoxicity in dopaminergic neurons (Feany & Bender 2000). Studies 
in mice have shown that overexpression of the protein led to the development of PD related 
features with findings of  mislocalization and accumulation of insoluble α-synuclein in neurons 
in the neocortex, hippocampus and SNpc, as well as loss of dopaminergic terminals in the 
striatum, with associated  motor disturbances (Masliah et al. 2000; Giasson et al. 2002).  
 
 
   
 
a) 
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Figure 1.9 Schematic representation of the α-synuclein protein and expression profile. The protein 
contains an N-terminal amphipathic domain which contains six imperfect repeats (with a KTKEGV 
consensus motif), a non-amyloid-β component (NAC) domain, and an acidic C-terminal region. The 
positions of the three pathogenic missense mutations are indicated with arrows (taken from (Moore et al. 
2005). b) Northern blot analysis of α-synuclein in various human tissues. Lane 1: heart, Lane 2: brain, 
Lane 3: placenta, Lane 4: lung, Lane 5: liver, Lane 6: skeletal muscle, Lane 7: kidney, Lane 8: pancreas 
(taken from (Ueda et al. 1993).   
 
 
1.5.2.2  LRRK2 
 
LRRK2 (OMIM 609007; chromosome 12q12) comprises 51 exons and encodes a 2,527 amino 
acid multi-domain protein (also known as dardarin) belonging to the ROCO protein family 
(Zimprich et al. 2004; Paisan-Ruiz et al. 2004). The physiological role of LRRK2 is unknown 
but the presence of multiple functional domains suggests involvement in a wide variety of 
functions (Thomas & Beal 2007). These functional domains include: Roc (Ras of complex 
proteins), COR (C-terminal of Roc), MAPKKK (mitogen-activated protein kinase kinase kinase) 
and WD40 (figure 1.10). The protein is suggested to be involved in the regulation of signal 
transduction cascades because of the presence of the Roc and MAPKKK domains (Guo et al. 
2006).    
 
LRRK2 is reported to be involved in approximately 10% of autosomal dominant familial PD and 
3.6% of sporadic PD (Berg et al. 2005; Khan et al. 2005; Mata et al. 2005; Di Fonzo et al. 
2006a; Johnson et al. 2007; Nichols et al. 2007; Xiromerisiou et al. 2007; Paisan-Ruiz et al. 
2008). To date, more than 100 sequence variants have been identified in this gene of which 
seven (N1437H, R1441H, R1441C, R1441G, Y1699C, I2020T and G2019S) have been proven 
to be pathogenic. These mutations are located within the functional domains of the protein as 
well as in evolutionary conserved regions (Hedrich et al. 2006; Healy et al. 2008). The G2019S 
mutation, which occurs in the MAPKKK domain, is the most common mutation across diverse 
populations in both familial and sporadic PD and has been shown to increase the kinase activity 
of LRRK2 (West et al. 2005). The age-specific penetrance of the G2019S mutation has been 
b) 
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determined to be 28% at an age of 59 years, 51% at an age of 69 years, and 74% at an age of 79 
years (Healy et al. 2008).  
 
 
Three haplotypes (one major and two extremely rare haplotypes) have been identified that are 
present in carriers of G2019S. The first haplotype is most common and occurs in individuals of 
European, North and South African, and Ashkenazi Jewish origin (Lesage & Brice 2009). The 
second haplotype is rare and has been reported in five families of European origin (Zabetian et 
al. 2006a). The third haplotype which is also rare is most common in Japanese individuals but 
has also been reported in a Turkish family (Zabetian et al. 2006b; Pirkevi et al. 2009).  
 
 
 
 
 
Figure 1.10 Schematic representation of the LRRK2 protein and expression profile. a) The protein 
contains the following domains: ARM, ANK, LRR, Roc, COR, MAPKKK, and WD40. Numbers indicate 
the amino acid positions (taken from (Lesage & Brice 2009). b) Northern blot analysis of LRRK2 in 
various human tissues. Lane 1: heart, Lane 2: brain, Lane 3: placenta, Lane 4: lung, Lane 5: liver, Lane 6: 
skeletal muscle, Lane 7: kidney, Lane 8: pancreas. The black arrowhead indicate the position of LRRK2 
(taken from (Paisan-Ruiz et al. 2004).  
 
 
 
 
 
a) 
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1.5.3 Other genes associated with PD 
 
In addition to the genes mentioned in Sections 1.5.1 and 1.5.2 a number of other genes have been 
reported to be linked to PD, but for many their involvement with this disorder is currently 
equivocal (Lesage & Brice 2009; Satake et al. 2009). Two of these genes, SNCAIP and MAPT, 
will be discussed in more detail as they have been selected as PD candidate genes in Chapter 6 of 
this study.   
 
1.5.3.1  SNCAIP 
 
Synuclein alpha interacting protein (SNCAIP) (OMIM 603779; chromosome 5q23.1-q23.3) has 
11 exons and encodes a 919 amino acid protein (synphilin-1) that contains several protein-
protein interaction domains including ankyrin repeat domains, a coiled-coil domain, and an ATP 
and GTP binding domain (figure 1.11a) (Engelender et al. 1999; Engelender et al. 2000). The 
protein is ubiquitously expressed throughout the human body including the SNpc, with highest 
levels in neurons (figure 1.11b; (Engelender et al. 1999). The importance of SNCAIP in PD was 
highlighted when it was found that two PD-linked gene products, α-synuclein and parkin, 
interact with synphilin-1 (Engelender et al. 1999; Chung et al. 2001).  Furthermore, it was found 
that synphilin-1 is present in 80-90% of LBs in brain samples of PD patients (Wakabayashi et al. 
2000).  
 
Very few mutations in this gene have been found in PD patients and therefore it has not been 
conclusively linked to this disorder. Functional studies investigating the role played by an 
R621C variant that was identified in two sporadic German PD patients showed that the variant 
caused an increase in cell susceptibility to cellular stress (Marx et al. 2003). The R621C variant 
has been observed in control samples indicating that it is not likely to be pathogenic (Myhre et 
al. 2008). A study conducted by Li and colleagues found that synphilin-1 has protective effects 
in vitro (Li et al. 2010). They observed that overexpression of synphilin-1 protected cells against 
rotenone-induced cell death by means of reducing caspase-3 activation and poly (ADP-ribose) 
polymerase cleavage. Rotenone is an environmental toxin that inhibits mitochondrial complex I 
activity and it has been shown to induce dopaminergic neurodegeneration in rats and Drosophila 
(Betarbet et al. 2000; Coulom & Birman 2004). It is therefore suggested that synphilin-1 might 
play a neuroprotective role in PD pathogenesis.   
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Figure 1.11 Illustration of the SNCAIP gene and expression profile. a) The positions of the ankyrin 
repeats (shaded in yellow), a coiled-coil domain (shaded in green) and translated regions (shaded in blue) 
are indicated. Numbers indicated the 11 exons of SNCAIP (taken from (Myhre et al. 2008). b) Northern 
blot analysis of synphilin-1 in various human tissues. Lane 1: heart, Lane 2: brain, Lane 3: placenta, Lane 
4: lung, Lane 5: liver, Lane 6: skeletal muscle, Lane 7: kidney, Lane 8: pancreas (taken from (Engelender 
et al. 1999).  
 
 
1.5.3.2  MAPT 
 
Microtubule-associated protein tau (MAPT) (OMIM 157140; chromosome 17q21.1) has 15 
exons and encodes a 776 amino acid protein which is more frequently referred to as tau (figure 
1.12). It has been found to be highly expressed in neurons and it is important for organizing and 
maintaining cell structure by modulating microtubules (Weingarten et al. 1975; Hirokawa 1994). 
Interactions between tau and microtubules occur via microtubule-binding repeat domains located 
in the carboxyl-terminus (Lee et al. 1989). Aggregation of the tau protein results in development 
of tauopathies and has been observed in several neurodegenerative disorders, such as Pick 
disease, AD, and disorders with parkinsonian features, such as progressive supranuclear palsy 
(PSP), corticobasal degeneration, and frontotemporal dementia with parkinsonism (FTDP-17) 
(Rademakers et al. 2004). 
 
Genome-wide association studies (GWAS) recently revealed MAPT to be a risk factor for 
idiopathic PD (Simon-Sanchez et al. 2009; Edwards et al. 2010). Mutations in MAPT have been 
shown to be involved in autosomal-dominant FTDP-17 (Hutton et al. 1998). FTDP-17 patients 
with MAPT mutations present with personality, behavioral or cognitive changes that are 
associated with rapidly progressive Parkinsonism with poor response to levodopa treatment 
a) 
b) 
  1  2   3  4  5  6   7  8 
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(Wszolek et al. 1992). Mutations in MAPT account for ~5-10% of sporadic and 30% of familial 
frontotemporal dementia cases (Wider et al. 2010a). MAPT has a polymorphic inversion 
resulting in two main haplotypes: H1 and H2. H1 has been shown to be associated with an 
increased risk for PD (Farrer et al. 2002; Zabetian et al. 2007; Tobin et al. 2008; Wider et al. 
2010b); however the functional variant within this haplotype still needs to be identified. 
 
Overexpression of tau has negative effects on neurons that might play a role in the development 
of PD. In neuronal cell cultures increased tau inhibited intracellular transport along microtubules 
resulting in disruption of cell function and increased vulnerability of the cells to oxidative stress 
(Stamer et al. 2002). Accumulation of neurofilaments, microtubules and organelles were 
observed in transgenic mice that overexpressed tau, and were sufficient to cause damage to 
central nervous system neurons (Spittaels et al. 1999). In addition, it has been found that tau 
promotes the assembly of α-synuclein into fibrils that could further aggregate into LBs (Giasson 
et al. 2003).  
 
 
 
 
Figure 1.12 Schematic representation of the tau protein and expression profile. a) The four 
microtubule-binding repeat domains (M1-M4) are indicated. b) Northern blot analysis of tau showing 
expression in the brain only. Lane 1: brain, Lane 2: kidney, Lane 3: liver, Lane 4: spleen, Lane 5: 
stomach, Lane 6: thymus (taken from (Lewis et al. 1986). 
 
 
1.5.4 PD susceptibility factors 
 
Susceptibility factors are genetic variations that affect penetrance, age at onset, severity and 
progression of PD. A number of susceptibility factors have been shown to be associated with PD, 
and some of these will be briefly discussed. The REP1 variant which occurs in the promoter 
region of SNCA has been confirmed as a risk factor for PD and was discussed in section 1.5.2.1 
a) 
b) 
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(Maraganore et al. 2006). GWAS have identified association of variants in SNCA, LRRK2 and 
MAPT with increased risk for PD (Simon-Sanchez et al. 2009). GWAS also showed association 
of the MAPT H1 haplotype and increased risk for PD (Farrer et al. 2002; Zabetian et al. 2007; 
Tobin et al. 2008; Wider et al. 2010b). Individuals who carried both the rs356219 SNCA SNP 
and the MAPT H1 haplotype have been shown to have double the risk of developing PD (Goris 
et al. 2007). The G2385R and R1628P variants in LRRK2 have been found to confer 
susceptibility to PD but only in Asian populations (Di Fonzo et al. 2006b; Ross et al. 2008b). 
The β glucocerebrosidase (GBA) gene has also been found to be a susceptibility factor for PD in 
Ashkenazi Jews (Aharon-Peretz et al. 2004) and North Americans (Nichols et al. 2009) and is 
associated with an earlier age at onset. Also, the common A340T variant in PINK1 has been 
found to contribute to the risk for late-onset PD in Chinese (Wang et al. 2006).  
 
1.6 Molecular pathways implicated in PD pathogenesis 
 
1.6.1 Mitochondrial dysfunction and oxidative stress 
 
Evidence for the involvement of the mitochondria in neurodegeneration in PD emerged after a 
group of heroin addicts developed PD symptoms after accidental injection of a synthetic by-
product of heroin production called MPTP (Langston et al. 1983). The active metabolite of 
MPTP is 1-methyl-4-phenyl-pyridinium ion (MPP+) and has been found to selectively be taken 
up into dopaminergic neurons by means of the dopamine transporter. The method in which 
MPTP is metabolized in the brain is shown in figure 1.13 (Dauer & Przedborski 2003). This 
active metabolite inhibits mitochondrial complex-I catalytic activity in the electron transport 
chain (ETC) and results in increased oxidative stress as well as decreased energy production, 
leading to neuronal damage and death.  
 
Oxidative stress is defined as an imbalance between ROS production and the antioxidant 
capacity of a cell and mitochondria have a central role in the generation of ROS. Mitochondrial 
dysfunction leading to increased ROS production can cause damage to various cellular 
components such as unsaturated lipids, proteins, and nucleic acids, and this has been implicated 
in various neurodegenerative disorders including PD, AD, and ALS (Lin & Beal 2006). Defects 
in the subunits and activity of mitochondrial complex-I have been observed in blood platelets 
and SNpc of PD affected patients (Keeney et al. 2006).   
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Figure 1.13 Illustration of MPTP metabolism. MPTP crosses the blood-brain barrier and is converted 
to MPDP+ by MAO-B in non-dopaminergic cells. It is then converted to MPP+ and released from the cell 
by an unknown mechanism. MPP+ is then transported into dopaminergic cells via the dopamine 
transporter. MPDP+: 1-methyl-4-phenyl-2,3-dihydropyridinium, MAO-B: Monoamine-oxidase-B, MPTP: 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPP+: 1-methyl-4-phenyl-pyridinium, DAT: dopamine 
transporter (taken from (Dauer & Przedborski 2003). 
 
 
As noted above, certain pesticides, such as rotenone and paraquat, have been found to produce 
similar pathological results by inhibiting mitochondrial complex-I activity (Lockwood 2000). 
Similarly, a complex-I inhibitor called annonacin, found in the tropical plant Annona muricata, 
has been suspected to be responsible for an atypical parkinsonsism in the French West Indies, 
and was found to  promote dopaminergic neuronal death by impairing the process of energy 
production (Lannuzel et al. 2003). 
 
The production of ROS may be a direct result of inhibition of the mitochondrial ETC or 
indirectly during the apoptotic process (programmed cell death) (Seaton et al. 1997). 
Mitochondria play an important part in controlling apoptosis, which involves the release of 
cytochrome c from the mitochondrial intermembrane space upon a specific trigger, in order to 
activate the cascade of caspases (cysteine proteases) responsible for degradation of the cell by 
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cleaving multiple cellular substrates (Gorman et al. 2000). In addition, changes in energy 
production by the mitochondria can induce apoptosis in neurons or increase their sensitivity to 
apoptosis (Gorman et al. 2000). Evidence has been found for the process of apoptosis in the 
SNpc of PD patients (Mochizuki et al. 1996).   
 
Interestingly, many of the genes involved in PD (parkin, PINK1, DJ-1, α-synuclein and LRRK2) 
have been found to encode either mitochondrial proteins, or proteins associated with 
mitochondrial dependent cell death. The participation of the different PD genes in pathways 
encompassing the mitochondria as well as the UPS, which will be discussed in the following 
section, is illustrated in figure 1.14.  
 
Studies with transgenic mice have shown that overexpression of α-synuclein impairs 
mitochondrial function, and can enhance the toxicity of MPTP with increased oxidative stress 
(Tanaka et al. 2001; Song et al. 2004). Parkin is known to associate with the outer mitochondrial 
membrane, where it protects against the release of cytochrome c and the activation of the 
caspases (Darios et al. 2003). Oxidized DJ-1 translocates to the mitochondria intermembrane 
space and matrix where it down-regulates the PTEN-tumor suppressor protein and protects cells 
form oxidative stress induced apoptosis (Kim et al. 2005). PINK1 localizes to the mitochondrial 
matrix and is proposed to protect against apoptosis (Petit et al. 2005). Furthermore, it has been 
shown that about 10% of LRRK2 also localizes to the mitochondria where it functions as a 
kinase (West et al. 2005). The role played by these different genes has reinforced the importance 
of mitochondrial dysfunction and oxidative stress as key mechanisms in PD pathogenesis. 
 
1.6.2 The ubiquitin proteasome system and the autophagy-lysosomal pathway 
 
The UPS is the major proteolytic system for the degradation of cytosolic, secretory and 
membrane proteins (Hershko & Ciechanover 1998). This system removes unwanted proteins that 
are no longer required by the cell. The UPS is important for several basic cellular processes, such 
as regulation of cell cycle and division, cellular differentiation and development, morphogenesis 
of neuronal networks, cellular responses to stress and extracellular effectors, and DNA repair 
(Ciechanover & Brundin 2003). 
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              Figure 1.14 Molecular pathways involved in PD pathogenesis.  The role played by parkin, PINK1, DJ-1, α-synuclein and LRRK2 is illustrated. 
              The green arrows indicate promoting or activating effects. The red lines with blunt ends indicate inhibitory effects (taken from (Thomas & Beal 2007). 
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Target proteins that must be removed by the UPS are covalently tagged with ubiquitin, which is 
a 76 amino acid residue protein (Hershko & Ciechanover 1998). This occurs through the 
formation of an iso-peptide bond between the ε-amino group of a lysine residue of the substrate 
and the C-terminal carboxylate of ubiquitin, and normally leads to the formation of a 
polyubiquitin chain on the substrate (Hershko & Ciechanover 1998; Lim & Tan 2007). The E1 
ubiquitin activating enzymes, E2 conjugating enzymes and E3 ligating enzymes are involved in 
this process of tagging proteins for degradation by the UPS and defects in any of them could lead 
to accumulation of protein degradation products. 
 
The involvement of the UPS in PD was strengthened after the identification of mutations in the 
parkin gene (Kitada et al. 1998) which, as previously mentioned, plays an important role in the 
UPS as an E3-type, E2 enzyme-dependent ubiquitin ligase. Inactivation of parkin results in 
decreased UPS mediated degradation of target proteins, and the accumulation of these leads to 
selective toxicity of dopaminergic neurons (Shimura et al. 2000; Yang et al. 2003; Sriram et al. 
2005). Parkin, PINK1 and DJ-1 interact to form a novel E3 complex, designated as the PPD 
complex, which regulates UPS-mediated protein degradation (Xiong et al. 2009). The complex 
was shown to play an important role in ubiquitination and degradation of un-/misfolded parkin 
substrates. The involvement of the PPD complex in PD is supported by the finding that the PD-
pathogenic mutants of PINK1 and parkin impair the E3 ligase activity of the complex (Xiong et 
al. 2009). 
 
Furthermore, there is evidence that the α-synuclein gene is also involved with dysfunction of the 
UPS, and PD pathogenesis. Studies in which α-synuclein was overexpressed showed a decrease 
in the function of the proteasome, resulting in abnormal protein aggregation and neurotoxicity in 
dopaminergic neurons (Tanaka et al. 2001). In addition, α-synuclein has been shown to be a 
major component of LBs (intracytoplasmic proteinaceous inclusions) in PD (Spillantini et al. 
1997). Interestingly, MPTP, rotenone and paraquat have also been shown to cause abnormalities 
in the UPS by impairing proteasome function in rats and mice (Fornai et al. 2005; Betarbet et al. 
2006). 
 
The autophagy-lysosome pathway (ALP) is another system by which unwanted proteins are 
removed from the cell. Impairment of this process also leads to the accumulation and 
aggregation of proteins, resulting in cellular toxicity and neurodegeneration (Pan et al. 2008). 
ALP is suggested to be the major mechanism involved in the degradation of long-lived, stable 
proteins as well as the mechanism by which organelles (e.g. mitochondria) are recycled. ALP 
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dysfunction may result from failure of autophagosome formation or autophagosome fusion with 
lysosomes, deficiency of enzymes in lysosomes, dysfunction of the molecular chaperone or 
lysosomal membrane receptor. It has been shown that α-synuclein is also cleared through ALP 
(Webb et al. 2003). Impaired clearance of α-synuclein by abnormal functioning ALP could 
therefore lead to toxic accumulation of the protein and neurodegeneration. The role played by 
ALP in PD has been further strengthened by the identification of mutations in the ATP13A2 gene 
which leads to insufficient lysosomal protein degradation (Ramirez et al. 2006; Di Fonzo et al. 
2007).  
 
1.7 Current therapeutic approaches for PD 
 
There is no cure for PD and current therapies are aimed primarily to offer relief from the motor 
symptoms. The therapeutics includes medications such as Levodopa (L-DOPA), Dopamine 
agonists, Monoamine-oxidase-B (MAO-B) inhibitors, Catechol-O-methyl transferase (COMT) 
inhibitors and deep brain stimulation (DBS). Recent advances have shown stem cell therapy and 
gene silencing to be experimental therapeutic approaches.  
 
1.7.1 Levodopa (L-DOPA) 
 
In 1967 it was discovered that L-DOPA can promptly and dramatically reduce PD motor 
symptoms and it is currently still the most effective treatment (Cotzias et al. 1967). L-DOPA is 
converted into dopamine in the dopaminergic neurons by the dopa-decarboxylase enzyme 
causing an increase in the levels of dopamine and improvement in PD motor symptoms. 
Increased dosing and prolonged use of this drug are reliably predicted to result in motor 
fluctuations, and abnormal movements referred to as dopamine-induced dyskinesias. 
 
1.7.2 Dopamine agonists 
 
Dopamine agonists stimulate the post-synaptic dopamine receptors and are useful agents, 
particularly since they have a longer half-life than dopamine, and a lower potential for inducing 
dyskinesias. Currently, dopamine agonists are used as initial therapy in order to reduce motor 
complications, particularly in young onset PD. Commonly used dopamine antagonists include, 
Ropinirole, Pramipexole, Rotigotine, and Bromocriptine (Davie 2008). Side effects include 
hallucinations, impulse control disorders, insomnia, nausea, low blood pressure, and sleepiness. 
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1.7.3 MAO-B inhibitors 
 
The function of monoamine-oxidase-B (MAO-B) is to break down dopamine that is secreted by 
dopaminergic neurons. MAO-B inhibitors act to reduce the breakdown of dopamine in order to 
prolong its half-life in the brain (Espay 2010). The dosage of L-DOPA is lower in combination 
with the MAO-B inhibitors. Examples of these drugs are Selegiline and Rasagiline, and some of 
their side effects include insomnia, hallucinations, dizziness, and headaches.  
 
1.7.4 COMT inhibitors 
 
Catechol-O-methyl transferase (COMT) is an enzyme that metabolizes dopamine. COMT 
inhibitors reduce the action of this enzyme, resulting in greater and more sustained plasma and 
central nervous system dopamine levels.  If motor fluctuations are present, COMT inhibitors 
have been shown to result in a decrease in ‘off time’. COMT inhibitors increase the half-life of 
L-DOPA by ~45% after each dose (Davie 2008).  Examples include Entacapone and Tolcapone. 
Some of the side effects of this medication are constipation, nausea, diarrhea, blood in urine and 
liver failure. 
 
1.7.5 Deep brain stimulation (DBS) 
 
DBS is a surgical procedure and is offered to patients in a number of settings, in particular, 
marked dyskinesias or tremor, and where medication has not materially affected motor 
fluctuations (Davie 2008). The DBS system consists of a lead, extension and the 
neurostimulator. The lead is inserted through a small opening in the skull and is implanted in the 
brain with the tip of the electrodes positioned in the target area where it delivers the necessary 
stimulation. The extension (an insulated wire) is passed under the skin of the head, neck and 
shoulder to connect the lead to the neurostimulator, a battery-operated medical device which is 
implanted under the skin near the collarbone. Electrical impulses are sent from this device to the 
electrodes implanted in the target brain area in order to block the abnormal electrical nerve 
signals that cause PD symptoms. Breakage of wires, infection and hematoma (a collection of 
blood outside a blood vessel) are complications that may arise from DBS. Side effects include 
impairment of verbal fluency and depression.  
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1.7.6 Experimental therapeutic approaches 
  
Stem cell therapy 
The above-mentioned therapeutic strategies provide symptomatic relief and do not change the 
course of PD. Therefore, methods that can change the course of the disease by restoring or 
regenerating dopaminergic neurons are necessary. Stem cells have been the focus for such 
therapy due to the fact that they are pluripotent cells that can spontaneously differentiate, or can 
be induced to differentiate, into mature dopaminergic cells. Embryonic stem cells (derived from 
the inner cell mass of the blastula of the embryo), neural stem cells (endogenous pluripotent cells 
in fetal or adult brain) and non-neural stem cells (derived from bone marrow and umbilical cord) 
are types of cells that have been investigated for stem cell therapy (Snyder & Olanow 2005). In 
order to produce beneficial effects in treating PD, a sufficient number of stem cell-derived 
dopaminergic cells (>100 000 cells) that are implanted into the brain must survive, reinnervate 
the host striatum, integrate into the host nigrostriatal system, establish functional contacts, and 
should not lead to tumor formation. Also, stem cells must first be demonstrated to reverse motor 
deficits in animal PD models (Arenas 2010). There have unfortunately been difficulties that have 
delayed the routine use of stem cell therapy in treating PD. Furthermore, an objective of stem 
cell therapy is to target the cells to produce dopamine. Non-motor symptoms are generally not 
related to dopamine deficiency and therefore will not necessarily be improved by stem cell 
therapy. 
 
Gene silencing 
The use of RNA interference (RNAi) to suppress α-synuclein expression has recently been 
identified as a new therapeutic approach to treat PD. It has been shown that α-synuclein 
expression can be reduced by means of RNAi in neuronal cells susceptible to neurodegeneration 
in primates (McCormack et al. 2010). In this study, small interfering RNA directed against α-
synuclein were directly infused into the SNpc of primates and resulted in a 40-50% reduction in 
α-synuclein expression. No adverse side effects were observed such as systemic or tissue-
specific toxicity, loss of dopaminergic cells in the SNpc or behavioral changes. However, further 
studies are necessary in order to safely apply this therapy in humans. 
 
Current treatment strategies focus mainly on relief from symptoms and none halt or lessen 
dopaminergic neuron degeneration and the progression of the disease. It is hoped that research 
into the molecular pathways involved in PD pathogenesis will lead to the development of 
improved and effective drugs that can target the underlying cause rather than only treating the 
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symptoms. These new treatment strategies may be pathway or mutation-specific if no unifying 
pathway for PD is found. As approximately, seventy percent of dopaminergic neurons are lost by 
the time motor symptoms start to manifest, one of the main aims of molecular research is to 
identify presymptomatic individuals who will be candidates for neuroprotective strategies to 
prevent further neurodegeneration, thereby preventing development of PD. 
 
1.8 PD molecular research in South Africa 
 
By September 2010, DNA from 250 families diagnosed with PD has been extracted and archived 
in our laboratory at the Division of Molecular Biology and Human Genetics at Stellenbosch 
University in Cape Town, South Africa. These patients have been recruited from the Movement 
Disorders clinic at Tygerberg Hospital, Cape Town, as well as from the Parkinson’s Association 
of South Africa with informed written consent according to the guidelines of the institutional 
review board (ethics approval number 2002/C059). The patients recruited at Tygerberg Hospital 
all met the UK Parkinson’s Disease Society Brain Bank Research criteria for diagnosis of PD  
(Gibb & Lees 1988). Other inclusion criteria for recruitment included early onset and/or a family 
history of the disorder.  
 
A breakdown of the mode of inheritance of PD is indicated in Table 1.2. The term ‘unknown/ 
indeterminate’ is used to describe either a single PD patient with no family history of the 
disorder or cases where, although there was more than one affected PD member, the mode of 
transmission could not be deduced from the pedigree. 
 
 
 
Table 1.2 Genetic categorization of 250 South African PD patients from which DNA has been 
archived  
Mode of inheritance Number of 
probands/ 
families 
(n=250) 
Number of 
individuals 
(n=645) 
Average 
AAO of 
probands 
(yrs) 
Number of 
probands with 
AAO ≤50 
Autosomal dominant 72 (28.8%) 224 53.6 32 
Autosomal recessive 14 (5.6%) 55 50.1 8 
Unknown/ indeterminate 164 (65.6%) 366 54.8 54 
      AAO: age at onset 
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In South Africa the population can be divided into various ethnic groups including Black, 
Caucasian, Afrikaner, mixed ancestry and Indian.  
• The Black population comprises individuals with indigenous African ancestry who speak 
traditional African languages such as Ndebele, Northern Sotho, Sotho, Swazi, Tswana, 
Tsonga, Venda, Xhosa and Zulu. Xhosa is the predominant language in the Western Cape 
Province, where the study participants had been recruited.  
• The Caucasian population consists of individuals of European descent.  
• The Afrikaner population is known to have undergone a genetic bottleneck in the 19th 
century. They are comprised of Afrikaans speaking individuals mainly of Dutch descent 
but also of French and German ancestry (Greeff 2007).  
• The mixed ancestry population has been defined as an admixture of indigenous African 
populations (San, Khoikhoi or Bantu-speaking) and immigrants from Western Europe, 
Madagascar, the Malaysian archipelago and India (Patterson et al. 2010).  
• The Indian population group is descended from individuals that migrated to South Africa 
from colonial India in the 19th century.  
The numbers of PD patients from each of the ethnic groups are indicated in Figure 1.15. About a 
third (28.4%) of the families belongs to the Afrikaner population group, which is most likely due 
to ascertainment bias, although founder effect in this population cannot be excluded. 
 
In addition, at least 50 individuals from each of these ethnic groups were recruited as controls 
from unrelated healthy blood donors at the South African Western Province Blood Transfusion 
Service blood collection clinics. Both Caucasian and Afrikaner controls were recruited and the 
ethnic group was self-identified by the donors. The controls had been ‘de-identified’ and had not 
been clinically assessed for signs of PD.  
 
1.8.1 The present study 
 
The aim of the present study was to establish the first investigation on the genetic etiology of PD 
in South Africa. The genetic basis of PD in patients from the various South African sub-
population groups was investigated and the study aimed to produce results which would, in the 
long term, be beneficial for the clinical management and improved genetic counseling of PD 
patients and at-risk family members. Predominantly early onset PD was investigated as this has 
been shown to have a significant genetic component. It is anticipated, however, that the findings 
may contribute to an understanding of the molecular mechanisms underlying the more common 
late onset idiopathic form of PD.  
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Autosomal dominant 
(n=72)
Autosomal recessive 
(n=14) Unknown (n=164) Total (n=250)
Caucasian 37 3 58 98
Afrikaner 22 6 43 71
Mixed ancestry 10 3 47 60
Black 3 1 13 17
Indian 0 1 3 4
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Figure 1.15 Distribution of AD and AR forms of PD across the different South African ethnic 
groups. 
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The objectives of the study were as follows: 
1. To screen for mutations in the known PD genes using the high-resolution melt (HRM) 
and the multiplex ligation-dependent probe amplification (MLPA) techniques. 
2. To identify novel PD candidate genes for mutation screening using the bioinformatics 
tool, CAESAR (CAndidatE Search And Rank). 
3. To determine the functional significance of a sequence variant detected in the DJ-1 gene 
using the Dual-Luciferase Reporter assay. 
Figure 1.16 shows an outline of the present study. In the different parts of this study, varying 
numbers of study participants were screened depending on the patient availability at the time of 
the study and on the specific clinical criteria applied. 
 
1.8.2 The experimental approaches used 
 
High-resolution melt (HRM) 
The HRM method makes it possible to assess the nucleotide sequence of a Polymerase chain 
reaction (PCR) amplification product according to its melting behavior as the sample changes 
from double stranded DNA (dsDNA) (pre-melt phase) to single stranded DNA (ssDNA) (post-
melt phase) during the rise in temperature as illustrated in figure 1.17. Initially, the DNA region 
of interest is PCR amplified during which an intercalating fluorescent dye (for example SYTO9) 
is incorporated into the dsDNA molecule. dsDNA produce higher fluorescence than ssDNA 
because the dye is more concentrated. The rise in temperature (typically 75ºC to 95ºC rising by 
0.1ºC each step) causes the molecule to become ssDNA resulting in the release of the fluorescent 
dye and subsequent decrease in its concentration. By measuring this melt behavior of the PCR 
product, it is possible to draw a thermal denaturation profile in which fluorescence (Y-axis) is 
plotted against temperature (X-axis). This profile is characteristic of the specific PCR product 
and is dependent on its sequence length, base and GC content. Therefore, changes in the 
nucleotide sequence will affect the melting behavior of a DNA molecule and will produce a 
different profile compared to the wild-type sample. In the present study, the Eppendorf® 
epMotionTM 5070 (Brinkmann Instruments, Canada) was used for automated liquid handling, and 
HRM analysis was performed on a Rotor-Gene 6000 analyzer (Corbett Life Science, Australia). 
All samples exhibiting altered thermal denaturation profiles were sequenced to characterize the 
sequence variant.  
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment of PD patients and controls 
Mutation screening 
High-Resolution Melt analysis 
and direct sequencing 
Functional study to investigate a promoter 
variant in DJ-1using a Dual-Luciferase 
Reporter assay system  
(Chapter 8) 
Known PD 
 Genes 
Candidate genes selected by 
the bioinformatic program 
CAESAR 
Parkin 
(Chapter 2) 
LRRK2 
(Chapter 4&7) 
PINK1 
(Chapter 5) 
SNCA 
(Chapter 7) 
SNCAIP 
(Chapter 6) 
MAPT 
(Chapter 6) 
MRC Holland kits P051 and P052: 
α-synuclein, parkin, PINK1, DJ-1, 
LRRK2, UCH-L1, ATP13A2, LPA, 
TNFRSF9, CAV2, CAV1, GCH1  
(Chapter 3) 
Figure 1.16 Flowchart showing the outline of the present study
Outline of the present study  
     MLPA 
36 
 
 
Figure 1.17 Illustration of the High-resolution melt technique. Double stranded DNA (dsDNA) melt 
to become single stranded DNA (ssDNA). During this process the fluorescent intercalating dye is 
released, and the fluorescence is measured to produce a thermal denaturation profile that is unique for a 
specific DNA sequence. Fluorescence (Y-axis) is plotted against temperature in degrees Celsius (X-axis) 
(taken from HRM Assay Design and Analysis Booklet, http://www.gene-quantification.de/hrm-
protocol-cls.pdf) 
 
 
Multiplex ligation-dependent probe amplification method (MLPA) 
This method makes it possible to assess genomic DNA for changes such as exon insertions and 
deletions which cannot be detected by HRM or direct sequencing. It detects alterations in a 
number of different exons and genes in a single reaction. In the present study two commercially 
available MLPA kits, SALSA P051 and P052 (MRC Holland, Amsterdam), were used and 
together the kits consisted of probes for exons of α-synuclein, parkin, PINK1, DJ-1, LRRK2, 
UCH-L1, ATP13A2, LPA, TNFRSF9, CAV2, CAV1, GCH1 and two point mutations (A30P in 
SNCA and G2019S in LRRK2). The MLPA probes are made up of two separate oligonucleotides 
containing a hybridization sequence and universal fluorescently-labeled primer sequences as 
shown in figure 1.18. In addition, one of the oligonucleotides also contain a stuffer fragment in 
order to produce PCR products of specific size which will make it possible to differentiate 
amplified exons after electrophoresis.  
 
Initially, denatured genomic DNA is hybridized with the MLPA probes (either P051 or P052). 
The probes are then ligated to form one complete probe fragment which is amplified in a 
multiplex PCR reaction using one universal primer pair. Amplification products of specific 
lengths are produced and electrophoresed using capillary electrophoresis which produces a peak 
profile unique for the DNA sample. For the present study MLPA products were electrophoresed 
on 3130xl Genetic Analyzer (Applied Biosystems, Foster City, USA) and analyzed using 
37 
 
GeneMapper software v3.7 (Applied Biosystems). The amount of fluorescence detected reflects 
the relative copy number of the exons being investigated. An in-house method was designed for 
copy number calculations. The peak height results for patients and reference wild-type samples 
were exported from GeneMapper software to a Microsoft office Excel spreadsheet which had 
been set up for automated calculations. 
 
The following steps were followed for the copy number calculations. The relative peak height 
(RPH) of each exon was obtained by dividing the single peak height by the sum of peak heights 
of all the internal control probes for the patient sample (intra-sample normalization). The same 
was done for the reference wild-type sample. A ratio was then generated by comparing each 
patient sample RPH to the value of the corresponding RPHs from the reference wild-type sample 
(inter-sample normalization). Ratios between 0.7-1.3 were considered to be normal (sample 
contains no exon rearrangements); a heterozygous deletion was expected at a ratio between 0.3-
0.6, a heterozygous duplication between 1.4-1.6, and a triplication at a ratio of ≥1.7. Absence of 
a peak would indicate either a homozygous deletion or possibly a point mutation at that probe 
recognition site (ratio 0.0). Possible mutation positive results were repeated in an independent 
MLPA experiment and then subjected to quantitative PCR on a LightCycler 1.5 (Roche 
Diagnostics, Mannheim, Germany) using the LightCycler® FastStart DNA MasterPLUS SYBR 
Green I kit (Roche Diagnostics). The samples were also sequenced to determine whether false 
positive results were due to point mutations occurring at the probe recognition site.  
 
 
Figure 1.18 Illustration of the MLPA method (taken from http://www.mlpa.com). 
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Dual-Luciferase Reporter Assay 
The functional significance of a novel 16bp deletion variant (g.-6_+10del), which was identified 
in the promoter region of DJ-1 in a PD patient, was investigated using a Dual-Luciferase 
Reporter Assay System (http://www.promega.com/pGL4). For this assay, the DJ-1 5’-UTR 
region containing the sequence flanking the 16bp deletion was cloned into a pGL4.10-Basic 
luciferase-reporter vector (figure 1.19) and co-transfected with a pRL-SV40 internal control 
vector into HEK293 as well as BE(2)-M17 neuroblastoma cells. Promoter activity under 
hydrogen peroxide-induced oxidative stress conditions was also investigated. In addition, 
computational (in silico) cis-regulatory analysis of the DJ-1 promoter sequence was conducted to 
identify possible transcription factor binding sites. This analysis was performed using the 
transcription factor-binding site database, TRANSFAC via the PATCH™ (http://www.gene-
regulation.com) and rVISTA (http://genome.lbl.gov/vista/index.shtml) platforms. 
 
 
 
 
 
Figure 1.19 Restriction map and multiple cloning site (MCS) of the pGL4.10[luc2] vector. 
a) The positions of the ampicillin resistance gene (Ampr), plasmid origin of replication, luc2, SV40 late 
poly(A) signal, synthetic poly(A) signal, and MCS are indicated on the map. b) Nucleotide sequence of 
the pGL4.10[luc2] MCS. The positions of all unique restriction enzymes and recognition sequences, the 
position of the RVprimer3 primer and the synthetic poly(A) signal are indicated on the sequence (Taken 
from http://www.promega.com/vectors/reporter_vectors.htm#b07).   
a) 
b) 
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1.8.3 Outline of the dissertation 
This dissertation is divided into nine chapters. Chapter 1 is the literature review and provides the 
rationale for the study. Chapter 2 describes analysis of the parkin gene. Chapter 3 reports the 
findings for exon dosage analysis in a number of PD genes using the MLPA technique. In 
Chapter 4 the frequency of the LRRK2 common G2019S mutation, and the associated haplotype, 
is investigated. Chapter 5 describes the analysis of PINK1. Chapter 6 describes the use of the 
bioinformatics tool CAESAR (Gaulton et al. 2007) to identify novel PD candidate genes for 
mutation screening in the study participants. Chapter 7 reports unpublished data on mutation 
screening of selected exons of the SNCA and LRRK2 genes. In Chapter 8 the results of a study to 
determine the functional significance of a novel 16bp deletion variant in the promoter region of 
DJ-1 are reported. Finally, Chapter 9 summarizes the main findings of the present study, and 
states the study limitations and the proposed future work. 
 
The findings from the present study have either been published (five manuscripts) or submitted 
for publication (one manuscript) in international peer reviewed journals, as listed below:  
 
Chapter 2 - Bardien S, Keyser RJ, Yako Y, Lombard D, Carr J. Molecular analysis of the parkin 
gene in South African patients diagnosed with Parkinson’s disease. Parkinsonism and Related Disorders 
2009;15(2):116-121. 
 
Chapter 3 - Keyser RJ, Lombard D, Veikondis R, Carr J, Bardien S. Analysis of exon dosage using  
MLPA in South African Parkinson's disease patients. Neurogenetics 2010; 11(3):305-312. 
 
Chapter 4 - Bardien S, Marsberg A, Keyser R, Lombard D, Lesage S, Brice A, Carr J. LRRK2 
G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients. J Neural 
Transm. 2010; 117(7):847-853. 
 
Chapter 5 - Keyser RJ, Lesage S, Brice A, Carr J, Bardien S. Assessing the prevalence of PINK1 
genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease. 
Biochem Biophys Res Commun. 2010; 398(1):125-129. 
 
Chapter 6 - Keyser RJ, Oppon E, Carr J, Bardien S. Identification of Parkinson’s disease 
candidate genes using CAESAR and screening in South African Parkinson’s disease patients 
 (submitted to Journal of Neural Transmission, September 2010) 
 
Chapter 7 – Additional unpublished results 
 
Chapter 8 - Keyser RJ, van der Merwe L, Venter M, Kinnear C, Lombard D, Warnich L, Carr J, 
Bardien S. Identification of a novel functional deletion variant in the 5’-UTR of the DJ-1 gene. BMC 
Medical Genetics 2009; 10:105.  
 
 
 
 
40 
 
1.9 Reference list 
 
Abeliovich, A., Y. Schmitz, I. Farinas, D. Choi-Lundberg, W. H. Ho et al.  2000 Mice lacking alpha-
synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252. 
Abou-Sleiman, P. M., M. M. Muqit, N. Q. McDonald, Y. X. Yang, S. Gandhi et al.  2006 A heterozygous 
effect for PINK1 mutations in Parkinson's disease? Ann.Neurol. 60: 414-419. 
Aharon-Peretz, J., H. Rosenbaum, and R. Gershoni-Baruch, 2004 Mutations in the glucocerebrosidase 
gene and Parkinson's disease in Ashkenazi Jews. N.Engl.J.Med. 351: 1972-1977. 
Alves, G., E. B. Forsaa, K. F. Pedersen, G. M. Dreetz, and J. P. Larsen, 2008 Epidemiology of 
Parkinson's disease. J.Neurol. 255 Suppl 5: 18-32. 
Arenas, E., 2010 Towards stem cell replacement therapies for Parkinson's disease. 
Biochem.Biophys.Res.Commun. 396: 152-156. 
Ashok, P. P., K. Radhakrishnan, R. Sridharan, and M. E. Mousa, 1986 Epidemiology of Parkinson's 
disease in Benghazi, North-East Libya. Clin.Neurol.Neurosurg. 88: 109-113. 
Beilina, A., B. M. van der, R. Ahmad, S. Kesavapany, D. W. Miller et al.  2005 Mutations in PTEN-
induced putative kinase 1 associated with recessive parkinsonism have differential effects on 
protein stability. Proc.Natl.Acad.Sci.U.S.A 102: 5703-5708. 
Berg, D., K. Schweitzer, P. Leitner, A. Zimprich, P. Lichtner et al.  2005 Type and frequency of 
mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 128: 3000-
3011. 
Betarbet, R., R. M. Canet-Aviles, T. B. Sherer, P. G. Mastroberardino, C. McLendon et al.  2006 
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide 
rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol.Dis. 22: 404-
420. 
Betarbet, R., T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov et al.  2000 Chronic systemic 
pesticide exposure reproduces features of Parkinson's disease. Nat.Neurosci. 3: 1301-1306. 
Bonifati, V., B. A. Oostra, and P. Heutink, 2004 Linking DJ-1 to neurodegeneration offers novel insights 
for understanding the pathogenesis of Parkinson's disease. J.Mol.Med. 82: 163-174. 
Bonifati, V., P. Rizzu, M. J. van Baren, O. Schaap, G. J. Breedveld et al.  2003 Mutations in the DJ-1 
gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259. 
Bonifati, V., C. F. Rohe, G. J. Breedveld, E. Fabrizio, M. M. De et al.  2005 Early-onset parkinsonism 
associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65: 87-95. 
Canet-Aviles, R. M., M. A. Wilson, D. W. Miller, R. Ahmad, C. McLendon et al.  2004 The Parkinson's 
disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial 
localization. Proc.Natl.Acad.Sci.U.S.A 101: 9103-9108. 
Chartier-Harlin, M. C., J. Kachergus, C. Roumier, V. Mouroux, X. Douay et al.  2004 Alpha-synuclein 
locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169. 
Chung, K. K., Y. Zhang, K. L. Lim, Y. Tanaka, H. Huang et al.  2001 Parkin ubiquitinates the alpha-
synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson 
disease. Nat.Med. 7: 1144-1150. 
41 
 
Ciechanover, A., and P. Brundin, 2003 The ubiquitin proteasome system in neurodegenerative diseases: 
sometimes the chicken, sometimes the egg. Neuron 40: 427-446. 
Conway, K. A., J. D. Harper, and P. T. Lansbury, 1998 Accelerated in vitro fibril formation by a mutant 
alpha-synuclein linked to early-onset Parkinson disease. Nat.Med. 4: 1318-1320. 
Cookson, M. R., and O. Bandmann, 2010 Parkinson's disease: insights from pathways. Hum.Mol.Genet. 
19: R21-R27. 
Cookson, M. R., P. J. Lockhart, C. McLendon, C. O'Farrell, M. Schlossmacher et al.  2003 RING finger 1 
mutations in Parkin produce altered localization of the protein. Hum.Mol.Genet. 12: 2957-2965. 
Cotzias, G. C., M. H. Van Woert, and L. M. Schiffer, 1967 Aromatic amino acids and modification of 
parkinsonism. N.Engl.J.Med. 276: 374-379. 
Coulom, H., and S. Birman, 2004 Chronic exposure to rotenone models sporadic Parkinson's disease in 
Drosophila melanogaster. J.Neurosci. 24: 10993-10998. 
Darios, F., O. Corti, C. B. Lucking, C. Hampe, M. P. Muriel et al.  2003 Parkin prevents mitochondrial 
swelling and cytochrome c release in mitochondria-dependent cell death. Hum.Mol.Genet. 12: 
517-526. 
Dauer, W., and S. Przedborski, 2003 Parkinson's disease: mechanisms and models. Neuron 39: 889-909. 
Davie, C. A., 2008 A review of Parkinson's disease. Br.Med.Bull. 86: 109-127. 
de Rijk, M. C., L. J. Launer, K. Berger, M. M. Breteler, J. F. Dartigues et al.  2000 Prevalence of 
Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic 
Diseases in the Elderly Research Group. Neurology 54: S21-S23. 
Di Fonzo, A., H. F. Chien, M. Socal, S. Giraudo, C. Tassorelli et al.  2007 ATP13A2 missense mutations 
in juvenile parkinsonism and young onset Parkinson disease. Neurology 68: 1557-1562. 
Di Fonzo, A., C. Tassorelli, M. M. De, H. F. Chien, J. Ferreira et al.  2006a Comprehensive analysis of 
the LRRK2 gene in sixty families with Parkinson's disease. Eur.J.Hum.Genet. 14: 322-331. 
Di Fonzo, A., Y. H. Wu-Chou, C. S. Lu, D. M. van, E. J. Simons et al.  2006b A common missense 
variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. 
Neurogenetics. 7: 133-138. 
Dluzen, D. E., and J. L. McDermott, 2000 Gender differences in neurotoxicity of the nigrostriatal 
dopaminergic system: implications for Parkinson's disease. J.Gend.Specif.Med. 3: 36-42. 
Edwards, T. L., W. K. Scott, C. Almonte, A. Burt, E. H. Powell et al.  2010 Genome-wide association 
study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson 
disease. Ann.Hum.Genet. 74: 97-109. 
Elbaz, A., and C. Tranchant, 2007 Epidemiologic studies of environmental exposures in Parkinson's 
disease. J.Neurol.Sci. 262: 37-44. 
Engelender, S., Z. Kaminsky, X. Guo, A. H. Sharp, R. K. Amaravi et al.  1999 Synphilin-1 associates 
with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat.Genet. 22: 110-114. 
Engelender, S., T. Wanner, J. J. Kleiderlein, K. Wakabayashi, S. Tsuji et al.  2000 Organization of the 
human synphilin-1 gene, a candidate for Parkinson's disease. Mamm.Genome 11: 763-766. 
42 
 
Ephraty, L., O. Porat, D. Israeli, O. S. Cohen, O. Tunkel et al.  2007 Neuropsychiatric and cognitive 
features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord. 22: 
566-569. 
Espay, A. J., 2010 Management of motor complications in Parkinson disease: current and emerging 
therapies. Neurol.Clin. 28: 913-925. 
Fahn, S., 2003 Description of Parkinson's disease as a clinical syndrome. Ann.N.Y.Acad.Sci. 991: 1-14. 
Farrer, M., L. Skipper, M. Berg, G. Bisceglio, M. Hanson et al.  2002 The tau H1 haplotype is associated 
with Parkinson's disease in the Norwegian population. Neurosci.Lett. 322: 83-86. 
Feany, M. B., and W. W. Bender, 2000 A Drosophila model of Parkinson's disease. Nature 404: 394-398. 
Fornai, F., O. M. Schluter, P. Lenzi, M. Gesi, R. Ruffoli et al.  2005 Parkinson-like syndrome induced by 
continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-
synuclein. Proc.Natl.Acad.Sci.U.S.A 102: 3413-3418. 
Foroud, T., S. K. Uniacke, L. Liu, N. Pankratz, A. Rudolph et al.  2003 Heterozygosity for a mutation in 
the parkin gene leads to later onset Parkinson disease. Neurology 60: 796-801. 
Gandhi, S., M. M. Muqit, L. Stanyer, D. G. Healy, P. M. bou-Sleiman et al.  2006 PINK1 protein in 
normal human brain and Parkinson's disease. Brain 129: 1720-1731. 
Gaulton, K. J., K. L. Mohlke, and T. J. Vision, 2007 A computational system to select candidate genes for 
complex human traits. Bioinformatics. 23: 1132-1140. 
Giasson, B. I., J. E. Duda, S. M. Quinn, B. Zhang, J. Q. Trojanowski et al.  2002 Neuronal alpha-
synucleinopathy with severe movement disorder in mice expressing A53T human alpha-
synuclein. Neuron 34: 521-533. 
Giasson, B. I., M. S. Forman, M. Higuchi, L. I. Golbe, C. L. Graves et al.  2003 Initiation and synergistic 
fibrillization of tau and alpha-synuclein. Science 300: 636-640. 
Gibb, W. R., and A. J. Lees, 1988 A comparison of clinical and pathological features of young- and old-
onset Parkinson's disease. Neurology 38: 1402-1406. 
Gibb, W. R., and A. J. Lees, 1991 Anatomy, pigmentation, ventral and dorsal subpopulations of the 
substantia nigra, and differential cell death in Parkinson's disease. J.Neurol.Neurosurg.Psychiatry 
54: 388-396. 
Gillies, G. E., and S. McArthur, 2010 Independent influences of sex steroids of systemic and central 
origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by 
estrogens. Horm.Behav. 57: 23-34. 
Gitler, A. D., A. Chesi, M. L. Geddie, K. E. Strathearn, S. Hamamichi et al.  2009 Alpha-synuclein is part 
of a diverse and highly conserved interaction network that includes PARK9 and manganese 
toxicity. Nat.Genet. 41: 308-315. 
Goris, A., C. H. Williams-Gray, G. R. Clark, T. Foltynie, S. J. Lewis et al.  2007 Tau and alpha-synuclein 
in susceptibility to, and dementia in, Parkinson's disease. Ann.Neurol. 62: 145-153. 
Gorman, A. M., S. Ceccatelli, and S. Orrenius, 2000 Role of mitochondria in neuronal apoptosis. 
Dev.Neurosci. 22: 348-358. 
Greeff, J. M., 2007 Deconstructing Jaco: genetic heritage of an Afrikaner. Ann.Hum.Genet. 71: 674-688. 
43 
 
Gu, W. J., O. Corti, F. Araujo, C. Hampe, S. Jacquier et al.  2003 The C289G and C418R missense 
mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol.Dis. 
14: 357-364. 
Guo, L., W. Wang, and S. G. Chen, 2006 Leucine-rich repeat kinase 2: relevance to Parkinson's disease. 
Int.J.Biochem.Cell Biol. 38: 1469-1475. 
Hayashi, S., K. Wakabayashi, A. Ishikawa, H. Nagai, M. Saito et al.  2000 An autopsy case of autosomal-
recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov 
Disord. 15: 884-888. 
Healy, D. G., M. Falchi, S. S. O'Sullivan, V. Bonifati, A. Durr et al.  2008 Phenotype, genotype, and 
worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. 
Lancet Neurol. 7: 583-590. 
Hedrich, K., C. Eskelson, B. Wilmot, K. Marder, J. Harris et al.  2004 Distribution, type, and origin of 
Parkin mutations: review and case studies. Mov Disord. 19: 1146-1157. 
Hedrich, K., S. Winkler, J. Hagenah, K. Kabakci, M. Kasten et al.  2006 Recurrent LRRK2 (Park8) 
mutations in early-onset Parkinson's disease. Mov Disord. 21: 1506-1510. 
Hershko, A., and A. Ciechanover, 1998 The ubiquitin system. Annu.Rev.Biochem. 67: 425-479. 
Hilker, R., C. Klein, M. Ghaemi, B. Kis, T. Strotmann et al.  2001 Positron emission tomographic 
analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with 
mutations in the parkin gene. Ann.Neurol. 49: 367-376. 
Hirokawa, N., 1994 Microtubule organization and dynamics dependent on microtubule-associated 
proteins. Curr.Opin.Cell Biol. 6: 74-81. 
Huai, Q., Y. Sun, H. Wang, L. S. Chin, L. Li et al.  2003 Crystal structure of DJ-1/RS and implication on 
familial Parkinson's disease. FEBS Lett. 549: 171-175. 
Hutton, M., C. L. Lendon, P. Rizzu, M. Baker, S. Froelich et al.  1998 Association of missense and 5'-
splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705. 
Huynh, D. P., D. R. Scoles, D. Nguyen, and S. M. Pulst, 2003 The autosomal recessive juvenile 
Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. 
Hum.Mol.Genet. 12: 2587-2597. 
Ibanez, P., A. M. Bonnet, B. Debarges, E. Lohmann, F. Tison et al.  2004 Causal relation between alpha-
synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171. 
Jo, E., J. McLaurin, C. M. Yip, P. St George-Hyslop, and P. E. Fraser, 2000 alpha-Synuclein membrane 
interactions and lipid specificity. J.Biol.Chem. 275: 34328-34334. 
Johnson, J., C. Paisan-Ruiz, G. Lopez, C. Crews, A. Britton et al.  2007 Comprehensive screening of a 
North American Parkinson's disease cohort for LRRK2 mutation. Neurodegener.Dis. 4: 386-391. 
Kahle, P. J., J. Waak, and T. Gasser, 2009 DJ-1 and prevention of oxidative stress in Parkinson's disease 
and other age-related disorders. Free Radic.Biol.Med. 47: 1354-1361. 
Keeney, P. M., J. Xie, R. A. Capaldi, and J. P. Bennett, Jr., 2006 Parkinson's disease brain mitochondrial 
complex I has oxidatively damaged subunits and is functionally impaired and misassembled. 
J.Neurosci. 26: 5256-5264. 
44 
 
Khan, N. L., S. Jain, J. M. Lynch, N. Pavese, P. bou-Sleiman et al.  2005 Mutations in the gene LRRK2 
encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory 
and functional imaging and genetic data. Brain 128: 2786-2796. 
Kim, R. H., M. Peters, Y. Jang, W. Shi, M. Pintilie et al.  2005 DJ-1, a novel regulator of the tumor 
suppressor PTEN. Cancer Cell 7: 263-273. 
Kitada, T., S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura et al.  1998 Mutations in the parkin 
gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608. 
Klein, C., A. Djarmati, K. Hedrich, N. Schafer, C. Scaglione et al.  2005 PINK1, Parkin, and DJ-1 
mutations in Italian patients with early-onset parkinsonism. Eur.J.Hum.Genet. 13: 1086-1093. 
Klein, C., and K. Lohmann-Hedrich, 2007 Impact of recent genetic findings in Parkinson's disease. 
Curr.Opin.Neurol. 20: 453-464. 
Kruger, R., W. Kuhn, T. Muller, D. Woitalla, M. Graeber et al.  1998 Ala30Pro mutation in the gene 
encoding alpha-synuclein in Parkinson's disease. Nat.Genet. 18: 106-108. 
Lang, A. E., and A. M. Lozano, 1998 Parkinson's disease. First of two parts. N.Engl.J.Med. 339: 1044-
1053. 
Langston, J. W., P. Ballard, J. W. Tetrud, and I. Irwin, 1983 Chronic Parkinsonism in humans due to a 
product of meperidine-analog synthesis. Science 219: 979-980. 
Lannuzel, A., P. P. Michel, G. U. Hoglinger, P. Champy, A. Jousset et al.  2003 The mitochondrial 
complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of 
energy metabolism. Neuroscience 121: 287-296. 
Lee, G., R. L. Neve, and K. S. Kosik, 1989 The microtubule binding domain of tau protein. Neuron 2: 
1615-1624. 
Lesage, S., and A. Brice, 2009 Parkinson's disease: from monogenic forms to genetic susceptibility 
factors. Hum.Mol.Genet. 18: R48-R59. 
Lev, N., D. Ickowicz, E. Melamed, and D. Offen, 2008 Oxidative insults induce DJ-1 upregulation and 
redistribution: implications for neuroprotection. Neurotoxicology 29: 397-405. 
Lewis, S. A., A. Villasante, P. Sherline, and N. J. Cowan, 1986 Brain-specific expression of MAP2 
detected using a cloned cDNA probe. J.Cell Biol. 102: 2098-2105. 
Li, X., Z. Liu, K. Tamashiro, B. Shi, D. D. Rudnicki et al.  2010 Synphilin-1 exhibits trophic and 
protective effects against Rotenone toxicity. Neuroscience 165: 455-462. 
Lim, K. L., and J. M. Tan, 2007 Role of the ubiquitin proteasome system in Parkinson's disease. 
BMC.Biochem. 8 Suppl 1: S13. 
Lin, M. T., and M. F. Beal, 2006 Mitochondrial dysfunction and oxidative stress in neurodegenerative 
diseases. Nature 443: 787-795. 
Lockwood, A. H., 2000 Pesticides and parkinsonism: is there an etiological link? Curr.Opin.Neurol. 13: 
687-690. 
Lohmann, E., M. Periquet, V. Bonifati, N. W. Wood, M. G. De et al.  2003 How much phenotypic 
variation can be attributed to parkin genotype? Ann.Neurol. 54: 176-185. 
Lucking, C. B., and A. Brice, 2000 Alpha-synuclein and Parkinson's disease. Cell Mol.Life Sci. 57: 1894-
1908. 
45 
 
Maraganore, D. M., A. M. de, A. Elbaz, M. J. Farrer, J. P. Ioannidis et al.  2006 Collaborative analysis of 
alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296: 661-670. 
Marion, S. A., 2001 The epidemiology of Parkinson's disease. Current issues. Adv.Neurol. 86: 163-172. 
Marx, F. P., C. Holzmann, K. M. Strauss, L. Li, O. Eberhardt et al.  2003 Identification and functional 
characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. 
Hum.Mol.Genet. 12: 1223-1231. 
Masliah, E., E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto et al.  2000 Dopaminergic loss and 
inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. 
Science 287: 1265-1269. 
Mata, I. F., J. M. Kachergus, J. P. Taylor, S. Lincoln, J. Aasly et al.  2005 Lrrk2 pathogenic substitutions 
in Parkinson's disease. Neurogenetics. 6: 171-177. 
Mata, I. F., P. J. Lockhart, and M. J. Farrer, 2004 Parkin genetics: one model for Parkinson's disease. 
Hum.Mol.Genet. 13 Spec No 1: R127-R133. 
McCormack, A. L., S. K. Mak, J. M. Henderson, D. Bumcrot, M. J. Farrer et al.  2010 Alpha-synuclein 
suppression by targeted small interfering RNA in the primate substantia nigra. PLoS.One. 5: 
e12122. 
Melcon, M. O., D. W. Anderson, R. H. Vergara, and W. A. Rocca, 1997 Prevalence of Parkinson's 
disease in Junin, Buenos Aires Province, Argentina. Mov Disord. 12: 197-205. 
Mochizuki, H., K. Goto, H. Mori, and Y. Mizuno, 1996 Histochemical detection of apoptosis in 
Parkinson's disease. J.Neurol.Sci. 137: 120-123. 
Moore, D. J., A. B. West, V. L. Dawson, and T. M. Dawson, 2005 Molecular pathophysiology of 
Parkinson's disease. Annu.Rev.Neurosci. 28: 57-87. 
Myhre, R., H. Klungland, M. J. Farrer, and J. O. Aasly, 2008 Genetic association study of synphilin-1 in 
idiopathic Parkinson's disease. BMC.Med.Genet. 9: 19. 
Nagakubo, D., T. Taira, H. Kitaura, M. Ikeda, K. Tamai et al.  1997 DJ-1, a novel oncogene which 
transforms mouse NIH3T3 cells in cooperation with ras. Biochem.Biophys.Res.Commun. 231: 
509-513. 
Naimark, D., E. Jackson, E. Rockwell, and D. V. Jeste, 1996 Psychotic symptoms in Parkinson's disease 
patients with dementia. J.Am.Geriatr.Soc. 44: 296-299. 
Nichols, W. C., V. E. Elsaesser, N. Pankratz, M. W. Pauciulo, D. K. Marek et al.  2007 LRRK2 mutation 
analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69: 1737-
1744. 
Nichols, W. C., N. Pankratz, D. K. Marek, M. W. Pauciulo, V. E. Elsaesser et al.  2009 Mutations in 
GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72: 
310-316. 
Ning, Y. P., K. Kanai, H. Tomiyama, Y. Li, M. Funayama et al.  2008 PARK9-linked parkinsonism in 
eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 70: 1491-1493. 
Okubadejo, N. U., J. H. Bower, W. A. Rocca, and D. M. Maraganore, 2006 Parkinson's disease in Africa: 
A systematic review of epidemiologic and genetic studies. Mov Disord. 21: 2150-2156. 
46 
 
Onyango, I. G., 2008 Mitochondrial dysfunction and oxidative stress in Parkinson's disease. 
Neurochem.Res. 33: 589-597. 
Paisan-Ruiz, C., S. Jain, E. W. Evans, W. P. Gilks, J. Simon et al.  2004 Cloning of the gene containing 
mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600. 
Paisan-Ruiz, C., P. Nath, N. Washecka, J. R. Gibbs, and A. B. Singleton, 2008 Comprehensive analysis 
of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. 
Hum.Mutat. 29: 485-490. 
Pan, T., S. Kondo, W. Le, and J. Jankovic, 2008 The role of autophagy-lysosome pathway in 
neurodegeneration associated with Parkinson's disease. Brain 131: 1969-1978. 
Pankratz, N., and T. Foroud, 2007 Genetics of Parkinson disease. Genet.Med. 9: 801-811. 
Park, J., S. B. Lee, S. Lee, Y. Kim, S. Song et al.  2006 Mitochondrial dysfunction in Drosophila PINK1 
mutants is complemented by parkin. Nature 441: 1157-1161. 
Partinen, M., 1997 Sleep disorder related to Parkinson's disease. J.Neurol. 244: S3-S6. 
Patterson, N., D. C. Petersen, R. E. van der Ross, H. Sudoyo, R. H. Glashoff et al.  2010 Genetic structure 
of a unique admixed population: implications for medical research. Hum.Mol.Genet. 19: 411-419. 
Periquet, M., M. Latouche, E. Lohmann, N. Rawal, M. G. De et al.  2003 Parkin mutations are frequent in 
patients with isolated early-onset parkinsonism. Brain 126: 1271-1278. 
Petit, A., T. Kawarai, E. Paitel, N. Sanjo, M. Maj et al.  2005 Wild-type PINK1 prevents basal and 
induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. 
J.Biol.Chem. 280: 34025-34032. 
Pirkevi, C., S. Lesage, C. Condroyer, H. Tomiyama, N. Hattori et al.  2009 A LRRK2 G2019S mutation 
carrier from Turkey shares the Japanese haplotype. Neurogenetics. 10: 271-273. 
Polymeropoulos, M. H., C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia et al.  1997 Mutation in the alpha-
synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047. 
Rademakers, R., M. Cruts, and B. C. van, 2004 The role of tau (MAPT) in frontotemporal dementia and 
related tauopathies. Hum.Mutat. 24: 277-295. 
Ramirez, A., A. Heimbach, J. Grundemann, B. Stiller, D. Hampshire et al.  2006 Hereditary parkinsonism 
with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. 
Nat.Genet. 38: 1184-1191. 
Rogaeva, E., J. Johnson, A. E. Lang, C. Gulick, K. Gwinn-Hardy et al.  2004 Analysis of the PINK1 gene 
in a large cohort of cases with Parkinson disease. Arch.Neurol. 61: 1898-1904. 
Ross, O. A., A. T. Braithwaite, L. M. Skipper, J. Kachergus, M. M. Hulihan et al.  2008a Genomic 
investigation of alpha-synuclein multiplication and parkinsonism. Ann.Neurol. 63: 743-750. 
Ross, O. A., Y. R. Wu, M. C. Lee, M. Funayama, M. L. Chen et al.  2008b Analysis of Lrrk2 R1628P as 
a risk factor for Parkinson's disease. Ann.Neurol. 64: 88-92. 
Satake, W., Y. Nakabayashi, I. Mizuta, Y. Hirota, C. Ito et al.  2009 Genome-wide association study 
identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat.Genet. 
41: 1303-1307. 
47 
 
Schultheis, P. J., T. T. Hagen, K. K. O'Toole, A. Tachibana, C. R. Burke et al.  2004 Characterization of 
the P5 subfamily of P-type transport ATPases in mice. Biochem.Biophys.Res.Commun. 323: 731-
738. 
Seaton, T. A., J. M. Cooper, and A. H. Schapira, 1997 Free radical scavengers protect dopaminergic cell 
lines from apoptosis induced by complex I inhibitors. Brain Res. 777: 110-118. 
Shadrina, M. I., E. V. Semenova, P. A. Slominsky, G. H. Bagyeva, S. N. Illarioshkin et al.  2007 
Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) 
exon 1-12 dosage. BMC.Med.Genet. 8: 6. 
Shimura, H., N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa et al.  2000 Familial Parkinson disease gene 
product, parkin, is a ubiquitin-protein ligase. Nat.Genet. 25: 302-305. 
Shulman, L. M., 2007 Gender differences in Parkinson's disease. Gend.Med. 4: 8-18. 
Siderowf, A., 2001 Parkinson's disease: clinical features, epidemiology and genetics. Neurol.Clin. 19: 
565-78, vi. 
Sim, C. H., D. S. Lio, S. S. Mok, C. L. Masters, A. F. Hill et al.  2006 C-terminal truncation and 
Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase 
activity of PTEN-induced kinase-1. Hum.Mol.Genet. 15: 3251-3262. 
Simon-Sanchez, J., C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs et al.  2009 Genome-wide association 
study reveals genetic risk underlying Parkinson's disease. Nat.Genet. 41: 1308-1312. 
Singleton, A. B., M. Farrer, J. Johnson, A. Singleton, S. Hague et al.  2003 alpha-Synuclein locus 
triplication causes Parkinson's disease. Science 302: 841. 
Snider, S. R., S. Fahn, W. P. Isgreen, and L. J. Cote, 1976 Primary sensory symptoms in parkinsonism. 
Neurology 26: 423-429. 
Snyder, B. J., and C. W. Olanow, 2005 Stem cell treatment for Parkinson's disease: an update for 2005. 
Curr.Opin.Neurol. 18: 376-385. 
Solano, S. M., D. W. Miller, S. J. Augood, A. B. Young, and J. B. Penney, Jr., 2000 Expression of alpha-
synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes 
associated with familial Parkinson's disease. Ann.Neurol. 47: 201-210. 
Song, D. D., C. W. Shults, A. Sisk, E. Rockenstein, and E. Masliah, 2004 Enhanced substantia nigra 
mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. 
Exp.Neurol. 186: 158-172. 
Spillantini, M. G., M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes et al.  1997 Alpha-synuclein in 
Lewy bodies. Nature 388: 839-840. 
Spittaels, K., H. C. Van den, D. J. Van, K. Bruynseels, K. Vandezande et al.  1999 Prominent axonopathy 
in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. 
Am.J.Pathol. 155: 2153-2165. 
Sriram, S. R., X. Li, H. S. Ko, K. K. Chung, E. Wong et al.  2005 Familial-associated mutations 
differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. 
Hum.Mol.Genet. 14: 2571-2586. 
Stamer, K., R. Vogel, E. Thies, E. Mandelkow, and E. M. Mandelkow, 2002 Tau blocks traffic of 
organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J.Cell 
Biol. 156: 1051-1063. 
48 
 
Sun, M., J. C. Latourelle, G. F. Wooten, M. F. Lew, C. Klein et al.  2006 Influence of heterozygosity for 
parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch.Neurol. 63: 
826-832. 
Tanaka, Y., S. Engelender, S. Igarashi, R. K. Rao, T. Wanner et al.  2001 Inducible expression of mutant 
alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-
dependent apoptosis. Hum.Mol.Genet. 10: 919-926. 
Tekle-Haimanot, R., M. Abebe, A. Gebre-Mariam, L. Forsgren, J. Heijbel et al.  1990 Community-based 
study of neurological disorders in rural central Ethiopia. Neuroepidemiology 9: 263-277. 
Thomas, B., and M. F. Beal, 2007 Parkinson's disease. Hum.Mol.Genet. 16 Spec No. 2: R183-R194. 
Tobin, J. E., J. C. Latourelle, M. F. Lew, C. Klein, O. Suchowersky et al.  2008 Haplotypes and gene 
expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 71: 
28-34. 
Touchman, J. W., A. Dehejia, O. Chiba-Falek, D. E. Cabin, J. R. Schwartz et al.  2001 Human and mouse 
alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene 
regulatory element. Genome Res. 11: 78-86. 
Ueda, K., H. Fukushima, E. Masliah, Y. Xia, A. Iwai et al.  1993 Molecular cloning of cDNA encoding 
an unrecognized component of amyloid in Alzheimer disease. Proc.Natl.Acad.Sci.U.S.A 90: 
11282-11286. 
Um, J. W., D. S. Min, H. Rhim, J. Kim, S. R. Paik et al.  2006 Parkin ubiquitinates and promotes the 
degradation of RanBP2. J.Biol.Chem. 281: 3595-3603. 
Um, J. W., C. Stichel-Gunkel, H. Lubbert, G. Lee, and K. C. Chung, 2009 Molecular interaction between 
parkin and PINK1 in mammalian neuronal cells. Mol.Cell Neurosci. 40: 421-432. 
Unoki, M., and Y. Nakamura, 2001 Growth-suppressive effects of BPOZ and EGR2, two genes involved 
in the PTEN signaling pathway. Oncogene 20: 4457-4465. 
Valente, E. M., P. M. bou-Sleiman, V. Caputo, M. M. Muqit, K. Harvey et al.  2004a Hereditary early-
onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160. 
Valente, E. M., S. Salvi, T. Ialongo, R. Marongiu, A. E. Elia et al.  2004b PINK1 mutations are 
associated with sporadic early-onset parkinsonism. Ann.Neurol. 56: 336-341. 
Van Den Eeden, S. K., C. M. Tanner, A. L. Bernstein, R. D. Fross, A. Leimpeter et al.  2003 Incidence of 
Parkinson's disease: variation by age, gender, and race/ethnicity. Am.J.Epidemiol. 157: 1015-
1022. 
Vilarino-Guell, C., A. I. Soto, S. J. Lincoln, Y. S. Ben, M. Kefi et al.  2009 ATP13A2 variability in 
Parkinson disease. Hum.Mutat. 30: 406-410. 
von Campenhausen S., B. Bornschein, R. Wick, K. Botzel, C. Sampaio et al.  2005 Prevalence and 
incidence of Parkinson's disease in Europe. Eur.Neuropsychopharmacol. 15: 473-490. 
Wagenfeld, A., C. H. Yeung, K. Strupat, and T. G. Cooper, 1998 Shedding of a rat epididymal sperm 
protein associated with infertility induced by ornidazole and alpha-chlorohydrin. Biol.Reprod. 58: 
1257-1265. 
Wakabayashi, K., S. Engelender, M. Yoshimoto, S. Tsuji, C. A. Ross et al.  2000 Synphilin-1 is present 
in Lewy bodies in Parkinson's disease. Ann.Neurol. 47: 521-523. 
49 
 
Wang, F., X. Feng, J. Ma, H. Zou, and P. Chan, 2006 A common A340T variant in PINK1 gene 
associated with late-onset Parkinson's disease in Chinese. Neurosci.Lett. 410: 121-125. 
Webb, J. L., B. Ravikumar, J. Atkins, J. N. Skepper, and D. C. Rubinsztein, 2003 Alpha-Synuclein is 
degraded by both autophagy and the proteasome. J.Biol.Chem. 278: 25009-25013. 
Weingarten, M. D., A. H. Lockwood, S. Y. Hwo, and M. W. Kirschner, 1975 A protein factor essential 
for microtubule assembly. Proc.Natl.Acad.Sci.U.S.A 72: 1858-1862. 
West, A. B., D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith et al.  2005 Parkinson's disease-
associated mutations in leucine-rich repeat kinase 2 augment kinase activity. 
Proc.Natl.Acad.Sci.U.S.A 102: 16842-16847. 
Wider, C., T. Foroud, and Z. K. Wszolek, 2010a Clinical implications of gene discovery in Parkinson's 
disease and parkinsonism. Mov Disord. 25 Suppl 1: S15-S20. 
Wider, C., C. Vilarino-Guell, B. Jasinska-Myga, M. G. Heckman, A. I. Soto-Ortolaza et al.  2010b 
Association of the MAPT locus with Parkinson's disease. Eur.J.Neurol. 17: 483-486. 
Wszolek, Z. K., R. F. Pfeiffer, M. H. Bhatt, R. L. Schelper, M. Cordes et al.  1992 Rapidly progressive 
autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. 
Ann.Neurol. 32: 312-320. 
Xiong, H., D. Wang, L. Chen, Y. S. Choo, H. Ma et al.  2009 Parkin, PINK1, and DJ-1 form a ubiquitin 
E3 ligase complex promoting unfolded protein degradation. J.Clin.Invest 119: 650-660. 
Xiromerisiou, G., G. M. Hadjigeorgiou, V. Gourbali, J. Johnson, I. Papakonstantinou et al.  2007 
Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant 
Parkinson's disease: identification of two novel LRRK2 variants. Eur.J.Neurol. 14: 7-11. 
Yang, Y., I. Nishimura, Y. Imai, R. Takahashi, and B. Lu, 2003 Parkin suppresses dopaminergic neuron-
selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37: 911-924. 
Yavich, L., H. Tanila, S. Vepsalainen, and P. Jakala, 2004 Role of alpha-synuclein in presynaptic 
dopamine recruitment. J.Neurosci. 24: 11165-11170. 
Zabetian, C. P., C. M. Hutter, S. A. Factor, J. G. Nutt, D. S. Higgins et al.  2007 Association analysis of 
MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann.Neurol. 62: 137-144. 
Zabetian, C. P., C. M. Hutter, D. Yearout, A. N. Lopez, S. A. Factor et al.  2006a LRRK2 G2019S in 
families with Parkinson disease who originated from Europe and the Middle East: evidence of 
two distinct founding events beginning two millennia ago. Am.J.Hum.Genet. 79: 752-758. 
Zabetian, C. P., H. Morino, H. Ujike, M. Yamamoto, M. Oda et al.  2006b Identification and haplotype 
analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67: 697-699. 
Zarranz, J. J., J. Alegre, J. C. Gomez-Esteban, E. Lezcano, R. Ros et al.  2004 The new mutation, E46K, 
of alpha-synuclein causes Parkinson and Lewy body dementia. Ann.Neurol. 55: 164-173. 
Zhang, L., M. Shimoji, B. Thomas, D. J. Moore, S. W. Yu et al.  2005a Mitochondrial localization of the 
Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum.Mol.Genet. 14: 
2063-2073. 
Zhang, Y., J. Gao, K. K. Chung, H. Huang, V. L. Dawson et al.  2000 Parkin functions as an E2-
dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-
associated protein, CDCrel-1. Proc.Natl.Acad.Sci.U.S.A 97: 13354-13359. 
50 
 
Zhang, Z. X., and G. C. Roman, 1993 Worldwide occurrence of Parkinson's disease: an updated review. 
Neuroepidemiology 12: 195-208. 
Zhang, Z. X., G. C. Roman, Z. Hong, C. B. Wu, Q. M. Qu et al.  2005b Parkinson's disease in China: 
prevalence in Beijing, Xian, and Shanghai. Lancet 365: 595-597. 
Zimprich, A., S. Biskup, P. Leitner, P. Lichtner, M. Farrer et al.  2004 Mutations in LRRK2 cause 
autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607. 
 
 
URL reference list 
 
Diseases & Conditions (AllRefer.com): [http://health.allrefer.com/health/parkinsons-disease-substantia-
nigra-and-parkinsons-disease.html] date accessed: 08/10/2010  
 
HRM Assay Design and Analysis Booklet: [http://www.gene-quantification.de/hrm-protocol-cls.pdf] date 
accessed: 08/10/2010 
 
MRC-Holland: [http://www.mlpa.com] date accessed: 08/10/2010 
 
Parkinson’s disease Foundation: [http://www.pdf.org/en/symptoms] date accessed: 08/10/2010  
  
Parkinson’s disease Mutation Database: [http://grenada.lumc.nl/LOVD2/TPI/home.php] date accessed: 
11/10/2010 
 
PATCH™: [http://www.gene-regulation.com] date accessed: 08/10/2010 
 
Promega gene expression and reporter assays: [http://www.promega.com/pGL4] date accessed: 
08/10/2010 
 
Promega pGL4 reporter vectors: [http://www.promega.com/vectors/reporter_vectors.htm#b07] date 
accessed: 08/10/2010 
 
rVISTA: [http://genome.lbl.gov/vista/index.shtml] date accessed: 08/10/2010 
 
51 
 
Chapter 2 
 
 
Molecular analysis of the parkin gene in South African patients diagnosed 
with Parkinson's disease 
 
 
Soraya Bardiena, Rowena Keysera, Yandiswa Yakoa, Debbie Lombarda, b and Jonathan Carrb 
 
 
aDivision of Molecular Biology and Human Genetics, Faculty of Health Sciences, University of 
Stellenbosch, PO Box 19063, Tygerberg 7505, Cape Town, South Africa 
bDivision of Neurology, Faculty of Health Sciences, University of Stellenbosch, PO Box 19063, 
Tygerberg 7505, Cape Town, South Africa 
 
 
 
 
Published in: Parkinsonism and Related Disorders 2009 Feb;15(2):116-121 
 
 
 
 
Impact factor of journal: 2.406  
My contribution to this project: PCR and HRM analysis  
     Sequencing 
Analysis and interpretation of data 
     Assisted with writing of manuscript 
 
 
 
 
 
 
52 
 
Abstract 
 
Parkinson's disease (PD) is a common movement disorder which may arise from mutations in the 
parkin gene. To date, more than 100 different parkin mutations have been reported. The aim of 
the present study was to determine the frequency of point mutations and homozygous exon 
deletions in the parkin gene in a group of 91 South African patients diagnosed with PD. 
Mutation screening of the 12 exons of parkin was performed using single strand conformation 
polymorphism analysis and the high-resolution melt technique. Six different mutations were 
identified: four putative disease-causing missense heterozygous changes (H200Q, D280N, 
E310D and R402C) and two homozygous exon deletions (exons 3 and 4, and exon 4). The 
D280N and R402C variants have both previously been described but their pathogenic status has 
been equivocal. In the present study, the D280N variant was observed in three early-onset PD-
affected siblings and was not present in a 63-year-old unaffected sibling. This data provide 
further support for the pathogenicity of this variant which is situated within the first RING finger 
of the RING-box. None of the four missense variants were detected in over 100 ethnic-matched 
control chromosomes. We conclude that point mutations and homozygous exon deletions in the 
parkin gene are not a major cause of PD in the South African population. Further studies on this 
group of patients are needed to determine the contribution of heterozygous exon deletions and 
insertions in parkin. The present study is the first report on the molecular etiology of PD in 
South African patients. 
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Introduction 
 
Parkinson's disease (PD) is characterized clinically by the disabling motor manifestations of 
rigidity, resting tremor, bradykinesia, and postural instability, as well as ‘non-motor’ 
disturbances including cognitive and autonomic dysfunction. PD is estimated to affect roughly 
1–2% of the population over the age of 65 years [1]. 
 
To date, at least five genes have been shown to cause PD. These include the PARK2 (parkin), 
PINK1 and PARK7 genes for autosomal recessive PD, and the SNCA and the LRRK2 genes for 
autosomal dominant forms of the disorder [2]. An understanding of the roles of these genes has 
provided important insights into the molecular patho-physiology of PD and thereby, ultimately, 
may provide possible targets for therapeutic intervention. It is proposed that the various 
biological pathways or processes involved include mitochondrial dysfunction, oxidative damage, 
abnormal protein accumulation, and protein phosphorylation, which may all play a role in 
dopamine neuronal function and survival [3,4]. 
 
A large number of PD-causing mutations have been found in the parkin gene, which is situated 
on chromosome 6q25.2–27, and comprises 12 exons (OMIM 602544). Mutations in parkin were 
first identified about a decade ago in Japanese families with autosomal recessive juvenile 
Parkinsonism [5]. Since then, parkin mutations have been identified in diverse populations 
worldwide and include whole exon deletions/insertions, small deletions/insertions and point 
mutations (http://www.thepi.org/altruesite/files/parkinson/Mutations/new_page_1.html). More 
than 100 different parkin mutations have been identified that are spread throughout the gene and 
currently there do not appear to be any major mutation hot-spots or founder effects in this gene. 
 
Parkin mutations have been found not only in early-onset PD but also in the late-onset (>60 
years) forms of PD [6,7,8]. It has therefore been proposed that individuals with late-onset PD 
should not be excluded from parkin mutation screening, particularly if they have a positive 
family history of the disorder. To date, there have been only 12 reports of genetic studies of 
Parkinson's disease in African populations [9]. The aim of the present study was to investigate 
the frequency of point mutations in the parkin gene in a group of South African patients. The 
population studied included unique sub-populations comprising individuals of Afrikaner descent, 
and Xhosa-speaking individuals from the Southern African Nguni group. The Afrikaner group is 
known to have had a genetic bottleneck at the end of the 19th century, and a number of 
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uncommon diseases are found at high frequency in this group, such as variegate porphyria and 
familial hypercholesterolemia. 
 
Subjects and methods 
 
Study participants 
This study was approved by the Committee for Human Research at the University of 
Stellenbosch (Protocol number 2002/C059). The South African group of patients consisted of 91 
unrelated individuals and was recruited from the Movement Disorders clinic at Tygerberg 
Hospital in Cape Town as well as through the Parkinson's Association of South Africa. Patients 
recruited from Tygerberg Hospital were examined by a movement disorders specialist (JC) and 
met the UK Parkinson's Disease Society Brain Bank Research criteria for diagnosis of PD [10]. 
Patients recruited through the Parkinson's Association had been diagnosed with Parkinson's 
disease by other neurologists. Inclusion criteria for recruitment included early-onset and/or a 
family history of PD. 
 
The average age at onset of the PD patients was 51.8 years ± 28.0, ranging from 17 years to 77 
years. A total of 67% was male. The ethnic breakdown was as follows: 57.1% (52/91) 
Caucasian, 16.5% (15/91) Black, 2.2% (2/91) Indian and 24.2% (22/91) Mixed ancestry. South 
African Mixed ancestry can be defined as an admixture of the indigenous African populations 
(San, Khoikhoi or Bantu-speaking) and immigrants from Western Europe, Madagascar, the 
Malaysian archipelago and India [11]. Ethnic-matched control samples were recruited from 
healthy unrelated blood donors at a blood donation clinic of the South African Western Province 
Blood Transfusion Service. These controls were not clinically assessed for any signs of PD and a 
family history was not taken. A total of 33% and 38% of the Caucasian and Mixed ancestry 
control samples were male, respectively. As the samples had been ‘de-identified’, no information 
was available on the ages of these controls. 
 
Genetic analyses 
After obtaining written informed consent from the study participants, peripheral blood samples 
were collected and genomic DNA was extracted according to established methods [12]. 
Polymerase chain reaction (PCR) primers were designed using Primer3 software for each of the 
12 exons of the parkin gene [13]. Primer sequences are available from the authors on request. 
PCR reactions were performed in a 2720 Thermal Cycler (Applied Biosystems, USA). Each 50 
μl reaction contained 200 ng template DNA, 20 pmol of each primer, 75 μM dNTPs (Promega, 
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USA), 1.5 mM MgCl2, 1 × NH4 buffer (Bioline, UK), 5% formamide (for selected primer sets) 
and 0.5 U of BIOTAQ DNA polymerase (Bioline). PCR cycling conditions comprised of an 
initial denaturation step of 94 °C for 5 min, 30 cycles of denaturation at 94 °C for 30 s, annealing 
at different temperatures according to each primer set for 30 s, extension at 72 °C for 45 s, and a 
final extension step of 72 °C for 7 min. 
 
Homozygous whole exon deletions were identified by the consistent absence, in four separate 
attempts, of the PCR product using agarose gel analysis and multiplex PCR. Mutation screening 
was performed using either single strand conformation polymorphism (SSCP) analysis or the 
high-resolution melt (HRM) technique. For SSCP analysis, PCR-amplified products were 
electrophoresed overnight at 22 W at 4 °C in 8% and 10% mildly-denaturing polyacrylamide 
gels containing 5% glycerol and 15% urea. DNA bands were visualized by silver staining. For 
the HRM analysis, PCR was performed with incorporation of 1 μM of the fluorescent dye, 
SYTO9 (Invitrogen, USA), and thereafter the products underwent a melt from 75 °C to 95 °C 
rising by 0.1 °C each step on a Rotor-Gene 6000 analyzer (Corbett Life Science, Australia). 
HRM is a mutation scanning method that monitors the shift in fluorescence as a PCR product 
dissociates from double stranded DNA (dsDNA) to single stranded DNA with increasing 
temperature. Initially, the fluorescence is high but this diminishes as the dsDNA intercalating 
dye is released. The observed thermal denaturation profile is characteristic of a specific PCR 
product and is dependent on its sequence length, base and GC content (HRM Assay Design and 
Analysis Booklet; http://www.corbettlifescience.com/shared/Rotor-
Gene%206000/hrm_corprotocol.pdf). 
 
Samples exhibiting altered mobilities on SSCP gels or different thermal denaturation profiles on 
HRM were sequenced in order to characterize the sequence variation. Direct sequencing was 
performed using the BigDye Terminator Sequence Ready Reaction kit version 3.1 (Applied 
Biosystems) and analyzed on a 3130 × l Genetic Analyzer (Applied Biosystems). BioEdit 
version 7.0.1 software was used for the analysis of the sequencing electropherograms [14]. The 
frequency of selected sequence variants was determined in ethnically-matched control 
chromosomes using either HRM analysis or by digestion of the PCR product with an appropriate 
restriction endonuclease. 
 
All sequence variations detected were named according to the nomenclature proposed by den 
Dunnen and Antonarakis [15] (http://www.hgvs.org/mutnomen/). The genomic sequence for 
parkin was obtained from NCBI's GenBank using accession number NT_007422. 
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Results 
 
In the present study, six sequence variants were identified in a group of 91 South African 
patients diagnosed with PD (Table 1). Two novel heterozygous variants (H200Q and E310D) 
were identified and were absent in over 100 control chromosomes. Four of the six variants 
identified were heterozygous point mutations and two were homozygous whole exon deletions. 
 
In the case of the four heterozygous missense variants, only the individual who harbored the 
D280N variant had a confirmed family history of early-onset PD. This variant was also present 
in two of the proband's PD-affected siblings (AAO 45 years and 47 years), and not in an 
unaffected 63-year-old sibling. The homozygous deletion of exon 4 was detected in two affected 
siblings and none of the unaffected family members. The deletion encompassing exons 3 and 4 
was found in only one individual who had no family history of the disease. 
 
Using the SSCP and HRM techniques, a number of different polymorphisms were identified in 
this study that are found spread throughout the gene (Table 2). This illustrates the efficacy of our 
mutation screening techniques and how highly polymorphic the parkin gene is. HRM was able to 
detect all the sequence variants previously identified by SSCP analysis. Some of the common 
variants detected include S167N, M192L and R334C which have previously been recorded as 
pathogenic mutations (http://www.thepi.org/altruesite/files/parkinson/Mutations 
/new_page_1.html). Most of these polymorphisms have previously been described but we have 
also detected novel changes including the Q34R, IVS2 + 10C > T and three variants in the 3′-
UTR (*16G > A, *94A > G and *103C > T). 
 
The D280N (Fig. 1) and H200Q variants were detected using the HRM technique. This is a 
relatively new technique that has been used mainly to detect known sequence variations. In the 
present study, we have used it to screen for known and novel disease-causing mutations in a 
group of South African patients who have previously not been investigated at a molecular level. 
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Table 1 Mutations identified in the parkin gene in the South African group of PD patients.  
 
 Exon Variant No. of 
patients 
Patient 
ethnicity* 
AAO (yrs) 
& 
phenotype 
Family 
history of PD 
In ethnic-matched 
control chromosomes 
 
Protein domain Previously 
reported 
Heterozygous 
point mutations 
5 p.H200Q 
(CAC>CAG) 
 
1 Caucasian 
(65.79)  
 
55 yrs 
Typical PD 
with motor 
fluctuations 
yes- 
probable 
0/106  
(HRM) 
In the unique 
parkin domain 
No 
 7 p.D280N 
(GAC>AAC) 
3 
affected 
siblings 
Indian 
(68.10)  
 
37 yrs 
45 yrs 
47 yrs 
Typical PD 
with motor 
fluctuations 
yes 0/118  
(HRM) 
In RING1 domain Oliveira et al. [7]; 
Lücking et al. 
[22];  
 8 p.E310D 
(GAG>GAC) 
 
 
1 Caucasian 
(Afrikaner) 
(51.70)  
 
42 yrs 
Typical PD 
with motor 
fluctuations 
no 0/110  
(MvaI digest) 
 
Between the 
RING1 and IBR 
domains 
No 
 11 p.R402C 
(CGT>TGT) 
 
1 Caucasian 
(Afrikaner) 
(42.06)  
 
37 yrs 
Typical PD 
with motor 
fluctuations 
no 0/100  
(SSCP) 
Between the IBR 
and RING2 
domains 
Bertoli-Avella et 
al. [19]; Schlitter 
et al. [20]; 
Chaudhary et al. 
[21] 
          
Homozygous 
deletions 
4  2 
affected 
siblings 
Caucasian  
(Afrikaner) 
(33.66)  
27 yrs (both 
siblings) 
Prominent 
dystonia 
yes ND  yes 
 3 & 4  1 Mixed 
Ancestry 
(53.44)  
27 yrs 
Foot 
dystonia, 
mild 
symptoms 
no ND  yes 
*  patient sample number in brackets; AAO, age at onset; ND, not determined 
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     Table 2 Parkin polymorphisms identified in the present study in both PD patients and controls.  
 
 Position in gene   Sequence variant Ethnicity of patients 
with variant 
Frequency in 
controls (%) 
promoter Exon Intron 3’ UTR    
Core promoter region    -227 A>G Caucasian & Mixed 
ancestry 
ND 
Core promoter region    -258 T>G Caucasian, Mixed 
ancestry & Black 
14.0 (Caucasian) 
18.0 (Mixed) 
 Exon 2   Q34R (CAG>CGG) Mixed ancestry 3.2 
 Exon 2   P37P (CCG>CCA) Mixed ancestry & 
Black 
ND 
  Intron 2  IVS2 +10C>T Mixed ancestry 0 
  Intron 2  IVS2 +25T>C Mixed ancestry & 
Black 
ND 
  Intron 2  IVS2 +35G>A Caucasian & Mixed 
ancestry 
ND 
  Intron 3  IVS3 -20T>C Caucasian ND 
 Exon 4   S167N (AGC>AAC) Mixed ancestry 7.9 
 Exon 5   M192L (ATG>CTG) Mixed ancestry 6.7 
 Exon 6   C238C (TGC>TGT) Black ND 
 Exon 7   L261L (TTA>TTG) Black ND 
  Intron 7  IVS7 -35G>A  Caucasian & Black ND 
  Intron 7  IVS7 -68C>G Caucasian ND 
  Intron 8  IVS8 +43A>G Mixed ancestry & 
Black 
ND 
  Intron 8  IVS8 +48C>T  Caucasian & Black ND 
  Intron 8  IVS8 -21_-17del Mixed ancestry ND 
 Exon 9   R334C (CGC>TGC) Mixed ancestry 2.0 
 Exon 10   V380L (GTA>CTA) Caucasian, Mixed 
ancestry & Black 
27.2 (Caucasian) 
 Exon 11   D394N (GAT>AAT) Caucasian, Mixed 
ancestry, Black & 
Indian 
6.0 (Caucasian) 
 Exon 11   R402R (CGT>CGC) Mixed ancestry & 
Black 
ND 
   3’ UTR *16G >A  Mixed ancestry ND 
   3’ UTR *94A>G   Caucasian ND 
   3’ UTR *103C>T  Black ND 
ND, not determined; Non-synonymous sequence variants are indicated in bold text. 
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Figure 1 High-resolution melt analysis: difference plot exhibiting the heterozygous D280N variant in 
exon 7 that could easily be differentiated from that of wild type samples. Normalized fluorescence 
subtracted from a reference sample is plotted on the Y-axis and temperature in degrees Celsius is plotted 
on the X-axis. 
 
Discussion 
 
To date there have been a very limited number of studies on PD in African populations, 
particularly genetic studies [9], whereas, by comparison, European and American PD 
populations have been extensively investigated. This is the first report on the molecular etiology 
of PD in a South African group of patients. Only six sequence variants (four heterozygous 
missense variants and two homozygous deletions) were detected in the parkin gene in 91 
individuals. No mutations were identified in any of the Black South African patients included in 
our study. PD in Black individuals has been reported to be atypical with a rigid-akinetic variant 
being more common [16] and it is therefore plausible that Black patients may harbor mutations 
in novel PD genes. 
 
In the present study, two novel putative pathogenic variants were identified. One is the H200Q 
variant in exon 5 which was identified in one PD individual with a probable family history of the 
disorder. The pathogenicity of this sequence variant is unknown but the variant was not found in 
106 control chromosomes and is situated in the unique parkin domain, in which other PD-
causing mutations have been reported [17,18]. Similarly, the novel E310D variant was observed 
only in one PD patient but not in 110 control chromosomes. This variant was also observed in 
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the patient's 51-year-old brother who, at this stage, does not exhibit any signs of PD. The E310D 
variant is situated between the RING1 and IBR domains of parkin. 
 
The R402C and D280N variants have both previously been described although their 
pathogenicity has been questioned. The R402C variant was previously observed in one patient of 
unknown ethnicity (AAO = 35 years) [19], one German PD patient (AAO = 65 years) [20] and 
one late-onset Indian patient [21]. The present study is the fourth report of the R402C variant in 
a PD patient with apparently no family history of PD. In all four patients harboring R402C, the 
variant was found in the heterozygous state and a second mutation was not found. It is therefore 
interesting to speculate that either the second mutation in all these cases has yet to be found or 
that the R402C variant on its own is sufficient to cause the disorder. The fact that it is situated 
between the IBR domain and the second RING finger, and that it affects an evolutionarily 
conserved amino acid suggests that it may be pathogenic. The D280N variant was previously 
reported in one family with early-onset PD (ancestry unknown) [22] and one Caucasian PD 
patient (AAO = 51 years) [7]. In the former study, the pathogenicity of D280N was questioned 
as both patients harboring this variant also had other parkin variants and in the latter study, it 
was speculated that this variant in the heterozygous state could act as a susceptibility allele for 
the development of late-onset PD. D280N is positioned within the first RING finger domain of 
parkin and it has been shown that both RING finger motifs are necessary for binding to the E2 
ubiquitin-conjugating enzyme, UbcH7, another component of the ubiquitin proteasome system 
[23]. Further support for the pathogenicity of this variant is that in the present study it was 
observed in three PD-affected siblings and not in an unaffected family member or in 118 control 
chromosomes. It is also possible, however, that the four heterozygous parkin variants identified 
in the present study are rare non-pathogenic polymorphisms [24]. 
 
It can be concluded that point mutations or homozygous exon deletions in the parkin gene are 
not a major cause of PD in these South African patients. Importantly, the lack of mutations 
identified is not due to the mutation screening method since a number of non-pathogenic 
sequence variants were identified in this study (Table 2). Therefore, either heterozygous parkin 
deletions or mutations in other genes account for the disorder in these South African PD patients. 
In the present study, we show that high-resolution melt curve analysis can be used successfully 
to screen for unknown sequence variants in the parkin gene. This technique is sufficiently 
sensitive to detect 1-bp differences in PCR-amplified products and is less time and labor-
intensive than other methods such as SSCP analysis. The novel variant identified in intron 2, 
IVS2 + 10C > T, was detected in one PD patient and was not present in 100 control 
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chromosomes. This variant could possibly have an effect on splicing of the gene but further 
studies are necessary to investigate this. Also, four other novel heterozygous variants, Q34R, 
*16G > A, *94A > G and *103C > T were identified and may prove useful for genetic 
association studies involving the parkin gene. Furthermore, the S167N, M192L and R334C 
variants have all been previously reported and have been speculated to be disease-causing but the 
present study shows that the variants are common in controls and are therefore unlikely to be 
associated with PD. 
 
More studies are needed to determine whether the molecular etiology of PD across diverse 
populations is accounted for by the handful of the same PD-causative genes. In this regard, South 
Africa's unique population, particularly the Black and the Mixed ancestry sub-populations, have 
the potential of harboring either novel mutations or novel PD-causative genes. 
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Abstract   
 
Genomic rearrangements (exon dosage) are common mutations reported in Parkinson's disease 
(PD) patients. In the present study, we aimed to investigate the prevalence of genomic 
rearrangements in 88 South African patients with predominantly early-onset PD (age-at-onset 
≤50 years). The multiplex ligation-dependent probe amplification method was used to detect 
exon dosage changes. Two commercially available probe kits, SALSA P051 and P052, were 
used and together the kits consisted of probes for exons of α-synuclein, parkin, PINK1, DJ-1, 
LRRK2, UCH-L1, ATP13A2, LPA, TNFRSF9, CAV2, CAV1, GCH1, and two-point mutations. 
We identified exonic rearrangements in parkin and α-synuclein in 8% of South African patients 
from different ethnic groups. One patient had a whole-gene triplication of α-synuclein; 
representing only the fourth family with this mutation reported to date. We found six patients 
with parkin mutations who had either heterozygous duplications and deletions, or homozygous 
deletions. A false positive result of an exonic deletion detected in one patient turned out to be 
homozygous point mutation (Y258X) in PINK1. No exonic rearrangements were found in four 
of the PD genes; LRRK2, PINK1, DJ-1, and ATP13A2. Mutations in parkin were the 
predominant genetic cause; however, the frequency of exon dosage in our study group is low 
compared with previous studies. This indicates the possible involvement of other as yet 
unidentified PD genes in the development of the disease in the South African population. 
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Introduction 
 
Parkinson's disease (PD; OMIM 168600) is a debilitating neurodegenerative disorder 
characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc), and prominent involvement of cognition and the autonomic system. To date, genetic 
defects in six genes, namely, α-synuclein (SNCA), parkin (PARK2), PTEN-induced putative 
kinase 1 (PINK1), oncogene DJ-1 (DJ-1), leucine-rich repeat kinase 2 (LRRK2), and ATPase 
type 13A2 (ATP13A2), have been conclusively implicated in the pathogenesis of PD [1]. 
Monogenic forms of PD are thought to represent less than 10% of cases in most populations. PD 
occurs worldwide, but the prevalence and incidence appear to exhibit substantial geographic and 
ethnic variability [2], with generally lower rates reported in Africa. 
 
Whole exon insertions or deletions (i.e., exon dosage), primarily in parkin, are a common 
mutation in PD patients, and have been identified in autosomal recessive and sporadic forms of 
the disease [3, 4]. Exonic deletions in parkin were first identified in Japanese families with 
autosomal recessive juvenile parkinsonism [5]. To date, more than 100 different mutations have 
been identified in parkin including point mutations and exonic rearrangements such as 
duplications and deletions [6–8], which can present in either homozygous or compound 
heterozygous states. Whole-gene multiplications (duplications or triplications) have been 
identified only in α-synuclein and lead to over-expression of the protein. It was found that 
individuals with duplications have a classical PD phenotype, whereas those with triplications 
have earlier onset, faster disease progression, marked dementia and frequent dysautonomia [9–
12]. Genomic rearrangements have also previously been reported for PINK1 [13] and DJ-1 [14] 
but have not been found in LRRK2 or ATP13A2. Due to the fact that mutation screening methods 
such as high resolution melt or DNA sequencing cannot detect exon dosage, the possibility exists 
that important disease causing mutations are missed using these traditional methods. It is 
therefore important to include exon dosage studies when conducting PD mutation screening in 
order to detect all possible pathogenic mutations. 
 
In the present study, we conducted an exon dosage analysis using the multiplex ligation-
dependent probe amplification (MLPA) (http://www.mrc-holland.com) method, in order to 
determine the prevalence of genomic rearrangements in the known PD genes in patients from the 
various South African sub-population groups. This method has been used successfully 
previously by other groups to identify exon dosage [15, 16]. MLPA is a rapid method for 
detection of exonic deletions, insertions, and multiplications and can also detect specific 
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recurrent point mutations. An advantage of MLPA is that it is possible to perform a multiplex 
polymerase chain reaction (PCR) reaction in which 33 exons (using kit P051) and 31 exons 
(using kit P052) of PD-causing genes are screened simultaneously using a single PCR primer-
pair. MLPA is cost effective, technically simple, reproducible, and large numbers of samples can 
be tested simultaneously, and it was therefore made use of in the present study. 
 
Materials and methods 
 
Study participants 
The study was approved by the Committee for Human Research at the University of 
Stellenbosch, South Africa (Protocol number 2002/C059). For the present study, 88 unrelated PD 
patients, from all South African ethnic groups, were recruited from the Movement Disorders 
clinic at Tygerberg Hospital as well as from the Parkinson's Association of South Africa. The 
patients recruited from Tygerberg Hospital had been examined by a movement disorder 
specialist (JC). The patients met the UK Parkinson's Disease Society Brain Bank Research 
criteria for diagnosis of PD [17]. The majority of patients had an apparently sporadic form of the 
disease, but in families with a positive family history (34.1%) both autosomal recessive and 
autosomal dominant patterns of inheritance were present. Inclusion criteria for recruitment of 
patients were early onset and/or a positive family history of PD. 
 
The ethnic breakdown was as follows: 34.1% South African Afrikaner, 25% Caucasian, 23.9% 
mixed ancestry (defined in 18), 13.6% Black, and 3.4% Indian. The average age at onset (AAO) 
of the study group was 50 years and ranged from 17 to 77 years. The percentage of males in our 
study group was 64.8%. 
 
MLPA assay 
For each study participant, a blood sample was collected for genetic analysis and genomic DNA 
was extracted using established methods. The MLPA method was made use of in order to detect 
exon dosage changes, caused by genomic rearrangements, of the known PD genes. Two 
commercially available probe kits, SALSA P051-B1 and P052-B1 Parkinson MLPA kits (MRC 
Holland, Amsterdam, The Netherlands; http://www.mlpa.com) were used for this assay. 
Together, the kits consisted of probes for all exons of α-synuclein, parkin, and PINK1, and 
specific exons of DJ-1 (exons 1,3,5,7); LRRK2 (exons 1,2,10,15,27,41,49); UCH-L1 (exons 
1,4,5,9); ATP13A2 (exons 2,9); LPA (exon 31); TNFRSF9 (exon 2); CAV2 (exon 3); CAV1 (exon 
3); GCH1 (exons 1,2,3,5,6) and two-point mutations (A30P in α-synuclein and G2019S in 
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LRRK2). The probes were distributed between two sets of probe mixes. All exons of parkin were 
included in both kits, and the probe sequences of the same exon were different between the two 
kits. The assay was performed for all the 88 samples for both kits, according to the 
manufacturer's protocol. 
 
Initially, 150 ng of genomic DNA was denatured at 98ºC for 5 min and then allowed to hybridize 
to the MLPA probe set P051 and P052 (in independent reactions for each probe set). Thereafter, 
ligation was performed at 54ºC for 15 min using a Ligase-65 enzyme. PCR reactions were 
performed in a 2720 Thermal Cycler (Applied Biosystems, Foster City, USA) for 33 cycles 
(95ºC for 30 s; 60ºC for 30 s; 72ºC for 1 min) and a final 20 min step at 72ºC. The primers used 
for the PCR reactions were the SALSA PCR forward primer (labeled) 5′-FAM-GGG TTC CCT 
AAG GGT TGG A-3′ and SALSA PCR reverse primer (unlabeled) 5′-GTG CCA GCA AGA 
TCC AAT CTA GA-3′.The PCR fragments were analyzed on a 3130x1 Genetic Analyzer 
(Applied Biosystems) with GeneScan™-500 LIZ™ Size Standard (Applied Biosystems) and 
GeneMapper software v3.7 (Applied Biosystems). The manufacturer's recommendations were 
followed for the electrophoresis and analysis of the fragments on the Genetic Analyzer. The size 
standard made it possible to identify the peaks corresponding to specific exons. Results were first 
visually analyzed to discard failed samples. Thereafter, peak height results were exported from 
GeneMapper to a Microsoft office Excel spreadsheet for copy number calculations. 
 
The results were analyzed as follows. The relative peak height (RPH) of each exon was obtained 
by dividing the single peak height by the sum of peak heights of all the internal control probes. A 
ratio was then generated by comparing each RPH to the mean value of the corresponding RPHs 
from a reference wild-type sample. Ratios between 0.7–1.3 were considered to be normal 
(sample contains no exon rearrangements); a heterozygous deletion was expected at a ratio 
between 0.3–0.6, a heterozygous duplication between 1.4–1.6, and a triplication at a ratio of 
≥1.7. Absence of a peak would indicate either a possible point mutation at that probe recognition 
site or a homozygous deletion (ratio 0.0). Possible mutation positive results were repeated for 
confirmation. 
 
Verification using quantitative PCR 
Possible exonic deletions or multiplications detected by the MLPA assay were verified by means 
of quantitative PCR (qPCR) on a LightCycler 1.5 (Roche Diagnostics, Mannheim, Germany) 
using the LightCycler® FastStart DNA MasterPLUS SYBR Green I kit (Roche Diagnostics). 
qPCR was performed in triplicate for each sample. The reagents used for amplification in 10 µl 
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reactions were: 2 µl Hybridization FastStart Mix (Roche Diagnostics), 0.5 µM of each primer 
and 25 ng of genomic DNA. The PCR conditions were: 95ºC for 10 min, 95ºC for 10 s, 55ºC for 
10 s, 72ºC for 15 s (45 cycles). For this method, the beta globin gene (HBB) served as the 
internal standard (i.e., reference gene) for subsequent delta-delta-CT (cycle threshold) 
calculations. The PD gene and HBB gene ratios generated by delta-delta-CT were within the 
same ranges to that produced for the MLPA assay. 
 
Results 
 
In the present study, seven out of 88 (8%) South African PD affected probands were found to 
have genomic rearrangements (Table 1). Six patients had exonic deletions or duplications in the 
parkin gene and one patient had a whole-gene triplication of α-synuclein. One patient was found 
to have a point mutation in the PINK1 gene. 
 
Parkin mutations 
In one male patient of Black ethnicity, a heterozygous duplication of exon 2 and a heterozygous 
deletion of exon 9 were detected in parkin using the MLPA method (Fig. 1a). The same 
mutations were observed in an affected female sibling. Both siblings had an AAO of <50 years 
and presented with typical tremor predominant PD. 
 
A heterozygous duplication of parkin exon 2 was found in a female patient of Afrikaner ethnicity 
who had no family history of the disease and an AAO of 56 years. The clinical features in this 
patient were of tremor predominant PD with a typical progressive course over 19 years. This 
patient had previously been screened for point mutations in parkin and no mutations had been 
identified [18]. 
 
One male patient of mixed ancestry had heterozygous duplications of parkin exons 2 and 3. This 
patient was diagnosed with atypical PD (bilateral, symmetrical Parkinsonism) and schizophrenia 
and was treated with clozapine 400 mg daily. This individual had no family history of the disease 
and had an AAO of 50 years. At this stage it is uncertain whether this individual has the 
duplication of exons 2 and 3 in cis or trans as all three of his unaffected siblings have the same 
duplication of the two exons. Further haplotype studies using microsatellites and single 
nucleotide polymorphisms at the parkin locus are needed to resolve this matter. 
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                Table 1 Mutations identified using MLPA kits P051 and P052 
 
Gene Zygosity Mutation AAO 
(years) 
Family 
history 
Ethnicity a Present in affected 
family member(s) 
Parkin Heterozygous Duplication of exon 2 + deletion 
of exon 9 
45 + Black (37.12) One sibling (37.13) 
Heterozygous Duplication of exon 2 56 - Caucasian (Afrikaner) (55.54) None 
Heterozygous  Duplication of exon 2 and exon 3 50 - Mixed ancestry (68.22) None 
Heterozygous Deletion of exon 3 25 + Caucasian (77.60) None 
Homozygous b  Deletion of exon 3 and exon 4 27 - Mixed ancestry (53.44) None 
Homozygous b  Deletion of exon 4 27 + Caucasian (Afrikaner) (56.45) One sibling (56.43) 
α-synuclein  Triplication 46 + Caucasian (French-Italian) (42.35) None 
PINK1 Homozygous Y258X 37 + Indian (68.10) Two siblings  
(71.93, 71.95) 
                    AAO = age at onset 
                              a = patient sample number shown in brackets 
                    b = previously reported in Bardien et al., 2009[18]  
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Fig. 1 a MLPA analysis results of an individual with a heterozygous duplication of parkin exon 2 
(ratioԜ=Ԝ1.5) and heterozygous deletion of parkin exon 9 (ratioԜ=Ԝ0.6). Arrows indicate the probes that were 
affected by the genomic rearrangements in the two exons of parkin. The vertical axis represents the ratios 
calculated, and the horizontal axis represents the different probes within the SALSA P051 Parkinson 
MLPA kit. b MLPA results of an individual with a whole-gene triplication of α-synuclein. Arrows 
indicate the probe amplification products of the α-synuclein exons that were affected by triplication of the 
gene: exon 1 (ratioԜ=Ԝ2), exon 3 (ratioԜ=Ԝ1.9), exon 4 (ratioԜ=Ԝ1.8), exon 5 (ratioԜ=Ԝ2), and exon 6 
(ratioԜ=Ԝ1.7). c MLPA results of an individual with an Y258X point mutation in PINK1 exon 3 which 
prevented binding of the probe for this exon (ratioԜ=Ԝ0.0) 
 
One male Caucasian patient had a heterozygous deletion of parkin exon 3, with a possible 
positive family history and an AAO of 25 years. The patient presented with gradual onset of 
dystonia in the legs, followed by onset of mild features of PD 9 years later. In this patient also, 
only one parkin mutation was identified as a screen for point mutations in parkin [18] did not 
yield any mutations. 
 
Furthermore, MLPA detected the previously reported homozygous deletions of parkin exons 3 
and 4 in one female patient of mixed ancestry with an AAO of 27 years and no family history of 
the disease [18]. The previously reported homozygous deletion of parkin exon 4 in two siblings 
of Afrikaner ethnicity was also detected by this method. Both individuals had an AAO of 27 
years and an autosomal recessive family history [18]. 
 
α-Synuclein mutations 
Triplication of the entire α-synuclein gene (Fig. 1b) was identified in one patient of French-
Italian ethnicity with an AAO of 46 years. The patient presented initially with typical features of 
PD, with levodopa responsiveness. He later developed dementia, associated with psychosis, and 
autonomic failure. He died at the age of 55 years with duration of illness of about 9 years. This 
individual had a family history of possibly autosomal dominant PD and had a PD-affected sister 
who had died at the age of 48 years. The sister had not been genetically tested. 
 
PINK1 mutations 
Using MLPA, we detected an apparent homozygous deletion of PINK1 exon 3 in one Indian 
female patient with a positive family history of the disease and an AAO of 37 years (Fig. 1c). 
The qPCR verification method did not, however, confirm the presence of the deletion of PINK1 
exon 3. Subsequent DNA sequencing revealed the presence of a homozygous C>A point 
mutation (Y258X; Fig. 2) at the target site for the PINK1 exon 3 MLPA probe. When assessed, 
the patient had had symptoms for 30 years; her disease had started asymmetrically, and remained 
so. Her symptoms were relatively well controlled on 500 mg levodopa daily. She reported 
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recently some difficulty with memory for recent events. This mutation was also observed in two 
affected siblings in a homozygous state and in two unaffected family members in a heterozygous 
state. The AAO of the other two affected family members were 45 and 47 years, respectively. 
The mutation leads to a premature stop codon which results in a significantly truncated PINK1 
protein. The site of the mutation is within a highly conserved region of the gene and 13 amino 
acids upstream from the functional serine/threonine kinase domain of PINK1 (Fig. 3). 
 
Wild-type
Homozygous Y258X
C>A
 
Fig. 2 Chromatogram illustrating the Y258X point mutation in PINK1 exon 3 that was shown to co-
segregate with PD in an Indian family 
 
 
 
Human   NISAGSSSEAILNTMSQELVPASRVALAGEYGAVTYRKSKRGPKQLAPHPNIIRVLRAFT 282 
Chimp   NISAGSSSEAILNTMSQELVPASRVALAGEYGAVTYRKSKRGPKQLAPHPNIIRVLRAFT 360 
Mouse   NISAGSSSEAILSKMSQELVPASRVALAGEYGAVTYRRSRDGPKQLAPHPNIIRVFRAFT 281 
Rat     NISAGSSSEAILSKMSQELVPASRMALDGEYGAVTYRRSRDGPKQLAPHPNIIRVFRAFT 281 
        ************..**********:** *********:*: **************:**** 
  
Fig. 3 Sequence alignment (using ClustalW) of PINK1 amino acid sequences of human (NP_115785.1), 
chimp (XP_001164912.1), mouse (NP_081156.2), and rat (XP_216565.2). The box indicates the position 
of the Y258X variant that leads to a premature stop codon. The serine/threonine kinase domain is shaded 
in grey. Identical amino acids are indicated by asterisks 
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The results for parkin and α-synuclein listed in Table 1 were detected by both MLPA kits and 
verified by qPCR on a LightCycler (Roche). Furthermore, in two patients, possible heterozygous 
deletions of parkin exon 5 were detected by kit P051 in two independent experiments. These 
deletions were, however, not detected with kit P052 and were also not confirmed by qPCR. DNA 
sequencing revealed that the common parkin polymorphism M192L [18] disrupts the ligation 
step in MLPA for kit P051 and therefore appears as a false deletion of exon 5 in the subsequent 
MLPA analysis. Kit P052 is not affected by the M192L variant as the probes are located at a 
different position. 
 
Discussion 
 
We report the results of an exon dosage study which was conducted on PD patients from all 
South African ethnic groups. In the present study, it was found that the frequencies of parkin and 
α-synuclein genomic rearrangements in a group of 88 patients were 6.8% and 1.1%, respectively. 
Genomic rearrangements were not restricted to any specific ethnic group. No genomic 
rearrangements were found in four of the major PD genes, namely, LRRK2, PINK1, DJ-1, and 
ATP13A2. 
 
Parkin presented with the highest proportion of genomic rearrangements in our study group 
compared with the other known PD genes. Parkin is predominantly involved in early onset forms 
of PD, which possibly explains the higher frequency of mutations detected in our study group. 
Approximately 50% of all known parkin mutations are thought to fall in the category of genomic 
rearrangements [19]. These mutations are proposed to result in the absence of functional proteins 
because of frame shift or alterations of splicing [4]. Exonic rearrangements often occur due to 
recombination events between repetitive elements. The size, relative orientation, distance 
between copies, and shared percentage identities of these repetitive elements can cause the 
genomic region to be more susceptible to rearrangements. These factors can also affect the type 
of rearrangement that occurs [20–23]. It is suggested that the high frequency of exonic 
rearrangement mutations in parkin is due to its large introns and the presence of numerous 
repetitive elements that lead to instability. 
 
The frequency of exonic rearrangements detected in the present study in parkin, however, is 
lower than that reported in previous studies in which up to 50% of the patients were found to 
have these mutations [19, 24]. No parkin mutations (point or exonic rearrangements) were 
detected in one of our patients who has a juvenile age at onset of 17 years. In two patients, only 
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single heterozygous exonic rearrangements were detected in parkin and no point mutations were 
found. It has been suggested that individuals heterozygous for parkin deletion mutations might 
suffer from haploinsufficiency because of reduced expression and enzymatic activity of the 
protein [25]. This might confer a greater risk for developing PD. It should be cautioned however 
that since parkin heterozygous deletions have been found in controls [26] the pathogenicity of 
these variants is not certain. 
 
The MLPA method identified a triplication of α-synuclein in an individual of French-Italian 
ethnicity with a positive family history. Of note, this family is only the 4th world wide to be 
reported to have an α-synuclein triplication. Previously, triplications have been reported in an 
English-German family (Iowan kindred) [12], a Swedish-American family (Lister kindred) [27], 
and recently a French family [28]. According to unconfirmed information, the other affected 
individuals in this family in previous generations had later ages at onset and less severe 
phenotypes than the proband and his sibling. This points to a possible duplication to triplication 
event and it would be interesting to determine whether our family is related to either the Lister 
family, in which this phenomenon had occurred, or the French triplication family. Duplication 
mutations in α-synuclein have been reported in nine families. The mechanism underlying α-
synuclein multiplication is currently unknown. The severity of the clinical phenotype is 
dependent on the level of exon dosage; duplication mutations are associated with typical, late-
onset PD [9, 10] whereas, triplication mutations lead to a more severe form of early-onset PD 
with autonomic dysfunction and subsequent dementia [12, 27]. This was also observed in our 
patient. Therefore, the higher the expression levels of α-synuclein, the more malignant the PD 
phenotype. This suggests that there is more widespread neurodegeneration in patients with 
higher levels of α-synuclein expression. α-Synuclein is suggested to play a role in synaptic 
vesicle recycling, as well as storage and compartmentalization of neurotransmitters [29, 30]. 
 
In the present study, a point mutation (Y258X) in PINK1 was found to cosegregate with PD in a 
family of Indian ethnicity. This mutation has previously been reported in an individual of Asian 
ethnicity (either Chinese, Malay, or Indian) with sporadic early-onset PD who presented with 
restless legs syndrome, resting tremors and bradykinesia [31]. The authors speculated that the 
restless leg syndrome in this patient was directly related to the specific mutation, however, none 
of the patients in our Y258X-positive family presented with restless legs syndrome. The Y258X 
mutation causes a significant truncation of the PINK1 protein, which results in loss of the 
functional serine/threonine kinase domain. PINK1 is a protein kinase that is localized to the 
mitochondrion and is ubiquitously expressed in the human brain [32]. Recent studies aimed at 
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elucidating the function of PINK1, have found that it has neuroprotective properties against 
mitochondrial dysfunction and proteasomally-induced apoptosis [33–36]. PINK1 phosphorylates 
specific mitochondrial proteins, and in so doing modulates their functions. Mutations in PINK1 
are the second most common cause after parkin of autosomal recessive early-onset PD, and it 
has been shown that the frequency of PINK1 mutations ranges from 1% to 8% in patients of 
different ethnicities [37–39]. Furthermore, some PINK1 mutation carriers are known to exhibit 
psychiatric symptoms [40], but none of the Y258X-positive individuals in the present study have 
psychiatric problems. 
 
The present study validates the importance of including exon dosage studies as part of mutation 
screening for PD-causing mutations. The MLPA method proved effective in detecting a variety 
of genomic rearrangements in our study group as well as a point mutation. However, our results 
show that it is necessary to verify all MLPA positive results with another method as false 
positive results could arise due to point mutations located in the MLPA probe recognition site 
(e.g., Y258X in PINK1). Furthermore, we found that, parkin exon 5 in kit P051 was prone to 
false positive (deletion) results as a result of the M192L polymorphism. 
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Abstract   
 
Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most significant genetic 
cause of Parkinson’s disease (PD). The exact function of LRRK2 is currently unknown but the 
presence of multiple protein interaction domains including WD40 and ankyrin indicates that it 
may act a scaffold for assembly of a multi-protein signaling complex. The G2019S mutation in 
LRRK2 represents the most clinically relevant PD-causing mutation and has been found in both 
familial and sporadic forms of the disorder. This mutation is situated in the highly conserved 
kinase MAPKKK domain, and has been found in up to 40% of PD patients from North African 
Arabic, 30% of Ashkenazi Jewish and ~10% of Portuguese and Spanish populations. Although 
extensively investigated in numerous European and North American populations, studies on the 
frequency of G2019S in African countries have been rare. The present study is the first on the 
South African population. High-resolution melt analysis was used to identify the G2019S 
mutation and it was found in 2% (4/205) of the patients studied. G2019S was not found in any of 
the Black PD patients screened. In all four G2019S-positive probands the mutation was shown to 
be present on the common haplotype referred to as haplotype 1. This reveals that the four South 
African G2019S-positive probands (three Caucasian and one of mixed ancestry) share a common 
ancestor with the other haplotype 1-associated families reported worldwide. 
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Introduction 
 
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder affecting roughly 
1–2% of the population aged 65 years or older (de Rijk et al. 2000). The lifetime risk of 
developing PD has been calculated to be 2.0% for men and 1.3% for women (Elbaz et al. 2002). 
PD typically occurs in individuals over the age of 60 years but approximately 15% of PD occurs 
in younger individuals. In this young-onset form of the disorder, disease-causing mutations have 
been identified in a number of genes. One of these, the leucine-rich repeat kinase 2 gene 
(LRRK2) has been implicated in both autosomal dominant and sporadic forms of PD, and is 
thought to be the most common genetic cause of PD identified to date (Giasson and Van Deerlin 
2008; Correia et al. 2010). 
 
LRRK2 encodes a protein consisting of multiple domains including Roc (Ras of complex 
proteins), COR (C-terminal of Roc), MAPKKK (mitogen-activated protein kinase) and WD40 
(Bosgraaf and Van Haastert 2003; Marin et al. 2008). Although the exact function of LRRK2 is 
currently unknown the presence of the Roc and MAPKKK domains suggests a role in the 
regulation of signal transduction cascades (Guo et al. 2006). 
 
The G2019S mutation in the MAPKKK domain likely increases the kinase activity of the protein 
(West et al. 2005). This mutation is present on only a limited number of haplotypes (Lesage and 
Brice 2009), of which the commonest, referred to as haplotype 1, is thought to have originated in 
the Ashkenazi Jewish population (Lesage et al. 2010). Two other G2019S-carrying haplotypes 
have been found in three families of European descent (haplotype 2, Zabetian et al. 2006a) and 
in one Turkish and two Japanese patients (haplotype 3, Zabetian et al. 2006b; Pirkevi et al. 
2009). Mainly due to founder effects, the prevalence of G2019S is 37–41% in North African 
Arab PD patients (Lesage et al. 2006, 2008) and 10–27% in Ashkenazi Jewish PD patients (Orr-
Urtreger et al. 2007; Ozelius et al. 2006). The prevalence is estimated to be 3–7% of familial and 
1–2% of sporadic PD in European and North American Caucasian patients (Di Fonzo et al. 2005; 
Healy et al. 2008; Lesage et al. 2007; Kachergus et al. 2005). 
 
In contrast, G2019S is rare in Asian populations. Studies have found that the G2385R variant in 
the WD40 region is frequent in Asian populations but infrequent in non-Asian populations. 
There have been reports of a significant association of the G2385R variant with PD in Han 
Chinese from Taiwan, Singapore and mainland China (Fung et al. 2006; An et al. 2008; Farrer et 
al. 2007; Di Fonzo et al. 2006; Tan et al. 2007). Recently, a second risk factor for the 
83 
 
development of PD, the R1628P variant in the COR domain, has been found in the Chinese 
population in independent studies (Ross et al. 2008; Zhang et al. 2009; Tan et al. 2008). The 
distribution and frequency of mutations and genetic susceptibility factors in LRRK2 therefore 
shows ethnic-specific differences. 
 
On the entire African continent, the only genetic studies on PD have been conducted on patients 
from the North African Arabic countries (Morocco, Algeria, and Tunisia) and Nigeria. G2019S 
was found to be frequent in the North African countries but, in contrast, neither this mutation nor 
any other mutations in the exon containing this mutation (exon 41) was present in a group of 
Nigerian patients (Okubadejo et al. 2008). Okubadejo et al. (2008) urged that the usefulness for 
Africa’s populations of commercially available PD-predictive genetic tests or therapeutic 
modalities, as developed by first world countries, will only be revealed once we know the 
genetic basis of this disorder in Africa’s diverse populations. In the present study we investigated 
the frequency of the G2019S mutation in a group of PD patients in South Africa of different 
ethnic groups. 
 
Materials and methods 
 
Study participants 
This study was approved by the Committee for Human Research at the University of 
Stellenbosch (Protocol number 2002/C059). A total of 205 South African PD probands were 
recruited for genetic analysis either from the Movement Disorders clinic at Tygerberg Hospital 
in Cape Town or from the Parkinson’s Association of South Africa. Patients recruited from 
Tygerberg Hospital had been examined by a movement disorders specialist (J.C.) and met the 
UK Parkinson’s Disease Society Brain Bank Research criteria for diagnosis of PD (Gibb and 
Lees 1988). The majority (65%) of the probands were male. The average age at onset (AAO) of 
PD was 54.4 ± 12.4 years (range 17–80). About a third of the probands (35%) had a positive 
family history of the disorder and the remainder (65%) either had no family history of PD or 
there was insufficient information about the family. In 104 of the patients the PARK2 and PINK1 
genes had previously been screened for mutations. The ethnic breakdown of the study group was 
as follows: 42% Caucasian, 31% Afrikaner, 17% mixed ancestry; 8% Black and 2% Indian. 
South African mixed ancestry can be defined as an admixture of the indigenous African 
populations (San, Khoikhoi or Bantu-speaking) and immigrants from Western Europe, 
Madagascar, the Malaysian archipelago and India (Patterson et al. 2010). A total of 79 Caucasian 
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controls were recruited from the Western Province Blood Transfusion Service clinics in Cape 
Town. These individuals had not been clinically assessed for the presence of PD. 
 
Genetic analysis 
After obtaining written informed consent from the study participants, peripheral blood samples 
were collected and genomic DNA was extracted according to established methods. To detect the 
LRRK2 G2019S mutation, the following polymerase chain reaction (PCR) primers were 
designed: forward primer: 5′ gca cag aat ttt tga tgc ttg 3′ and reverse primer: 5′ gag gtc agt ggt tat 
cca tcc 3′. PCR reactions were performed in a 2720 Thermal Cycler (Applied Biosystems, Foster 
City, USA). Each 25 μl reaction contained 200 ng template DNA, 10 pmol of each primer, 75 
μM dNTPs (Promega, USA), 1.5 mM MgCl2, 1× NH4 buffer (Bioline, UK), 0.25 units of 
BIOTAQ DNA polymerase (Bioline, UK) and 2 μM of the green fluorescent dye, SYTO9 
(Invitrogen, USA). PCR cycling conditions comprised of an initial denaturation step of 94°C for 
5 min, 30 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, extension at 72°C 
for 45 s, and a final extension step of 72°C for 7 min. 
 
High-resolution melt (HRM) analysis from 75 to 95°C rising by 0.1°C each step was performed 
on a Rotor-Gene 6000 analyzer (Corbett Life Science, Australia). HRM is a mutation scanning 
method that monitors the shift in fluorescence as a PCR product dissociates from double 
stranded DNA (dsDNA) to single stranded DNA (ssDNA) with increasing temperature. Third 
generation fluorescent dyes such as SYTO9 have low toxicity in an amplification reaction and 
therefore can be used at higher concentrations for greater saturation resulting in increased melt 
sensitivity and higher resolution melt profiles. The observed thermal denaturation profile is 
characteristic of a specific PCR product and is dependant on its sequence length, base and GC 
content (Erali et al. 2008; Wittwer et al. 2003). Samples exhibiting altered thermal denaturation 
profiles were sequenced in order to characterize the sequence variation. Direct sequencing was 
performed using the BigDye Terminator Sequence Ready Reaction kit version 3.1 (Applied 
Biosystems) and analyzed on a 3130xl Genetic Analyzer (Applied Biosystems). 
 
Haplotype analysis 
Haplotypes were constructed using the following microsatellite markers and single nucleotide 
polymorphisms (SNPs): D12S2194, rs726624, D12S2514, rs28903073, D12S2516, D12S2518, 
rs3952596, rs7308560, D12S2519 and D12S2520, as described previously (Lesage et al. 2010). 
Briefly, genotyping of the four SNPs was performed using direct sequencing. Genotyping of the 
six microsatellite markers was performed using fluorescently labeled primers and the products 
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were analyzed on a 3130xl Genetic Analyzer (Applied Biosystems) using GeneMapper Software 
(version 3.7; Applied Biosystems). Haplotypes were constructed manually. 
 
Results 
 
Only 4 out of 205 (2%) (95% CI 0.8–4.9) South African PD probands screened were shown to 
harbor the LRRK2 G2019S mutation, all in a heterozygous state. G2019S was not present in 158 
Caucasian control chromosomes. The mutation was successfully detected using the cost-effective 
HRM technique (Fig. 1). As can be seen from both the normalized (Fig. 1a) and the difference 
graphs (Fig. 1b), the G2019S variant produces a different melt profile to that of the wild type. 
All G2019S-positive samples as determined by HRM were verified by direct sequencing. 
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Fig. 1 High-resolution melt (HRM) analysis of the G2019S mutation illustrating that the mutation can be 
distinguished from the wild-type allele. a Normalized graph. b Difference curve 
 
The one G2019S-positive individual (individual II-1; Fig. 2, family A) is of South African mixed 
ancestry and her affected father (individual I-1) was German. The proband developed typical 
features of PD at the age of 47. She showed a good response to dopamine therapy, complicated 
by marked motor fluctuations, with subsequent development of autonomic failure and psychosis. 
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The family exhibits an autosomal dominant inheritance pattern with reduced penetrance as 
individuals II-4 and III-1 also harbor the G2019S mutation but are currently asymptomatic. 
Individual II-2 who also has the G2019S mutation was diagnosed with schizophrenia in her early 
20s. She presented at age 40 with marked bilateral tremor and bradykinesia which was possibly 
related to her antipsychotic medication depot fluphenazine. She was treated with 
carbilev/levodopa and demonstrated improvement in her tremor and bradykinesia. 
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Fig. 2 Pedigrees of the South African families (family A, B, C and D) with the G2019S mutation. The 
disease-associated haplotype is depicted in a box beneath each individual. AAO age at onset, AAE age at 
examination. Arrow proband, open square male, open circle female, filled square and circle PD affected 
individual, square and circle with a strike through deceased individual, open diamond gender disguised 
 
The second G2019S-positive family is of Russian Ashkenazi Jewish ancestry (Fig. 2, family B). 
The proband (individual III-2) had an AAO of 42 years and underwent a pallidotomy for tremor 
in Sweden at the age of 57 years. She displayed a good response to dopamine therapy, and has 
been troubled by only minor dyskinesias at last review at the age of 70. Other than constipation, 
she has had no symptoms of autonomic disturbance, REM sleep behavior disorder or loss of 
olfaction. This family also exhibits a possible autosomal dominant inheritance pattern with 
reduced penetrance. Her maternal uncle (individual II-4) had an AAO of 70 years but no further 
information could be obtained from him as he was not willing to take part in the study. 
 
In addition, two Caucasian patients with sporadic PD were also found to carry the G2019S 
mutation. The two patients, one female (Fig. 2, family C) and one male (Fig. 2, family D) both 
presented with late-onset PD, with AAO of 70 and 63 years, respectively. The female patient has 
Polish Jewish ancestry. Her disease progression has not been severe, although she also suffers 
from depression and insomnia. She showed a good response to dopamine, and has had only mild 
motor fluctuations and mild dyskinesias when assessed 15 years after onset of her illness. The 
male patient has Jewish ancestry from Eastern Europe and he has had PD for approximately 15 
years with a very slow disease progression. At time of last assessment he was 79 years old and 
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maintained a good response to dopamine, albeit with motor fluctuations. He had no autonomic 
impairment or cognitive impairment, but did have REM sleep behavior disorder, and severe 
freezing of speech. His mother had been diagnosed with motor neuron disease. 
 
Haplotype analysis using ten markers spanning the LRRK2 locus revealed that all four probands 
harbor the common G2019S haplotype referred to as haplotype 1 (Fig. 2; families A, B, C and 
D). Three of these probands are known to have Jewish ancestry and the fourth has German 
ancestry. 
 
Discussion 
 
In the present study we show that the frequency of the LRRK2 G2019S mutation is relatively low 
(~2%) in a group of 205 South African PD patients and is absent in our Afrikaner and Black 
South African patients. Two of the G2019S-positive patients have onset of PD of <50 years and 
a possible autosomal dominant family history. The remaining two patients have sporadic late-
onset PD. We also demonstrate that the HRM technique is a technically simple and cost-effective 
method for detecting the presence of this common PD-causing mutation. 
 
In one of our G2019S-positive families (family A), the proband presented with both PD and 
psychosis, and her sister has PD and schizophrenia. It has previously been shown that the 
G2019S mutation can manifest in phenotypes other than PD: in one patient diagnosed with 
corticobasal syndrome and a family history of dementia (Chen-Plotkin et al. 2008) and another 
patient with Alzheimer’s disease and PD (Santos-Reboucas et al. 2008). These findings suggest 
that the screening for G2019S and possibly other LRRK2 mutations should not be restricted to 
only PD patients. However, a limitation of the present study is the lack of autopsy material for 
the two siblings with PD and psychiatric problems, which precludes pathological examination 
and diagnostic confirmation. 
 
This is the first report on the frequency of G2019S in the South African population and only the 
second sub-Saharan country in Africa to be studied. G2019S was not detected in any of the 16 
Black patients screened and to our knowledge this mutation has never been found in a Black PD 
patient. Three of our four patients are of Eastern European Jewish origin, and the identification 
of the G2019S mutation in the South African PD population is likely to represent limited 
preferential immigration policies to South Africa from Eastern Europe in the late nineteenth and 
early twentieth century. Compared with many other countries the frequency of G2019S is 
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relatively low in the South African patients studied. In the present study it was detected at a 
frequency of 2.8% in patients with familial PD (2/72 patients) and 1.5% in apparently sporadic 
patients (2/133 patients). Our preliminary data therefore indicates that genetic screening for 
G2019S is possibly less important in the general South African setting, particularly in the Black 
PD population. The low frequency also indicates that there are no apparent founder effects in 
South African populations for this particular mutation. This is interesting, given that the South 
African Afrikaner population, in particular, is well known to have founder effects for a number 
of different inherited disorders. Furthermore, finding LRRK2 mutations in apparently sporadic 
PD cases concurs with the findings of many other studies and effectively blurs the distinction 
between early-onset familial (classified as ‘genetic’) and late-onset sporadic (‘non-genetic’) 
forms of this disorder. 
 
It was shown that the four South African G2019S-positive families share a common ancestor in 
that they all have the same disease-associated haplotype. This haplotype, referred to as haplotype 
1, has been found in numerous families worldwide of diverse origins including Ashkenazi 
Jewish, North African Arabs as well as Caucasian European and North American populations. 
The fact that this haplotype is found in so many different populations on different continents 
indicates that the mutation is very old. Current age estimates date the mutation to have originated 
approximately 1,830–2,600 years ago (Bar-Shira et al. 2009; Warren et al. 2008). Further studies 
on G2019S and the disease-associated haplotypes in diverse populations are warranted in order 
to assess the contribution of LRRK2 as a cause of PD worldwide. On a broader level, this 
collective data will assist with more accurate age estimates of the mutation and will provide 
insight into the migratory patterns of humans many thousands of years ago. To this end, studies 
to determine whether or not G2019S is present in the Black PD population are of major 
relevance. 
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Abstract 
 
Mutations in the PINK1 gene are the second most common cause after parkin of autosomal 
recessive early-onset Parkinson’s disease (PD). PINK1 is a protein kinase that is localized to the 
mitochondrion and is ubiquitously expressed in the human brain. Recent studies aimed at 
elucidating the function of PINK1, have found that it has neuroprotective properties against 
mitochondrial dysfunction and proteasomally-induced apoptosis. In the present study, we aimed 
to investigate the prevalence of PINK1 genetic variants in 154 South African PD patients from 
all ethnic groups. Mutation screening was performed using the High-Resolution Melt technique 
and direct sequencing. A total of 16 sequence variants were identified: one known homozygous 
mutation (Y258X), two heterozygous missense variants (P305A and E476K), and 13 
polymorphisms of which five were novel. No homozygous exonic deletions were detected. The 
novel P305A variant was found in a female patient of Black Xhosa ethnicity who has a positive 
family history of the disease and an age at onset of 30 years. This variant has the potential to 
modulate enzymatic activity due to its location in the kinase domain. This is the first report on 
mutation screening of PINK1 in the South African population. Results from the present study 
showed that point mutations and homozygous exonic deletions in PINK1 are not a common 
cause of PD in the South African population. 
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Introduction 
 
The PINK1 (PTEN-induced putative kinase 1) gene (PARK6; OMIM 608309) encodes a 581 
amino acid protein kinase that is localized to the mitochondrion and is ubiquitously expressed in 
the human brain [1,2]. It contains an N-terminal mitochondrial-targeting motif and a highly 
conserved serine/threonine kinase domain. Mutations in PINK1 are the second most common 
cause after parkin of autosomal recessive early-onset Parkinson’s disease (PD), a common and 
incurable progressive neurodegenerative disorder that is characterized by motor impairments 
involving resting tremors, bradykinesia, postural instability and rigidity. Atypical PD clinical 
features, such as psychiatric disturbances, dystonia at onset and sleep benefit, have been 
observed in PD patients with PINK1 mutations [3,4]. 
 
The involvement of PINK1 in PD was first discovered in 2004 with the identification of 
homozygous point mutations in families of Italian and Spanish origin [1]. Since then, missense 
mutations, genomic rearrangements and truncating mutations have been identified in diverse 
populations. It has been shown that the frequency of PINK1 mutations ranges from 1% to 8% in 
patients of different ethnicities [5,6,7]. The discovery of the involvement of PINK1 in PD was 
the first evidence that a kinase signaling pathway may be important in the pathogenesis of 
dopaminergic nigral cell death. Also, it provided a molecular link between the mitochondria and 
neurodegeneration in PD [1,8]. Mitochondrial dysfunction is thought to play an integral role in 
the pathogenesis of PD [9]. 
 
PINK1-deficient Drosophila has been shown to display mitochondrial defects leading to 
degeneration of flight muscles and loss of dopaminergic neurons [10,11,12]. PINK1 is thought to 
have neuroprotective properties since overexpression in neuroblastoma cells is associated with a 
decrease in the susceptibility of the cells to neurotoxin-induced cell death [1,13]. The mechanism 
of PINK1’s suggested ability to prevent cell death is by the inhibition of release of cytochrome C 
from mitochondria and maintenance of the mitochondrial membrane potential [1,13,14]. PINK1 
phosphorylates mitochondrial proteins in response to cellular stress and in so doing protects 
against mitochondrial dysfunction [1]. It has been reported that PINK1 phosphorylates TNF 
receptor-associated protein 1, which causes the cells to be protected against oxidative stress-
induced apoptosis [15]. Parkin and PINK1 are thought to function in the same pathway in 
maintaining mitochondrial integrity and function, with PINK1 functioning upstream from parkin 
[11,16]. 
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Currently, the majority of PINK1 mutations are distributed throughout the serine/threonine 
kinase domain. Some of these mutations have been reported to cause reduction in enzymatic 
activity [17,18] and could affect substrate recognition as well. The mutations that are located 
outside the domain might affect protein stability, which could indirectly influence kinase 
activity. In the present study, we conducted genetic mutation screening, in order to determine the 
prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-
onset PD. 
 
Materials and methods 
 
Study participants 
The study was approved by the Committee for Human Research at the University of 
Stellenbosch, South Africa (Protocol number 2002/C059). A total of 154 unrelated PD patients 
from all South African ethnic groups were recruited with informed consent. They were recruited 
from the Movement Disorders clinic at Tygerberg Hospital, Cape Town, as well as from the 
Parkinson’s Association of South Africa. The patients were examined by a movement disorder 
specialist (JC) and met the UK Parkinson’s Disease Society Brain Bank Research criteria for 
diagnosis of PD [19]. Inclusion criteria of patients in this study were early-onset and/or a 
positive family history of PD. 
 
The ethnic breakdown was as follows: 35.3% Caucasian, 30.9% South African Afrikaner, 19.8% 
mixed ancestry (defined in Bardien et al., 2009 [20]), 11.8% Black, and 2.2% Indian. The 
average age at onset (AAO) of the study group was 52 years ± 12.83. Among the patients, 65 
(48%) were ≤50 years old at onset of the disease (age range 17–50 years) and 71 (52%) were 
>50 years old at onset (age range 51–77). The percentage of males in our study group was 62%. 
The percentage of patients with positive family history was 36% and both autosomal recessive 
and autosomal dominant patterns of inheritance were present. Seventy-two mixed ancestry 
control samples (male = 72%) and 54 black control samples (male = 57%) were recruited from 
unrelated blood donors at the South African Western Province Blood Transfusion Service blood 
collection clinics. The controls had been ‘de-identified’ and had not been clinically assessed for 
signs of PD. 
 
Genetic analysis 
For each study participant, a blood sample was collected for genetic analysis and genomic DNA 
was extracted using established methods. Polymerase chain reaction (PCR) primers were 
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designed for each of the eight exons of the PINK1 gene using Primer3 software. Primer 
sequences are available from the authors on request. PCR reactions were performed in a 2720 
Thermal Cycler (Applied Biosystems, USA). The 25 μl reactions contained 10 ng template 
DNA, 10 pmol of each primer, 75 μM dNTPs (Promega, USA), 1.5 mM MgCl2, 1× NH4 buffer 
(Bioline, UK), 5% DMSO (for selected primer sets), 2 μM SYTO9 fluorescent dye (Invitrogen, 
USA) and 0.25 U of BIOTAQ DNA polymerase (Bioline, UK). The PCR cycling parameters 
were as follows: initial denaturation at 94 °C for 5 min, followed by 30 cycles of denaturation at 
94 °C for 30 sec, annealing at different temperatures (ranging from 55 to 61 °C) according to 
each primer set for 30 s, extension at 72 °C for 45 s, and a final extension step at 72 °C for 7 
min. 
 
Thereafter, the PCR products were subjected to high-resolution melt (HRM) analysis. For this, 
the samples underwent a melt from 75 to 95 °C rising by 0.1 °C each step on a Rotor-Gene 6000 
analyzer (Corbett Life Sciences, Australia). In HRM, double stranded DNA dissociates into 
single stranded DNA as the temperature increases up to 95 °C, during which the shift in 
fluorescence is monitored. The thermal denaturation profile that is produced is characteristic of a 
specific PCR product and is dependent on its sequence length, base and GC content [21,22]. The 
samples that showed different HRM profiles when compared to profiles produced by the wild-
type sample were sequenced in order to characterize the genetic variant. Direct sequencing was 
performed using the BigDye Terminator Sequence Ready Reaction kit version 3.1 (Applied 
Biosystems) and analyzed on a 3130xl Genetic Analyzer (Applied Biosystems). The primers 
used for sequencing were the same as those used to generate the PCR products for HRM 
analysis. For eighteen of the samples, mutation screening was performed using direct sequencing 
of all eight exons and not the HRM method. The frequency of selected sequence variants was 
determined in ethnically matched control samples. 
 
Results 
 
The genomic DNA of 154 South African PD patients were screened for mutations in PINK1 
using the HRM method and direct sequencing. No homozygous exonic deletions were detected. 
A total of 16 sequence variants were identified (Table 1A and B) of which one (Y258X) is a 
known mutation that had previously been identified using the Multiplex Ligation-dependent 
Probe Amplification method (MLPA) [23]. The homozygous Y258X mutation (Fig. 1A) was 
found in one patient of Indian ethnicity and was also present in both of her affected siblings. 
Although her duration of illness at the time of assessment was 30 years, her symptoms were 
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relatively well controlled on only 500 mg of levodopa daily. She experienced occasional 
freezing, and had mild dyskinesias affecting the legs. There were no features of autonomic 
dysfunction, but she did self-report impairment of memory for recent events. Detection of 
Y258X by HRM in the present study showed the efficacy of this mutation screening method in 
detecting sequence variants. 
 
Two other sequence variants (P305A, E476K) were also identified as well as 13 polymorphisms. 
The novel P305A variant (Fig. 1B) was identified in a heterozygous state in a female patient of 
Black Xhosa ethnicity. This patient had a positive family history of the disease and an AAO of 
30 years. However, the variant was not present in the proband’s affected sibling who had an 
AAO of 45 years. P305A is located within an evolutionarily conserved region of the gene (Fig. 
2). PolyPhen analysis (http://genetics.bwh.harvard.edu/pph/) revealed that this variant is 
‘probably damaging’ although it was found in 1.9% of control chromosomes. 
 
The E476K variant (Fig. 1C) was identified in a heterozygous state in a female patient of mixed 
ancestry who had an AAO of 48 years and no family history of the disease. This variant has been 
previously reported in a number of studies [3,5,6,8]. PolyPhen analysis revealed that E476K is 
‘benign’ and in the present study it was found in 1.4% of control chromosomes. This variant is 
not located in an evolutionarily conserved region of PINK1 (data not shown). All three of these 
variants occur in the functional serine/threonine kinase domain of PINK1. The P305A variant 
occurs within the third kinase insert domain [24], which is suggested to contain regulatory motifs 
important for kinase activity and substrate selectivity [25,26]. Y258X and E476K are located in 
the second kinase insert domain and eleventh kinase subdomain, respectively [24]. 
 
PINK1 was found to be polymorphic in the South African population although very few 
pathogenic mutations were found. Out of the 13 polymorphisms detected, 5 were novel variants 
and included 5′UTR-35 C > T, IVS4 + 56 G > T, IVS7-8 T > G, 3′UTR + 37 A > T, and 3′UTR 
+ 43 G > A. The IVS1-7 A > G polymorphism had the highest frequency (22%) in the study 
group compared to the other variants. 
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                  Table 1A Known and putative mutations identified in PINK1 in South African PD patients 
Exon Variant Zygosity Number of patients/Ethnicity# 
AAO 
(yrs) 
Family 
history 
Protein 
domain 
Frequency in 
control 
chromosomes 
Previously reported/ 
Reference 
3 Y258X 
(TAC-TAA) 
Homozygous 1/Indian 
(68.10) 
37 + Kinase 
domain 
0/130 [23,37] 
4 P305A 
(CCT-GCT) 
Heterozygous 1/Black 
(42.03) 
30 + Kinase 
domain 
2/108 
(1.9%) 
Novel 
7 E476K 
(GAG-AAG) 
Heterozygous 1/Mixed ancestry 
(63.69) 
48 - Kinase 
domain 
2/144 
(1.4%) 
[3,5,6,8] 
                         # = patient sample number shown in brackets; AAO = age at onset 
 
 
 
 
                                     Table 1B Polymorphisms identified in PINK1 in South African PD patients 
Location Variant Ethnicity of patients with variant Frequency in patients (n=154) 
5’-UTR -35 C>T Afrikaner 1 
Exon 1 L63L Afrikaner 6 
Exon 1 Q115L Afrikaner 1 
Intron 1 IVS1-7 A>G Afrikaner, Caucasian, Mixed ancestry, Indian and Black 30 
Intron 1 IVS1-65 C>G Afrikaner 1 
Intron 4 IVS4+56 G>T Black 1 
Intron 4 IVS4+72 G>C Indian 1 
Exon 5 A340T Afrikaner, Caucasian, Mixed ancestry, Indian and Black 10 
Intron 6 IVS6+43 C>T Afrikaner and Caucasian 4 
Intron 7 IVS7-8 T>G Afrikaner, Caucasian, Mixed ancestry, Indian and Black 18 
Exon 8 N521T Afrikaner, Caucasian, Mixed ancestry, Indian and Black 10 
3’-UTR *37 A>T Afrikaner, Caucasian and Mixed ancestry, Indian and Black 24 
3’-UTR *43 G>A Mixed ancestry and Indian 2 
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Fig. 1 Difference graphs produced by the high-resolution melt technique illustrating that sequence 
variants can be distinguished from wild-type alleles. Melt curves of the A) previously reported Y258X 
mutation, B) novel P305A variant, C) previously reported E476K variant. 
 
 
 
Human      YPDVLPSRLHPEGLGHGRTLFLVMKNYPCTLRQYLCVNTPSPRLAAMMLLQLLEGVDHLV  
Chimp      YPDVLPSRLHPEGLGHGRTLFLVMKNYPCTLRQYLCVNTPSPRLAAMMLLQLLEGVDHLV  
Mouse      YPDMLPPHYYPEGLGHGRTLFLVMKNYPCTLRQYLEEQTPSSRLATMMTLQLLEGVDHLV  
Rat        YPDMLPPHYYPEGLGHGRTLFLVMKNYPCTLRQYLEEQTPSSRLATMMTLQLLEGVDHLV  
Cow        YPDVLPPRLHPAGLGHGRTLFLVMKNYPCTLRQYLRGNTPSPRLATVMTLQLLEGVDHLV  
Chicken    YPDVLPVSLNPRGIGRSHTLFLVMKNYPCTLCQYLRDNSPDSRLSTMMILQLLEGVDHLV  
Zebrafish  YPDVLPTRLNPHGLGSNRTLFLVMKNYPCTLRQYLEVCVPKRTQASLMFLQLLEGVDHLC  
           ***:**    * *:* .:************* ***    *.   :::* **********   
Fig. 2 Sequence alignment (using ClustalW) of PINK1 amino acid sequences of human (NP_115785.1), 
chimp (ENSPTRP00000000500), mouse (NP_081156.2), rat (XP_216565.2), cow (NP_001093171.1), 
chicken (XP_423139.2), and zebrafish (NP_001008628.1).The box indicates the position of the novel 
P305A variant. Identical amino acids are indicated by asterisks 
 
 
 
A 
B 
C 
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Discussion 
 
We report the results of genetic mutation screening of the PINK1 gene which was conducted on 
PD patients from all South African ethnic groups. The study participants had previously been 
screened for mutations in the parkin gene [20] and the G2019S mutation in the LRRK2 gene 
[27]. For parkin, only two patients with mutations were found (both homozygous whole exon 
deletions) and only four individuals were found to harbor the G2019S mutation. These results 
indicate that parkin and LRRK2 are not a common cause of PD in South African patients and the 
PINK1 gene was therefore investigated. 
 
In the present study one previously identified mutation (Y258X) and two missense variants 
(P305A and E476K) were identified as well as 13 polymorphisms. The novel P305A variant was 
found in one PD patient of Black Xhosa ethnicity who had a positive family history of the 
disease. The clinical features of PD in Black individuals have been reported to be atypical and 
that it is a late-onset akinetic-rigid syndrome [28]. However, the individual harboring the P305A 
variant has typical clinical features of PD but she had an earlier onset and a more severe 
phenotype than her affected sibling. The P305A variant, due to its location in the 
serine/threonine kinase domain, has the potential to influence the function of PINK1 by affecting 
its autophosphorylation ability [29], and it is predicted to be ‘probably damaging’ by PolyPhen 
analysis. However, the fact that P305A was not present in the proband’s affected sibling as well 
as the fact that it was found in 1.9% of ethnic matched control chromosomes suggests that it is a 
non-pathogenic polymorphism. 
 
The E476K variant has previously been found in heterozygous form in four unrelated PD 
patients [3,5,6,30] but has also been found at very low frequencies in control subjects [5,8]. This 
variant has been shown to impair mitochondrial membrane potential after cellular stress induced 
by proteasomal inhibition [8]; however, its pathogenic status is currently equivocal. In the 
present study E476K was observed at a frequency of 1.4% in control chromosomes, which 
together with the fact that this residue is evolutionarily poorly-conserved and is also predicted by 
PolyPhen analysis to be ‘benign’, indicates that it may be a non-pathogenic polymorphism. 
 
HRM detected 13 polymorphisms in the present study. The previously reported IVS1-7 A > G 
variant had the highest prevalence in the study group compared to the other polymorphisms. This 
variant might have an effect on splicing of the gene; however, further studies are necessary to 
investigate this. The presence of the IVS1-7 A > G variant has been shown to decrease the AAO 
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in patients exposed to various environmental risk factors [31]. Since we do not have 
comprehensive data on environmental exposures for all our study participants, this finding could 
not be verified in the present study. However, preliminary analysis showed that the average 
AAO for patients with (44.1 ± 9.9 years; 30/154) and without (52.7 ± 12.5 years; 124/154) the 
IVS1-7 A > G variant was significantly different     (p < 0.001; t-test). 
 
A few recent studies have reported either no PINK1 mutations in PD patients from Brazil [32], 
China [33] and Portugal [34] or only a few heterozygous variants of unknown pathogenic 
significance in patients from Australia [35] and India [36]. These findings are in contrast to the 
high frequencies observed in earlier studies. This may reflect that the contribution of this gene 
varies according to ethnicity or that the frequency of PINK1 mutations is not as common as was 
previously thought. Therefore, innovative bioinformatic in silico and wet-bench experimental 
strategies are urgently needed to identify novel disease-causing genes for PD. 
 
Conclusion 
 
Results from the present study showed that point mutations, small insertions or deletions, and 
homozygous exonic deletions in PINK1 are not a common cause of PD (<1%) in the South 
African population. Therefore, it is proposed that as yet unknown genes are responsible for PD in 
this population. Further studies are necessary to determine whether the P305A variant could 
possibly alter or modulate the enzymatic activity of PINK1. 
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Abstract  
Assuming that a significant cause of Parkinson’s disease (PD) is genetic, genetic factors have 
been shown to account for < 10% of all PD cases to date, and it is therefore necessary to identify 
novel genes. The aim of the present study was to identify PD candidate genes using a 
bioinformatics approach and to screen them for possible PD-causing mutations. The CAESAR 
(CAndidatE Search And Rank) program was used in the present study to identify and prioritize 
PD candidate genes. CAESAR ranks annotated human genes as candidates by using ontologies 
to semantically map natural language descriptions of the trait under investigation to gene-centric 
databases. Two of the candidates were selected and screened for mutations in 202 South African 
PD patients using the High-Resolution Melt (HRM) method. Samples exhibiting altered HRM 
profiles were sequenced. CAESAR generated a prioritized list of candidates including both 
known and novel PD genes. The MAPT and SNCAIP genes were selected for mutation screening 
from the list of ten highest scoring genes. Two novel missense (A91V and V635I), four 
synonymous and three intronic sequence variants were identified in MAPT. For SNCAIP, three 
novel missense (T383N, R606Q, N906H), one known (E709Q), four synonymous and one 
intronic sequence variant were found. A bioinformatics approach was used to aid in the 
identification and selection of PD candidate genes in a group of South African patients. Mutation 
screening of MAPT and SNCAIP identified novel sequence variants in both genes and further 
studies are necessary to determine their possible functional consequences. 
 
 
 
Keywords Parkinson’s disease; CAESAR; bioinformatic tools; MAPT, SNCAIP 
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Introduction 
Parkinson’s disease (PD) (OMIM#168600) is a neurodegenerative disorder which presents with 
tremor and bradykinesia, in addition to a wide range of non-motor disturbances. To date, six 
genes (PARK2, PINK1, DJ-1, SNCA, LRRK2 and ATP13A2) have been conclusively implicated 
in the pathogenesis of PD (Lesage and Brice 2009), although mutations in these genes account 
for < 10% of all PD cases. Our studies have shown that the main PD causing genes do not play a 
significant role in the South African population (Bardien et al. 2009; Bardien et al. 2010; Keyser 
et al. 2010a; Keyser et al. 2010b and unpublished data), and therefore it is important to identify 
novel PD candidate genes. Identification of novel PD genes may also reveal new molecular 
pathways that could be involved in neurodegeneration and development of the disorder.   
 
Traditional linkage analysis and genome-wide association studies (GWAS) have been used to 
identify candidate genes for PD (Maraganore et al. 2005; Fung et al. 2006; Simon-Sanchez et al. 
2009; Funayama et al. 2002). A limited number of candidate genes have been found using these 
methods. Also, some of the findings have not been reproduced in follow-up studies, which may 
be due to small sample size, inadequate correction for multiple testing and population 
stratification. Searching through online databases to select candidate genes has become 
extremely difficult and time consuming because the wealth of molecular information in 
databases has increased exponentially. Bioinformatic tools such as GeneSeeker (van Driel et al. 
2003), TOM (Rossi et al. 2006), Gene Prospector (Yu et al. 2008) and CAESAR (Gaulton et al. 
2007) have been developed to assist with this challenging task. These in-silico methods are 
rapid, cost effective and are not prone to many of the biases invariably introduced by researchers.  
 
GeneSeeker searches for relevant genes within a specific chromosomal region as defined by the 
user (van Driel et al. 2003). The program gathers and combines positional, expression and 
phenotypic data in an automated way from nine different web-based databases in order to obtain 
an overview of the candidate genes in the specified chromosomal region. Transcriptomics of 
OMIM (TOM) requires the user to have knowledge of another disease associated gene as well as 
the linkage area, or knowledge of two disease loci (Rossi et al. 2006). TOM’s algorithm uses 
information on mapping, expression and function stored in public databases. The Gene 
Prospector tool selects and prioritizes potential disease-related genes by using HuGe Navigator, a 
curated published literature database of genetic association studies (Yu et al. 2008).  It ranks 
genes according to the amount of literature available in human genome epidemiology as well as 
published research on both rat and mouse animal models. 
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In the present study, CAESAR (CAndidatE Search And Rank) (Gaulton et al. 2007) was used 
because it was designed specifically for complex diseases such as PD in which the relevant 
biological processes are not well understood and for which a large number of reasonable 
candidate genes exist. CAESAR is a computational system that uses ontologies to semantically 
map trait information to gene and protein-centric information including protein-protein 
interactions, metabolic pathways and tissue-specific gene expression data from various public 
data sources such as SwissProt, KEGG and Ensembl.  The data mining results are then integrated 
and a ranked list of candidate genes produced that may be involved with the complex trait. The 
CAESAR approach mimics the individual steps a researcher would undertake to select candidate 
genes, but it conducts this faster and in a more quantitative and systematic manner.  
 
In the present study, a bioinformatics strategy was used to identify candidate genes for PD. Two 
candidates were selected from this strategy and mutation screening was performed to identify 
possible disease-causing mutations in South African PD patients.  
 
Materials and methods 
Study participants 
The Committee for Human Research at the University of Stellenbosch, South Africa, approved 
the study (Protocol number 2002/C059) and all study participants were recruited with informed 
written consent. The study was conducted on 202 unrelated PD patients recruited from the 
Movement Disorders clinic at Tygerberg Hospital, Cape Town as well as from the Parkinson’s 
Association of South Africa, and the inclusion criteria included early onset and/or a positive 
family history of the condition. A movement disorder specialist (JC) examined the patients and 
they met the UK Parkinson’s Disease Society Brain Bank Research criteria for diagnosis of PD 
(Gibb and Lees 1988).  
 
The study group had an average age at onset (AAO) of 54 ± 12.34 years and 65% were male. 
Among the patients, 74 (37%) were ≤50 years old at onset of the disease (age range 17-50 years) 
and 128 (63%) were >50 years old at onset (age range 51-77). The patients were from all South 
African sub-population groups, these being distributed as follows: 73.2% Caucasian, 17.3% 
mixed ancestry (defined in Bardien et al. 2009), 8% Black, and 1.5% Indian. Thirty-six percent 
of patients had a positive family history and both autosomal recessive and autosomal dominant 
patterns of inheritance were present. Control samples (62 mixed ancestry, 62 Caucasian and 70 
Black) were recruited from unrelated blood donors at the South African Western Province Blood 
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Transfusion Service blood collection clinics. The controls were ‘de-identified’ and had not been 
clinically assessed for signs of PD.  
 
Bioinformatic analysis (CAESAR)   
The CAESAR program was obtained from the authors (http://visionalb.bio.unc.edu/) and 
installed on an Intel Pentium PC running on Ubuntu Linux 9.10 operating system with internet 
connectivity.  Four literature reviews on PD (Bonifati 2007; Klein and Lohmann-Hedrich 2007; 
Thomas and Beal 2007; Onyango 2008) were downloaded from NCBI’s PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and used as the corpus (i.e. input text for CAESAR). The 
selected publications had to be converted from PDF format to text using the Linux utility 
program ‘pdf2text’. The texts were then edited to remove references and remnants of the image 
files.  
 
In CAESAR, human gene symbols from the corpus are extracted using a reference list of 
standard names, symbols, database identifiers and corresponding mouse homologs from Entrez 
Gene (Maglott et al. 2005) and Ensembl (Birney et al. 2006). The selected genes are then 
weighted based on the frequency of occurrence of the respective genes and quantified using four 
catalogued biomedical ontologies namely, gene ontology biological process (GO bp) (Harris et 
al. 2004), gene ontology molecular function (GO mf) (Harris et al. 2004), mammalian phenotype 
ontology (MP) (Smith et al. 2005) and eVOC anatomical ontology (Kelso et al. 2003). The 
quantification is achieved through a similarity search using a vector-space model.  
 
The quantified gene information is then ranked by mapping them onto eight sources of gene-
centric information databases resulting in eight scores for each gene. The gene-centric data 
sources are Mouse Genome Database (MGD), Genetic Association Database (GAD), UniProt 
Database, Gene Ontology Annotation Database (GOA), Biomolecular Interaction Network 
Database (BIND), Human Protein Reference Database (HPRD), Kyoto Encyclopaedia of Genes 
and Genomes Pathway Database (KEGG), and InterPro Protein Domain Database (IPro). 
Finally, scores generated for each gene through mapping are mathematically integrated to 
produce a ranked list of candidate genes. Two of the top ten ranked genes from this list were 
selected as possible candidate genes for mutation screening. 
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Genetic analysis 
Peripheral blood samples were collected for each study participant for genetic analysis and 
genomic DNA was extracted using established methods. Polymerase chain reaction (PCR) 
primers for exons of the MAPT and SNCAIP genes that span known functional domains were 
designed using Primer3 software (http://frodo.wi.mit.edu/primer3/). Primer sequences are 
available from the authors on request. PCR reactions were performed in a 2720 Thermal Cycler 
(Applied Biosystems, USA). The 25µl reactions contained 10ng template DNA, 10 pmoles of 
each primer, 75µM dNTPs (Promega, USA), 1.5mM MgCl2, 1X NH4 buffer (Bioline, UK), 5% 
formamide (for the MAPT primer sets), 2µM SYTO9 fluorescent dye (Invitrogen, USA) and 0.25 
units of BIOTAQ DNA polymerase (Bioline, UK). The PCR cycling parameters were as follows: 
initial denaturation at 94°C for 5min, followed by 30 cycles of denaturation at 94°C for 30sec, 
annealing at different temperatures (ranging from 55 to 60°C) according to each primer set for 
30sec, extension at 72°C for 45sec, and a final extension step at 72°C for 7min.  
 
The PCR products were then subjected to high-resolution melt (HRM) analysis on a Rotor-Gene 
6000 analyzer (Corbett Life Sciences, Australia) in which they underwent a melt from 75ºC to 
95ºC rising by 0.1ºC. During ‘melting’ of the DNA, the release of the fluorescent intercalating 
dye SYTO9 is measured in order to produce thermal denaturation profiles which are 
characteristic of a specific PCR product. These profiles are dependent on sequence length, base 
and GC content of the PCR product (Erali et al. 2008;Wittwer et al. 2003). HRM profiles that 
differed significantly from that of the wild-type sample were sequenced in order to characterize 
the genetic variant. Sequencing was performed using the BigDye Terminator Sequence Ready 
Reaction kit version 3.1 (Applied Biosystems, USA) and analyzed on a 3130xl Genetic Analyzer 
(Applied Biosystems). The primers used for sequencing were the same as those used to generate 
the PCR products for HRM analysis. Ethnically matched control samples were screened in order 
to determine the frequency of selected sequence variants. For naming of missense variants, 
protein sequences NP_001116538.2 and NP_005451.2 was used for MAPT and SNCAIP, 
respectively. The PolyPhen tool (http://coot.embl.de/PolyPhen/) was used to predict the possible 
functional consequence of the missense variants. This tool combines information on sequence 
features, a multiple alignment with homologous proteins and several structural parameters to 
predict the effect of a variant on the protein function. PolyPhen’s output is a prediction that the 
variant is either ‘damaging’ i.e. is supposed to affect protein function or ‘benign’ i.e. most likely 
lacking any phenotypic effect. 
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Results 
Bioinformatic analysis 
CAESAR generated a prioritized list of genes of which the top ten (in order of ranking) were 
SNCA, PARK2, SNCAIP, APP, MAPT, HD, BCL2L1, SNCB, TH and UCHL1 (Supplementary 
Table 1) The SNCA and PARK2 genes have been conclusively implicated in the pathogenesis of 
PD (Lesage and Brice 2009) which accounts for their ranking as number one and two, 
respectively. The UCHL1 gene is currently classified as a PD associated gene with unknown 
relevance (Lesage and Brice 2009). The APP and HD genes are associated with Alzheimer’s 
disease and Huntington’s disease, respectively (Sisodia and Price 1995; Hoogeveen et al. 1993). 
After excluding the known PD genes (SNCA, PARK2 and UCHL1) and genes involved in other 
disorders (APP and HD), the remaining genes in the list were SNCAIP, MAPT, BCL2L1, SNCB 
and TH. Of these, the two genes with the highest CAESAR scores were selected for further 
investigation. 
 
Mutation screening  
The MAPT (microtubule-associated protein tau) and SNCAIP (synuclein alpha interacting 
protein) genes were selected as plausible candidates for mutation screening in a group of 202 
South African PD patients. For MAPT, two novel missense variants A91V and V635I were 
identified in two patients (Table 1). A91V was present in one male patient of mixed ancestry 
who had an AAO of 32 years. This variant was absent from 124 ethnic-matched control 
chromosomes. V635I was found in a male Black patient (AAO of 60 years) as well as his three 
unaffected children. It was also present in 0.7% of control chromosomes. A91V and V635I were 
predicted by PolyPhen to be benign variants even though they are both located at amino acid 
positions that are evolutionarily conserved from dog to human (Figure 1). 
 
For SNCAIP, we found three novel missense variants T383N, R606Q and N906H as well as one 
previously-identified sequence variant E709Q (Table 1). T383N was found in one Black patient 
who had a positive family history and an AAO of 50 years. R606Q was identified in one 
Caucasian patient who had a late AAO of 70 years and no family history of PD. This variant is 
located in the ankyrin repeat 5 domain. N906H was found in one Caucasian patient with an AAO 
of 64 years and no family history of PD. The previously reported E709Q variant (Marx et al. 
2003) was identified in one Caucasian patient with an AAO of 64 years and is located in the 
ankyrin repeat 6 domain. E709Q was found in 1.6% of control chromosomes, indicating that it is 
probably a non-pathogenic polymorphism.  
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Table 1 Missense sequence variants identified in MAPT and SNCAIP in South African PD patients 
 
Gene Location Variant Zygosity Number of 
patients/ 
Ethnicity 
AAO 
(yrs) 
Family 
history 
Protein domain Conserved 
region 
Frequency in 
ethnic matched 
control 
chromosomes 
Previously 
reported/ 
Reference 
PolyPhen 
prediction 
MAPT 
Exon 4 A91V (GCG-GTG ) Heterozygous 
1/  
mixed 
ancestry 
32 - No Yes 0/124 Novel Benign 
Exon 12 V635I (GTC-ATC) Heterozygous 
1/  
Black 60 - 
Microtubule-
binding repeat 2 Yes 
1/140 
(0.7%) Novel Benign 
SNCAIP 
Exon 5 T383N (ACT-AAT) Heterozygous 
1/  
Black 50 + 
Between 
ankyrin repeat 
1and 2 
No 0/124 Novel Benign 
Exon 10 
R606Q 
(CGG-CAG) Heterozygous 
1/ 
Caucasian 70 - 
Ankyrin    
repeat 5 Yes 0/124 Novel Benign 
E709Q 
(GAG-CAG) Heterozygous 
1/ 
Caucasian 64 - 
Ankyrin 
repeat 6 Yes 
2/124 
(1.6%) 
Marx et 
al., 2003 Benign 
N906H 
(AAC-CAC) Heterozygous 
1/ 
Caucasian 64 - No Yes 0/124 Novel 
 
Possibly 
damaging 
                      
AAO, age at onset; -, Negative family history of PD; +, Positive family history of PD. 
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Table 2 Synonymous and intronic sequence variants identified in MAPT and SNCAIP in South African PD patients 
 
Gene Location Variant Protein domain Ethnicity of patients with variant 
Frequency 
in patients 
(n=202) 
Previously 
reported/ 
Reference 
MAPT 
Intron 3 IVS3+18 C>T  Caucasian, Mixed ancestry, Indian, Black 49 Novel 
Exon 4 A90A 
(GCC-GCT) 
- Mixed ancestry 1 Novel 
Intron 4 IVS4+9 A>G  Caucasian, Mixed ancestry 31 Novel 
Exon 11 A562A 
(GCA-GCG) 
- Caucasian, Mixed ancestry 19 Novel 
Exon 11 N590N 
(AAT-AAC) 
Microtubule-binding repeat 1 Caucasian, Mixed ancestry 19 Novel 
Exon 11 P605P 
(CCG-CCA) 
Microtubule-binding repeat 1 Caucasian, Mixed ancestry, Indian, Black 27 Kim et al., 2010 
Intron 11 IVS11+40 C>T  Caucasian 2 Novel 
       
SNCAIP 
Exon 5 G390G 
(GGC-GGA) 
Ankyrin repeat 2 Black 1 Novel 
Exon 6 S406S 
(AGC-AGT) 
Ankyrin repeat 2 Mixed ancestry 1 Novel 
Intron 6 IVS6-23 T>C  Caucasian, Black 3 Novel 
Exon 8 L504L 
(CTG-TTG) 
Between ankyrin repeat 4 and coiled-coil domain Caucasian 2 Novel 
Exon 10 L638L 
(CTG-CTC ) 
Between ankyrin repeat 5 and 6 Black 1 Novel 
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V635I                         
Human KCGSKDNIKHVPGGGSVQIVY 
Chimp KCGSKDNIKHVPGGGSVQIVY
Mouse KCGSKDNIKHVPGGGSVQIVY
Rat   KCGSKDNIKHVPGGGSVQIVY
Dog   KCGSKDNIKHVPGGGSVQIVY
*********************
MAPT
SNCAIP
A91V
Human DEGAPGKQAAAQPHTEIPEGT 
Chimp DEGAPGKQAAAQPHTEIPEGT 
Mouse DERAPDKQAAAQPHTEIPEGI 
Rat   EERAPDKQATAQSHTEIPEGT 
Dog   DEGTPGEQAAAQPPMEIPEGA 
:* :*.:**:**.  ***** 
T383N
Human MGEDCLNERNTEKLTPAGLAI
Chimp MGEDCLNERNTEKLTPAGLAI
Mouse MGEDCLNERNTEQLTPAGLAI
Rat   MGEDCLNERNAEQLTPAGLAI
Cow   MGEDCLNERNVEKLTPAGLAI
Dog   MGEDCLSERNAEKLTPAGLAI
******.***.*:********
E709Q
Human PRPQPIVESVESMDSAESLHL 
Chimp PRPQPIVESVESMDSAESLHL 
Mouse PRPQPIVESVENVDSAESLHL 
Rat   PRPQPIVESVENMDSAESLHL 
Cow   PRPQPIVESVEGVDSAESLHL 
Dog   PRPQPIVGSVESVDSAESLHL 
******* ***.:********
R606Q
Human SLSASSRARPKAKDEDSDKIL
Chimp SLSASSRARPKAKDEDSDKIL
Mouse SLSVSSRARTKGKDEDSDKIL
Rat   --NLSSRARTKGKDEDSDKIL
Cow   SLSASSRARAKVKDEDSDKIL
Dog   SLSASSRARAKVKDEDSDKIL
. *****.* *********
N906H
Human K-TDAKGNPASSASKGKNKAA
Chimp K-TDAKGNPASSASKGKNKAA
Mouse KTADAKGNPVSPASKGKNKA-
Rat   KTADAKGNPVSPASKGKNKAA
Cow   KVTDGKGNTGSSASKGKNKAA
Dog   KTTDAKGNPVSSASKGKNKAA
* :*.***. *.********  
Figure 1 Comparative protein alignments (using ClustalW) of selected regions of MAPT and 
SNCAIP across different species to determine whether they are evolutionarily-conserved. The 
protein sequences used were as follows: For MAPT: human (NP_001116538.1), chimp 
(NP_001009068.1), mouse (NP_001033698.1), rat (ENSRNOP00000006856) and dog 
(XP_850032.1). For SNCAIP: human (NP_005451.2), chimp (ENSPTRP00000041122), mouse 
(NP_080684.2), rat (XP_225768.4), cow (XP_591868.3) and dog (XP_538600.2). The arrows indicate 
the positions of variants. Identical amino acids are indicated by asterisks. 
 
 
The remaining three SNCAIP variants were not found in 124 ethnic-matched control 
chromosomes and occur within evolutionarily conserved regions of the protein (Figure 1). 
PolyPhen analysis predicted that they are benign except for N906H which was predicted to be 
possibly damaging. A number of synonymous and intronic variants were found in both genes 
(Table 2). The MAPT  IVS3+18 C>T, IVS4+9A>G, A562A, N590N and P605P are probably 
non-pathogenic polymorphisms due to the high frequencies observed in our study and the 
remaining variants are of unknown functional significance but are not likely to be pathogenic. 
 
Discussion 
It is important that novel candidate genes for PD are identified. PD genes may exhibit 
population specificity as has been shown for disease-causing mutations in the LRRK2 gene 
which are a relatively common cause of PD in non-Asian populations but to date have not 
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been found in Asian populations. In the present study, we used a bioinformatics approach to 
search for novel PD candidates for screening in a South African population. Bioinformatics is 
a useful tool because it can be used to systematically and methodically search through vast 
amounts of information stored in various databases and is free of inherent human biases. 
CAESAR is also much faster, and to have attempted this work manually may have taken 
many months to accomplish. The SNCAIP and MAPT were selected and screened in a group 
of South African PD patients. In both genes, a number of novel variants were found of 
unknown functional significance.  
 
The MAPT gene was selected as a plausible PD candidate as it has been shown to be a 
susceptibility factor for PD in a number of independent GWAS studies (Edwards et al. 2010; 
Simon-Sanchez et al. 2009). It is possible that a single gene may harbour both disease-causing 
and susceptibility alleles for PD, as illustrated by LRRK2 in which several disease-causing 
mutations have been found, as well as two susceptibility factors G2385R and R1628P. 
MAPT, which is highly expressed in neurons, consists of 15 exons which undergo complex 
and regulated alternative splicing to produce a number of protein isoforms. The longest 
version, isoform 6, encodes a 776 amino acid protein. MAPT is needed for organizing and 
maintaining cell structure by modulating microtubules (Weingarten et al. 1975; Hirokawa 
1994). Interactions between MAPT and the microtubules occur via the microtubule-binding 
repeat domains located in the carboxyl-terminus (Lee et al. 1989). Aggregation of MAPT 
protein results in the formation of filamentous cytoplasmic inclusions which lead to the 
development of tauopathies including frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17) (Rademakers et al. 2004). The phosphorylation status of this 
protein is important since hyperphosphorylation of MAPT produces conformational changes 
which reduce the ability of the protein to interact with microtubules and leads to the formation 
of the aggregations (Morishima-Kawashima et al. 1995; Rademakers et al. 2004). MAPT has 
a polymorphic inversion resulting in two main haplotypes: H1 and H2. H1 has been shown to 
be associated with an increased risk for PD (Farrer et al. 2002; Zabetian et al. 2007; Tobin et 
al. 2008; Wider et al. 2010); however the functional variant within this haplotype still needs 
to be identified. It would be interesting to determine in future studies whether the A91V and 
V635I variants found in the present study have any effect on the normal functioning of 
MAPT.   
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SNCAIP was selected for mutation screening in the present study due to the fact that it has 
been shown to interact with α-synuclein (Engelender et al. 1999) and parkin (Chung et al. 
2001). It has been suggested that synphilin-1 assembles α-synuclein and parkin in a multi-
protein complex. The SNCAIP gene has 11 exons and encodes a 919 amino acid protein that 
contains several protein-protein interaction domains including ankyrin repeat domains, a 
coiled-coil domain, and an ATP and GTP binding domain (Engelender et al. 1999;Engelender 
et al. 2000). Synphilin-1 is ubiquitously expressed throughout the human body including the 
substantia nigra, with highest levels found in neurons (Engelender et al. 1999). Although its 
exact function is not known, it is proposed to localize to the presynapse where it could affect 
dopamine release by binding to synaptic vesicles (Ribeiro et al. 2002). Synphilin-1 is a major 
component of Lewy bodies, a pathological hallmark of PD, and has been shown to promote 
the formation of Lewy-body-like ubiquitin-positive cytosolic inclusions when co-expressed 
with α-synuclein and parkin (Chung et al. 2001). 
 
Only one SNCAIP mutation, R621C has been shown to be associated with PD and was found 
in two unrelated late-onset idiopathic PD German patients (Marx et al. 2003). R621C is also 
commonly found in controls (Myhre et al. 2008). However, functional studies have 
established that it causes an increase in cell vulnerability to cellular stress (O'Farrell et al. 
2001;Marx et al. 2003) and transgenic mice overexpressing R621C exhibit decreased motor 
skill learning and motor performance (Nuber et al. 2010). It is possible that the R606Q variant 
identified in the present study might have a similar effect as the R621C mutation since both 
occur in the ankyrin repeat 5 domain of the protein.   
 
Future work is planned to determine the biological effect of the various variants identified in 
the present study. It will be determined whether A91V and V635I in MAPT have an effect on 
mRNA splicing by altering the ratios of isoforms containing either the four repeat or three 
repeat microtubule binding domains, which has been found to be increased in parkinsonian 
disorders (Takanashi et al. 2002; Connell et al. 2005). The variants might also affect 
phosphorylation of the protein or possibly lead to tau aggregation in the cell. For the T383N, 
R606Q and N906H variants in SNCAIP, it will be investigated whether mutant synphilin-1 is 
able to form cytoplasmic inclusions and is able to be ubiquitinated by parkin. The majority of 
these variants were predicted to be benign by PolyPhen analysis but this requires verification 
by wet-lab functional studies. Previously, the E476K variant in PINK1 was predicted to be 
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benign but was shown to adversely affect mitochondrial membrane potential in transfected 
neuroblastoma cells (Abou-Sleiman et al. 2006).  
 
Conclusion 
Bioinformatic approaches are useful and constitute an important toolset to identify disease-
causing genes especially in complex diseases such as PD as they can systematically search 
through vast amounts of information and are free of inherent human biases. Using the 
CAESAR program in the present study, the MAPT and SNCAIP genes were selected as 
plausible candidates. Mutation screening identified a number of novel missense sequence 
variants in both genes in South African PD patients. Functional studies are planned to 
investigate whether these novel variants affect the normal functioning of these proteins and 
the possible role they play in PD neurodegeneration.   
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Supplementary Table 1 
            
Table 1 Ranked list of PD candidate genes selected by the CAESAR program 
Rank Gene Symbol Mathematically integrated score    Publicly available data sources     
   
Genetic 
association 
data 
Gene ontology 
biological 
process data 
Gene ontology 
molecular 
function data 
Biomolecular 
interaction 
network data 
InterPro 
protein 
domain data 
Mouse 
genome data 
Kyoto 
encyclopedia 
of genes and 
genomes 
pathway data 
UniProt data 
1 SNCA (α-synuclein) 0.000477719 ND 2.33E-05 3.93E-05 4.39E-05 0.000179919 1.89E-05 0.000139595 3.29E-05 
2 PARK2 (parkin) 0.000474014 ND 2.68E-05 3.93E-05 0.00017545 2.25E-05 7.03E-05 0.000139595 ND 
3 SNCAIP (synphilin-1) 0.000466342 ND 1.61E-05 3.93E-05 0.00017545 6.30E-05 ND 0.000139595 3.29E-05 
4 
APP 
(amyloid beta (A4) 
precursor protein) 
0.000456547 ND 4.25E-05 3.93E-05 0.00017545 2.25E-05 4.29E-06 0.000139595 3.29E-05 
5 
MAPT 
(microtubule-associated 
protein tau) 
0.000453194 ND 2.55E-05 3.97E-05 0.00017545 1.35E-05 2.66E-05 0.000139595 3.29E-05 
6 HD (huntingtin) 0.000449758 ND 6.31E-05 3.93E-05 5.70E-05 6.30E-05 5.49E-05 0.000139595 3.29E-05 
7 BCL2L1 (bcl-2-like protein 1) 0.000448355 ND 6.49E-05 2.53E-05 0.00017545 ND 1.03E-05 0.000139595 3.29E-05 
8 SNCB (β-synuclein) 0.000427042 ND ND 1.48E-05 0.00017545 0.000179919 2.40E-05 ND 3.29E-05 
9 TH (tyrosine hydroxylase) 0.000426525 1.92E-05 5.95E-05 1.15E-05 0.00017545 1.35E-05 7.71E-06 0.000139595 ND 
10 
UCHL1 
(ubiquitin carboxyl-
terminal esterase L1) 
0.000426485 ND 2.15E-05 3.21E-05 0.00017545 4.50E-05 1.29E-05 0.000139595 ND 
Genes selected for mutation screening are shaded. Known PD causing genes are shown in bold. The eight scores generated by CAESAR for each gene using the publically available 
data sources are shown in the columns. ND, no meaningful data retrieved from that data source and the score generated was too low.  
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Chapter 7 
 
Additional unpublished results 
 
Additional data obtained that has not been published are presented in this Chapter. 
   
Mutation screening of the SNCA gene 
 
Only three missense mutations (A30P, E46K and A53T) have been found in SNCA and these 
occur in exons 2 and 3. These two exons were subjected to mutation screening by HRM analysis 
in 119 patients that were diagnosed with early- and late-onset PD. No pathogenic mutations or 
novel sequence variants were identified. 
 
Mutation screening of the LRRK2 gene 
 
Nine out of the 51 exons of LRRK2, namely, exons 21, 23, 24, 25, 27, 31, 32, 35 and 41, in 
which putative disease-causing mutations have previously been reported were screened by direct 
sequencing in 195 patients. The patients were selected according to AAO>40 years and 
autosomal dominant inheritance patterns. Results obtained from this study are shown in Table 
7.1. Two known pathogenic mutations were found. One individual had a heterozygous R1441C 
mutation and another was homozygous for G2019S. Notably, both of these individuals have late 
AAO of 62 years and 58 years, respectively. This finding brings the total number of G2019S-
positive patients in our study group to five. A putative pathogenic mutation (S1228T) was 
detected in one individual. S1228T has previously been found in two affected siblings and was 
not present in 1200 controls (Berg et al. 2005). PolyPhen analysis predicted that S1228T is a 
benign variant. 
 
Furthermore, three novel missense sequence variants were found (E899D, R924H, I997N) which 
occur in evolutionary conserved regions of the gene. PolyPhen analysis predicted the E899D 
variant to be benign and the R924H variant to be possibly damaging. Both of these variants 
occur between two functional domains (ANK and LRR). The I997N variant is located in the 
LRR domain and was predicted by PolyPhen analysis to be probably damaging. A number of 
synonymous and intronic variants were also identified. Future work will be to assess the 
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prevalence of the missense variants in ethnic matched control individuals and to determine their 
pathogenic significance by means of functional studies.  
 
Haplotype studies were performed, according to the methodology in Chapter 4, for the individual 
with the homozygous G2019S mutation and this revealed that she was homozygous for 
haplotype-1 (Figure 7.1). 
 
 
Figure 7.1 Pedigree of the patient with the homozygous G2019S mutation. The disease-
associated haplotype is shown. Arrow indicates the proband, open square male, open circle 
female, filled square and circle PD affected individual, square and circle with a strike through 
deceased individual, AAO: age at onset.   
 
 
 
 
 
 
 
 
 
AAO = 58 
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               Table 7.1 Pathogenic mutations and novel sequence variants identified in LRRK2 in South African PD patients 
Location Variant Zygosity Number of 
patients/ethnicity 
AAO 
(yrs) 
Family 
history 
Protein domain Previously reported 
Intron 20  IVS20-65 A>T Heterozygous 2/Black    Novel 
 Exon 21 E899D Heterozygous 1/Black  51 + between ANK and 
LRR domain 
Novel 
 Exon 21 R924H Heterozygous 1/Afrikaner  44 - between ANK and 
LRR domain 
Novel 
 Exon 23 I997N Heterozygous 1/Caucasian  65 - LRR Novel 
Intron 23  IVS23+78 C>T Heterozygous 1/Caucasian     Novel 
Intron 26  IVS26-89 T>A Heterozygous 3/Black;  
2/Mixed ancestry 
   Novel 
Intron 26  IVS26-33 T>C Heterozygous 2/Black;  
1/Mixed ancestry 
   Novel 
Intron 26  IVS26-29 G>A Heterozygous 2/Mixed ancestry    Novel 
 Exon 27 E1224E Heterozygous 1/Mixed ancestry 
1/Black 
48 
40 
- LRR Novel 
 Exon 27 S1228T Heterozygous 1/ Caucasian  50 + LRR (Berg et al. 2005) 
Intron 27  IVS27+7 C>T Heterozygous 1/Caucasian    Novel 
 Exon 31 R1441C Heterozygous 1/ Mixed ancestry  62 - ROC (Mata et al. 2005)  
 Exon 32 R1514Q Heterozygous 4/Caucasian   COR Known polymorphism 
(Toft et al. 2007) 
 Exon 32 P1542S Heterozygous 3/Afrikaner; 
2/Caucasian 
  COR Known polymorphism 
(Di Fonzo et al. 2006) 
 Exon 35 S1721S Heterozygous 1/Caucasian 
1/Black 
56 
74 
+ 
- 
COR Novel 
Intron 35  IVS35+23 T>A Heterozygous 
and 
homozygous 
122/Afrikaner, 
Caucasian, Mixed 
ancestry, Black, 
Indian 
   Novel 
 Exon 41 G2019S Homozygous 1/ Caucasian 
(Russian)  
58 + MAPKKK (Kachergus et al. 2005; 
Lesage et al. 2009)  
                          Pathogenic mutations are shown in bold. AAO: age at onset; ANK: Ankyrin repeat; COR: C-terminal of ROC; LRR: leucine rich repeat;  
                   Roc: Ras of complex protein; MAPKKK: mitogen-activated protein kinase kinase kinase 
 
127 
 
Reference list 
 
Berg, D., K. Schweitzer, P. Leitner, A. Zimprich, P. Lichtner et al.  2005 Type and frequency of 
mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128: 3000-
3011. 
Di Fonzo, A., C. Tassorelli, M. M. De, H. F. Chien, J. Ferreira et al.  2006 Comprehensive analysis of the 
LRRK2 gene in sixty families with Parkinson's disease. Eur.J.Hum.Genet. 14: 322-331. 
Kachergus, J., I. F. Mata, M. Hulihan, J. P. Taylor, S. Lincoln et al.  2005 Identification of a novel 
LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder 
across European populations. Am.J.Hum.Genet. 76: 672-680. 
Lesage, S., C. Condroyer, A. Lannuzel, E. Lohmann, A. Troiano et al.  2009 Molecular analyses of the 
LRRK2 gene in European and North African autosomal dominant Parkinson's disease. 
J.Med.Genet. 46: 458-464. 
Mata, I. F., J. M. Kachergus, J. P. Taylor, S. Lincoln, J. Aasly et al.  2005 Lrrk2 pathogenic substitutions 
in Parkinson's disease. Neurogenetics. 6: 171-177. 
Toft, M., I. F. Mata, O. A. Ross, J. Kachergus, M. M. Hulihan et al.  2007 Pathogenicity of the Lrrk2 
R1514Q substitution in Parkinson's disease. Mov Disord. 22: 389-392. 
 
  
 
URL reference list 
 
Polymorphism Phenotyping (PolyPhen): [http://genetics.bwh.harvard.edu/pph/] date accessed 11/10/2010 
 
128 
 
Chapter 8 
 
 
Identification of a novel functional deletion variant in the 5'-UTR of the       
DJ-1 gene 
 
 
Rowena J Keyser1, Lize van der Merwe2,3, Mauritz Venter4, Craig Kinnear1, Louise Warnich4, 
Jonathan Carr5, and Soraya Bardien1 
 
 
1Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, University of 
Stellenbosch, Cape Town, 8001, South Africa 
2Biostatistics Unit, Medical Research Council, Cape Town, 8001, South Africa 
3Department of Statistics, University of Western Cape, Cape Town, 8001, South Africa 
4Department of Genetics, University of Stellenbosch, Stellenbosch, 7600, South Africa 
5Division of Neurology, Faculty of Health Sciences, University of Stellenbosch, Cape Town, 
8001, South Africa 
 
 
 
Published in: BMC Medical Genetics 2009 Oct 13;10:105.   
 
 
 
 
Impact factor of journal: 2.84 
My contribution to this project: Planning of study 
Performed all experimental procedures including: 
generation of constructs, cell culture, transfections and 
luciferase assay, clonogenic survival assay, RFLP analysis 
and sequencing 
Analysis and interpretation of data 
     Writing of manuscript 
129 
 
Abstract 
 
Background 
DJ-1 forms part of the neuronal cellular defence mechanism against oxidative insults, due to its 
ability to undergo self-oxidation. Oxidative stress has been implicated in the pathogenesis of 
central nervous system damage in different neurodegenerative disorders including Alzheimer's 
disease and Parkinson's disease (PD). Various mutations in the DJ-1 (PARK7) gene have been 
shown to cause the autosomal recessive form of PD. In the present study South African PD 
patients were screened for mutations in DJ-1 and we aimed to investigate the functional 
significance of a novel 16 bp deletion variant identified in one patient. 
 
Methods 
The possible effect of the deletion on promoter activity was investigated using a Dual-Luciferase 
Reporter assay. The DJ-1 5'-UTR region containing the sequence flanking the 16 bp deletion was 
cloned into a pGL4.10-Basic luciferase-reporter vector and transfected into HEK293 and BE(2)-
M17 neuroblastoma cells. Promoter activity under hydrogen peroxide-induced oxidative stress 
conditions was also investigated. Computational (in silico) cis-regulatory analysis of DJ-1 
promoter sequence was performed using the transcription factor-binding site database, 
TRANSFAC via the PATCH™ and rVISTA platforms. 
 
Results 
A novel 16 bp deletion variant (g.-6_+10del) was identified in DJ-1 which spans the 
transcription start site and is situated 93 bp 3' from a Sp1 site. The deletion caused a reduction in 
luciferase activity of approximately 47% in HEK293 cells and 60% in BE(2)-M17 cells 
compared to the wild-type (P<0.0001), indicating the importance of the 16 bp sequence in 
transcription regulation. The activity of both constructs was up-regulated during oxidative stress. 
Bioinformatic analysis revealed putative binding sites for three transcription factors AhR, 
ARNT, HIF-1 within the 16 bp sequence. The frequency of the g.-6_+10del variant was 
determined to be 0.7% in South African PD patients (2 heterozygotes in 148 individuals). 
 
Conclusion 
This is the first report of a functional DJ-1 promoter variant, which has the potential to influence 
transcript stability or translation efficiency. Further work is necessary to determine the extent to 
which the g.-6_+10del variant affects the normal function of the DJ-1 promoter and whether this 
variant confers a risk for PD. 
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Background 
 
The DJ-1 gene (PARK7; OMIM 602533) was first described about a decade ago [1] and encodes 
a 189 amino acid protein which belongs to the DJ-1/Thi/PfpI protein super family [2,3]. It is 
ubiquitously expressed in a variety of mammalian tissues including the brain, and was initially 
described in association with oncogenesis and male rat infertility [1,4,5]. Later it was shown to 
be associated with autosomal recessive early-onset Parkinson's disease (PD) [3,6]. A few PD-
causing mutations have been identified including exon deletions, truncations, homozygous and 
heterozygous point mutations, which predominantly result in loss of function [3,7]. The 
expression of DJ-1 in the central nervous system (CNS) is not restricted to specific anatomical or 
functional systems and it is located in neuronal and glial cells within the substantia nigra [8,9]. 
 
DJ-1 is proposed to play a role in protecting neurons from oxidative stress and protecting against 
mitochondrial damage [10,11]. Oxidative stress can be defined as an imbalance between reactive 
oxygen species (ROS) production and the antioxidant capacity of a cell. Mitochondrial 
dysfunction leading to increased ROS can cause damage to various cellular components such as 
unsaturated lipids, proteins, and nucleic acids, and this has been implicated in various 
neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and PD 
[12]. Recent studies aimed at elucidating the function of DJ-1, have found that it is able to 
undergo self oxidation in order to eliminate hydrogen peroxide (H2O2) and, in so doing, acts as a 
scavenger of ROS [11,13]. An increase in susceptibility to oxidative stress of mammalian cells in 
cases where DJ-1 was knocked down has been reported [10,11]; cells were more susceptible to 
H2O2-induced cell death due to DJ-1 knockdown and over-expression of wild-type DJ-1 rescued 
the cells [14]. It has been reported that DJ-1 is oxidatively damaged in the brains of PD patients 
[15,16]. Studies showed that under oxidative stress conditions, DJ-1 undergoes a shift in its 
isoelectric point which leads to the accumulation of acidic isoforms in PD frontal cortex tissue 
compared to age-matched controls [15]. Up-regulation of DJ-1 as well as the intracellular 
redistribution of DJ-1 to the mitochondria under oxidative stress conditions has been reported 
[10,17]. The mitochondria have a central role in free radical generation and it has been proposed 
that DJ-1 in the mitochondria may have a role in preventing mitochondrial injury or decreasing 
mitochondrial ROS production. Redistribution of DJ-1 to the mitochondria might be the neuronal 
cellular defence mechanism against oxidative insults [9,10,18]. 
 
DJ-1 is highly conserved across diverse species [19] and there have been limited reports of 
sequence variants. An 18 bp insertion/deletion polymorphism (g.168_185del) in DJ-1's promoter 
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region has been reported to not confer a risk for PD [20,21]. However, a homozygous 
duplication of this 18 bp sequence (g.168_185dup), as well as a homozygous E163K mutation, 
have been identified in an Italian family with a Parkinsonism-Dementia-Amyotrophic Lateral 
Sclerosis phenotype [22]. The duplication and the E163K variants were not found in 1,400 and 
500 control chromosomes, respectively. It has been reported that the E163K mutation 
compromises the ability of DJ-1 to protect against oxidative stress induced by H2O2 [23]. It is not 
known whether the phenotype in this family was due to the g.168_185dup mutation or the 
E163K mutation, or both. 
 
In the present study, we investigated the functional significance of a novel 16 bp deletion which 
we identified in the promoter region of DJ-1 in a PD patient by means of luciferase functional 
expression studies. Unlike the 18 bp insertion/deletion variant, the 16 bp deletion occurs in a 
transcriptionally important region of the gene as it spans the transcription start site. 
 
Methods 
 
Study participants 
The study protocol was approved by the Committee for Human Research at the University of 
Stellenbosch, South Africa (Protocol number 2002/C059). In the initial part of the study 30 
unrelated South African PD patients were recruited with informed written consent from the 
Movement Disorders clinic at Tygerberg Hospital in South Africa. The patients were examined 
by a movement disorder specialist (JC) and all met the UK Parkinson's Disease Society Brain 
Bank Research criteria for diagnosis of PD [24]. Inclusion criteria for recruitment of patients 
were early onset and/or positive family history of PD. The average age at onset (AAO) of the 
study group was 43 years and ranged from 17 years to 77 years. The percentage of males in our 
study group was 66%. Once the 16 bp deletion variant was detected, the frequency of the variant 
was determined in a total of 148 unrelated South African PD patients (average AAO = 52 years). 
Blood samples for 62 controls representing the mixed ancestry ethnic group were recruited from 
unrelated blood donors at the South African Western Province Blood Transfusion Service blood 
collection clinics. The controls had been 'de-identified' and had not been clinically assessed for 
signs of PD. 
 
Genetic analysis 
The single-strand conformational polymorphism analysis method was used to screen the 30 PD 
patients for genetic variations in all 7 exons and the 5' UTR of DJ-1. Samples exhibiting altered 
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mobilities on mildly-denaturing polyacrylamide gels (containing 5% glycerol and 15% urea) 
were sequenced in order to characterize the sequence variation. Direct sequencing was 
performed using the BigDye Terminator Sequence Ready Reaction kit version 3.1 (Applied 
Biosystems, Foster City, USA) and analysis was conducted on a 3130 xl Genetic Analyser 
(Applied Biosystems). 
 
Construction of luciferase vectors 
Functional analysis of a novel 16 bp deletion identified in the 5'-UTR was performed using a 
Dual-Luciferase Reporter Assay System (http://www.promega.com/pGL4). In this assay, the 
activities of the firefly (Photinus pyralis; the experimental reporter gene) and the Renilla (Renilla 
reniformis or sea pansy; the internal control gene) luciferases are measured sequentially from a 
single sample. The firefly luciferase gene is present on the promoterless pGL4.10 [luc2] vector 
and the Renilla luciferase gene is on the phRL-SV40 vector. The pGL4 luciferase reporter vector 
was used in this study because it has been codon optimized for more efficient expression in 
mammalian cells. The reporter gene and the vector backbone have been engineered to reduce the 
number of consensus transcription factor binding sites, which leads to reduced background 
luminescence and the risk of anomalous transcription. In this experiment the pGL4.10 [luc2] and 
phRL-SV40 vectors are used to co-transfect mammalian cells and due to their distinct 
evolutionary origins the activity of two luciferases can be distinguished since they have different 
enzyme structures and substrate requirements. 
 
The promoter region of DJ-1 containing sequence spanning the 16 bp deletion was PCR 
amplified from genomic DNA from the individual harbouring the deletion variant using primers 
containing restriction sites for cloning. Primers were designed to PCR amplify a fragment from 
position 1 to 2119 bp (GenBank accession number AB045294). It was decided to include the 
entire 5'UTR sequence in the luciferase assay to ensure that all sites important for transcription 
initiation and regulation, especially under hydrogen peroxide-induced oxidative stress 
conditions, were present. A similar sized construct had previously been used successfully to 
assess promoter function of DJ-1 in a study done by Taira et al., 2001 [19]. 
 
Two constructs were generated; wild-type [pDJ-1(wt)Luc] and a 16 bp deletion variant [pDJ-
1(del)Luc]. Primer sequences used were: forward 5'-ATC GTA TCG CTC GAG GGA TCC TTC 
TAA GCT CAT TC-3' and reverse 5'-CAG AGC TCT TTT GGA AGC AAG CTT 
CGATACGAT-3'. PCR reactions were performed in a 2720 Thermal Cycler (Applied 
Biosystems). The 50 μl reactions contained 200 ng template DNA (wild-type or deletion), 20 
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pmoles of each primer, 75 μM dNTPs (Promega), 1.5 mM MgCl2, 1× NH4 buffer (Bioline), 5% 
DMSO and 0.5 units of BIOTAQ DNA polymerase (Bioline). The PCR cycling parameters 
entailed an initial denaturation step at 95°C for 7 min, followed by 30 cycles of denaturation at 
95°C for 30 sec, annealing at 50°C for 30 sec and extension at 72°C for 2 min, and a final 
extension step at 72°C for 10 min. The 2,151-kb sized PCR products (either wild-type sequence 
or 16 bp deletion sequence), as well as pGL4.10 [luc2] were digested with XhoI and HindIII 
(Fermentas) and purified (Wizard SV Gel and PCR Clean-up system, Promega). Vector arms 
were dephosphorylated (CIP, Promega) and ligated overnight to the digested PCR fragments. 
The pDJ-1(wt)Luc and pDJ-1(del)Luc constructs were subcloned into E. coli DH5α cells and 
single colonies were miniprepped (GeneJET plasmid miniprep kit, Promega). Insertion of the 
DJ-1 promoter sequence in-frame with the firefly luciferase gene in the pGL4.10 [luc2] vector 
was verified by direct sequencing using the BigDye Terminator Sequence Ready Reaction kit 
version 3.1 (Applied Biosystems) and analyzed on a 3130 xl Genetic Analyzer (Applied 
Biosystems). 
 
PCR-restriction fragment length polymorphism (RFLP) analysis 
PCR-restriction fragment length polymorphism (RFLP) analysis was used to screen 148 PD 
patients and 62 control samples for the presence of the 16 bp deletion variant. The control 
samples were of South African mixed ancestry descent which can be defined as an admixture of 
indigenous African populations and immigrants from mainly Western Europe, Madagascar, 
Malaysia and India. The following PCR primers were designed which span the 16 bp deletion: 
forward 5'-ACC CAG GGC TGT CCA GCT A-3' and reverse 5'-GTC CAG CAC AGG GAC 
ACC-3' and produced a PCR product of 321 bp and 305 bp for the wild type and deletion alleles, 
respectively. A total of 8 μl of the PCR product was digested overnight at 37°C with 5 units of 
KpnI (Promega) in a final volume of 20 μl. Thereafter, the digested products were 
electrophoresed on 12% polyacrylamide gels and the bands visualized by silver staining. 
Following the KpnI digest, the samples could be genotyped since the wild type allele produced 
two fragments of 129 bp and 192 bp whereas the 16 bp deletion allele produced two fragments of 
129 bp and 176 bp. 
 
Cell culture 
Human embryonic kidney cells (HEK293) (Highveld Biological, Pty, Ltd, South Africa) and 
human dopaminergic neuroblastoma BE(2)-M17 cells (American Type Culture Collection, USA) 
were cultured separately under sterile conditions in Dulbecco-modified Eagle medium (LONZA 
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BioWhittaker®) supplemented with 10% fetal calf serum, penicillin (100 units/ml), and 
streptomycin (100 μg/ml) in 5% CO2 humidified atmosphere at 37°C. 
 
Plasmid transfection and luciferase assay 
Cultured HEK293 and M17 cells were plated 24 hrs prior to transfection into 6-well culture 
dishes at 80-90% confluence and maintained at an atmosphere of 5% CO2 at 37°C. For 
transfections, 1 μg of DNA was added with 3 μl Fugene (Roche Biochemicals) and serum-free 
media to a total volume of 100 μl (DNA/Fugene/media complex). The complex was then added 
to the cells in the culture dishes in a drop-wise manner. The pDJ-1(wt)Luc and pDJ-1(del)Luc 
constructs were co-transfected with phRL-SV40, an internal control vector containing the 
Renilla luciferase gene (Promega), in a ratio of 50:1 (pGL4 versus phRL-SV40), in order to 
control for transfection efficiency. Twenty four hours after transfection, the cells were exposed 
to H2O2 (0-75 μM), in order to produce ROS formation. Forty eight hours after transfection, the 
cells were gently rinsed with phosphate buffered saline and harvested with Passive Lysis Buffer 
(Promega). The Dual-luciferase® Reporter Assay System (Promega) was used to measure 
luciferase activity. Twenty microliters of cell lysate were added to 100 μl of luciferase assay 
reagent II (Promega) and the firefly luminescence was read using a Modulus 96 Luminometer. 
Next, 100 μl of Stop&Glo® reagent (Promega) was added to the lysates and renilla 
luminescence was read. Luminescence values of firefly were normalized with renilla for each 
construct within an experiment. The luciferase assay was repeated in four independent 
experiments for each cell type and the luminescence readings were read in triplicate. 
 
Clonogenic survival assay 
A clonogenic survival assay was conducted in order to determine the appropriate concentration 
of H2O2 to use in the luciferase assay. The cultured HEK293 and M17 cells were plated in 
appropriate dilutions (1000-2000 cells/well) into 6-well plates, and incubated for 48 hrs. The 
cells were then exposed to varying concentrations of H2O2 (0, 25, 50 and 75 μM) and incubated 
for approximately one week. Thereafter, the cells were fixed and stained with 0.2% crystal violet 
(Merck) overnight for visual colony count. The IC50 values (concentration of H2O2 required to 
inhibit colony formation by 50%) were determined for both cell lines. 
 
Bioinformatics 
Computational (in silico) cis-regulatory analysis of DJ-1 promoter sequence was performed 
using the transcription factor-binding site database, TRANSFAC via the PATCH™ platform 
(http://www.gene-regulation.com). For PATCH™ analysis, the primary parameter settings were 
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set as: Minimum Length of Sites at 4 and Lower Score Boundary at 85%. The multi-species 
conserved sequence analyses were performed using the rVISTA (regulatory VISTA) platform 
(http://genome.lbl.gov/vista/index.shtml) at default cut-off criteria: ≥ 70% identity over a 
contiguous paired sequence length ≥ 100 bp. rVISTA combines searching the major transcription 
factor binding site database TRANSFAC with a comparative sequence analysis. DJ-1 promoter 
sequences (2 kb upstream and 5'-UTR) from human (Ensembl Gene ID: ENSG00000116288; H. 
sapiens), chimpanzee (ENSPTRG00000000102, P. troglodytes), orangutan 
(ENSPPYG00000001925, P. pygmaeus), macaque (ENSMMUG00000019671, M. mulatta), tree 
shrew (ENSTBEG00000009474, T. belangeri), horse (ENSECAG00000017251, E. caballus), 
dog (ENSCAFG00000019674, C. familiaris), cow (ENSBTAG00000020518, B. taurus), mouse 
(ENSMUSG00000028964, M. musculus) and rat (ENSRNOG00000018289, R. norvegicus) were 
retrieved from the Ensembl Genome Browser (archive version at 
http://jul2008.archive.ensembl.org/index.html). 
 
Statistical analysis 
The open-source programming environment R (freely available from http://www.r-project.org) 
was used for the statistical analysis. A linear mixed-effects model was created to analyse the 
data. All the relative light units (RLU) values were first log-transformed towards symmetry, and 
then modelled as a function of the factors including cell line (HEK293 or M17), Type (WT or 
deletion) and H2O2 concentration (0, 25, 50 or 75 μM) as fixed effects. We also included 
interactions between Type and cell line, as well as between Type and H2O2 concentration, both 
of which were independently significant after adjusting for all the other effects. As the individual 
experiments yielded RLU values that were dissimilar, each experiment were included in the 
model as a random effect. All the results reported here come from the same model, and were 
therefore adjusted for all the other factors in the model, as well as the random effect of individual 
experiments.  
 
Results 
 
During mutation screening of South African PD patients a novel 16 bp deletion in the promoter 
region of DJ-1 was identified. The frequency of this deletion (g.-6_+10del) was estimated to be 
0.7% (95% confidence interval 0.2% to 2.4%), based on 2 heterozygotes in 148 South African 
PD patients screened. Both patients were sporadic individuals of South African mixed ancestry. 
One of the patients presented with PD at age 38 years. He had displayed early onset of prominent 
autonomic dysfunction and hallucinations (with psychosis) and had died at the age of 47 years. 
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The other patient had an age at onset of 56 years and also has a history of psychotic episodes. 
Furthermore, the g.-6_+10del variant was observed in a homozygous state in one of 62 mixed 
ancestry control individuals screened (1.6%). This individual was aged 34 years and had not 
been clinically assessed for signs of PD. 
 
The 16 bp deletion spans the transcription start site of DJ-1 which had previously been identified 
by Taira et al. [19] using the method of 'CAP site hunting'. This variant is situated 93 bp 
downstream of a Sp1 site, which has been shown to be necessary for DJ-1 transcription [19], and 
157 bp upstream from the known g.168_185del polymorphism (Figure 1). We hypothesized that 
this deletion would disrupt transcription of DJ-1 and this hypothesis was tested using a luciferase 
reporter assay. DJ-1 has previously been shown to be expressed in the HEK293 cell line [19] and 
these cells were therefore used in the initial experiments. 
 
To determine the in vitro effect of the deletion variant on DJ-1 promoter activity, two different 
constructs (wild-type and deletion variant) were generated. The promoter region of DJ-1 
containing the sequence spanning the 16 bp deletion, as well as transcriptionally important sites 
such as the transcription start site and Sp1 site, was linked to the firefly luciferase gene and the 
luciferase activity was measured in RLU. Both constructs contained the 18 bp of the 
polymorphic variant (g.168_185del). The results obtained are therefore likely to be due only to 
the presence or absence of the 16 bp sequence. 
 
The linear mixed-effects model for log(RLU) values, showed a significant interaction between 
construct type and H2O2 concentration (p = 0.0010) and also between construct type and cell line 
(p = 0.0119). All three factors: cell line, construct type and H2O2 concentration, had highly 
significant effects (p < 0.0001) on log(RLU) after adjusting for the interactions and experiments. 
All the P-values presented in the present study come from this model and they are therefore 
adjusted for the differences between the individual experiments as well as all the other factors in 
the model [the cell line (HEK293 or M17), construct type (WT or deletion) and H2O2 
concentration (0, 25, 50 or 75 μM) as well as the interactions between Type and cell line, and 
between Type and H2O2 concentration]. We compared the geometric means (the mean of the 
logs, which is then anti-logged) of the observed RLU values obtained for each combination of 
the M17 cells, the construct type and the H2O2 concentration to the predicted means generated by 
the model (results not shown). These results indicated that the model fitted the data well and we 
therefore have confidence in our results. 
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Figure 1 Nucleotide sequence of the promoter region of the human DJ-1 gene (GenBank Accession 
number AB045294) showing the positions of significant sites. The +1 indicates the transcription start site. 
The position of the 16 bp deletion sequence is indicated by a single underline and the Sp1 site by a double 
underline. The position of the 18 bp insertion/deletion polymorphism (g.168_185del) is indicated in blue 
font and the positions of the primers used to generate the luciferase constructs are shown in bold green 
font. The positions of putative cis-motifs (AhR/ARNT and HIF-1) present in the 16 bp deletion sequence 
are indicated by arrows. 
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The wild-type construct produced consistently higher luciferase activity compared to the activity 
of a promoterless vector, which indicated that the insert contained a functional promoter (results 
not shown). Figure 2 shows the distribution of the normalized RLU values obtained for the wild-
type and deletion variant in both cell lines. There was a significant difference between the wild-
type and the deletion variant in the HEK293 cell line, after adjusting for experiments and all 
other factors. The deletion caused a reduction in luciferase activity of approximately 47% 
compared to the wild-type, indicating that the 16 bp sequence is probably important for the 
transcriptional regulation of DJ-1 (Figure 2A). Conducting the assay in M17 neuroblastoma cells 
(Figure 2B) produced similar results with an even larger reduction of 60% in luciferase activity 
observed for the deletion compared to the wild-type. From the box plots of the data, it was noted 
that for both cell lines, approximately 75% of the RLU values of the deletion variant were less 
than the lower 25% quartile of the RLU values for the wild-type (Figure 2), which illustrates the 
significant difference in the RLU values between the two constructs. 
 
 
Figure 2 The DJ-1 16 bp deletion variant exhibited significantly reduced transcription levels compared to 
the wild-type (P < 0.0001) in two different cell lines. Box plots of dual-luciferase assays of the wild-type 
and deletion variant using (A) HEK293 cells and (B) neuroblastoma M17 cells. They include median 
(horizontal line within box), inter-quartile interval i.e. 25th to 75th percentile (box) and the range of 
variation (whiskers). The 2 kb promoter fragments (containing either wild-type sequence or the deletion) 
were linked to the luciferase gene and the constructs were transfected into two mammalian cell lines. For 
each experiment, firefly luciferase activity was divided by renilla activity to normalize for transfection 
efficiency. Data are representative of four transfection experiments (triplicate points obtained over four 
independent experiments). WT: wild-type; D: deletion variant; RLU: relative light units. 
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H2O2 treatment of the M17 neuroblastoma cells 
The effect of the deletion variant on DJ-1 promoter activity under H2O2-induced oxidative stress 
conditions was investigated using M17 neuroblastoma cells. DJ-1 is a scavenger of ROS and is 
proposed to play a role in protecting neurons from oxidative stress. A clonogenic survival assay 
was first performed to assess the concentration of H2O2 to use for these experiments. The IC50 
values (concentration of H2O2 required to inhibit colony formation by 50%) were shown to be 50 
μM for both cell lines (results not shown). The H2O2 concentration of 75 μM had the highest 
cytotoxic effect on both cell lines. 
 
Under H2O2-induced oxidative stress conditions, the deletion variant again exhibited 
significantly reduced promoter activity compared to the wild-type for the untreated as well as at 
all three concentrations of H2O2 (Figure 3). The promoter activity of both the wild-type and 
deletion was moderately upregulated during these oxidative stress conditions with increasing 
concentrations of H2O2. However, this trend was not observed at the highest H2O2 concentration 
of 75 μM, possibly because of increased cell death at this dosage. Although both the wild-type 
and deletion exhibited increased promoter activity with increasing concentrations of H2O2, the 
promoter activity for the deletion variant was always lower than that of the wild-type. In a post-
hoc analysis with H2O2 as dichotomous [treated (all concentrations > 0) versus untreated] we 
found a highly significant difference (p < 0.0001) in promoter activity between untreated cells 
and H2O2 treated cells (after adjusting for all other factors in model, namely the construct type, 
the cell line and the H2O2 concentrations (0, 25, 50 or 75 μM) and the interactions between type 
and each of the other two factors). 
 
Computational cis-regulatory analysis of DJ-1 
Interestingly, the 16 bp deletion sequence contains three perfect 5'-GCGT-3' and one imperfect 
repeat (5'-GCTG-3'). The functionality of this particular motif is currently not known. Analysis 
of the 16 bp deletion sequence (using the TRANSFAC database via PATCH and rVISTA) 
revealed the over-representation of three putative cis-motifs that correlate to the transcription 
factors Aryl hydrocarbon receptor (AhR; TRANSFAC Acc. Nr. T00018), Ahr nuclear 
translocator (ARNT; T01797) and Hypoxia induced factor 1 (HIF-1; T01609) within the 16 bp 
sequence (Figure 1). The core binding sequence for AhR and ARNT is 5'-CACGC-3' and for 
HIF-1 is 5'-RCGTG-3'. These transcriptional regulators control a variety of developmental and 
physiological events including metabolism of toxins and responses to hypoxia [25,26], and share 
regulatory cross-talk with many other transcription factors.  
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Figure 3 H2O2 dose-dependent up-regulation of DJ-1 promoter activity. Box plots of the dual-luciferase 
assay of the 16 bp DJ-1 deletion variant using the neuroblastoma M17 cell line and exposure to different 
concentrations of H2O2 (0, 25, 50 and 75 μM). *: geometric means; WT: wild-type; D: deletion variant; 0, 
25, 50, 75: H2O2 concentrations. 
 
When the 16 bp sequence is deleted a transcription factor site is created. In silico promoter 
analysis revealed that the sequence in the (-) strand (GCGCGTTC) of the 16 bp deleted region 
conforms to a novel cis-motif that putatively correlated to cis/trans interaction with the E2F-
class of transcription factors. 
 
Multi-species comparative analysis using rVISTA, [27], showed regions of ≥ 70% conserved 
identity (over contiguous sequence length: 100 bp) of the human DJ-1 promoter region to 
chimpanzee (1754 bp), orangutan (1347 bp), macaque (1239 bp), tree shrew (233 bp) and horse 
(248 bp). All the other species investigated including rat and mouse showed ≤ 70% conservation 
(Figure 4).  
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Figure 4 Comparative multi-species analysis using rVISTA of the DJ-1 promoter region of approximately 
2000 bp + 5'-UTR. Conserved percentage identity is indicated with cut-off criteria: ≥ 70% identity over ≥ 
100 bp are indicated in orange and the white regions represent either no alignment or ≤ 70% sequence 
identity over 100 bp contiguous sequence length. The 16 bp deletion sequence is represented by an arrow 
on a dashed line and is found in a region sharing highly conserved identity between species. 
 
Discussion 
 
In the present study we report a novel 16 bp deletion (g.-6_+10del) in the promoter region of DJ-
1. The deletion was shown to span the transcription start site, according to Taira et al. 2001 [19] 
and is situated 93 bp downstream of a Sp1 transcription regulatory sequence which is essential 
for DJ-1 promoter activity. In addition, the g.-6_+10del variant is located 157 bp upstream from 
a known 18 bp duplication mutation (g.168_185dup). The duplication mutation has previously 
been reported to co-segregate, together with a homozygous E163K mutation, with early-onset 
Parkinsonism-Dementia-Amyotrophic Lateral Sclerosis in an Italian family [22]. Due to its 
location within the DJ-1 promoter, we hypothesised that the 16 bp deletion variant might 
influence the level of DJ-1 expression, the transcript stability or the translation efficiency. 
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Functional expression studies using the dual-luciferase reporter system found that the g.-
6_+10del variant significantly reduced DJ-1 promoter activity in both HEK293 and 
neuroblastoma M17 cells, with the M17 cells exhibiting a higher reduction in activity. This 
indicates the possible importance of the 16 bp sequence in transcriptional regulation of DJ-1. 
Recent studies aiming to elucidate the function of DJ-1, have identified it as a scavenger of ROS 
due to its ability to undergo self oxidation in order to eliminate H2O2 [11]. It was therefore 
decided to assess the effect of the deletion variant on DJ-1 promoter activity under H2O2-induced 
oxidative stress conditions using the neuroblastoma M17 cell line. In the present study it was 
shown that cells placed under oxidative stress conditions showed a dose-dependent moderate up-
regulation in both wild-type and deletion variant's promoter activities with the deletion variant 
retaining its lower RLU values compared to the wild-type. 
 
Furthermore, bioinformatic analysis identified binding sites for the transcription factors; Aryl 
hydrocarbon receptor (AhR), Ahr nuclear translocator (ARNT) and Hypoxia induced factor 1 
(HIF-1) within the 16 bp deletion sequence. AhR and ARNT are known to dimerize to form an 
active transcription factor complex that binds defined DNA sequences, the xenobiotic-responsive 
element (XRE), with high affinity causing an increase in transcription of AhR-regulated genes 
[26,28,29]. The AhR/ARNT complex up-regulates cytochrome P450 enzymes that play diverse 
roles in metabolism of endogenous substances, environmental chemicals and various drugs [29]. 
AhR functions as the prime transcription factor and ARNT as a DNA binding partner. 
Transcriptional up-regulation during hypoxia is mediated principally by HIF-1 (a dimer of HIF-
1α and ARNT). The anticancer property of curcumin has been shown to be due to inactivation of 
HIF-1 by degradation of ARNT via oxidation and ubiquitination processes [30]. It was also 
shown that curcumin induces proteasomal degradations of both AhR and ARNT and this is 
mediated by oxidative stress [31]. It is possible that the AhR/ARNT or HIF-1 complexes may 
interact with DJ-1's promoter thereby regulating its transcription and therefore indirectly 
influencing the transcription of various genes associated with oxidative stress, apoptosis and 
neurotoxicity that are regulated by DJ-1 [32]. 
 
Further analysis found that when the 16 bp sequence is deleted, a binding site for the E2F-class 
of transcription factors is created. E2F has been shown to induce transcription of pro-apoptotic 
proteins and repression of E2F-responsive genes is required for neuronal survival [33]. Recent 
studies found that the pRb/E2F cell-cycle pathway is activated in dopaminergic neurons in PD 
patients, as well as in a PD mouse model [34]. 
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DJ-1 is highly conserved at both the nucleotide and amino acid level, possibly due its important 
role in protection against oxidative stress. Mouse and human DJ-1 is 83% and 90% identical at 
the DNA and protein level, respectively [19]. Similarly, the conservation between porcine and 
human DJ-1 is 96% at the protein level [35]. There have been no reports however on the level of 
conservation of DJ-1's 5'-UTR sequence. We showed through multi-species comparative analysis 
that the promoter region of DJ-1 is highly conserved, as expected, between man and other 
primates as well as to a few other species. More importantly, the 16 bp deletion sequence is 
present in a highly conserved promoter region (Figure 4) indicating the possible significance of 
this sequence in higher order mammals and thus an evolutionarily retained functionality. 
 
It would be interesting to determine the prevalence of the g.-6_+10del variant in other 
populations and to establish whether it plays a role in susceptibility to neurodegenerative 
diseases such as PD. Further studies are necessary to determine whether endogenous levels of 
DJ-1 are affected by the 16 bp deletion and whether an alternative transcriptional start site is 
present. In addition, introducing point mutations into the predicted transcription factor binding 
sites within the 16 bp sequence to determine the effect on DJ-1's transcription and the cell's 
response to oxidative stress would be of interest. 
 
Conclusion 
 
We report a novel sequence variant in the highly conserved DJ-1 gene. Functional expression 
studies found that this variant significantly reduced DJ-1 promoter activity in two separate 
mammalian cell lines, which indicates the possible importance of the 16 bp sequence in 
transcriptional regulation of DJ-1. In addition, the activity of three transcription factors with 
recognition sites within the deletion sequence might be influenced by the g.-6_+10del variant. 
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PD had been considered the archetypal non-genetic disorder until the discovery 13 years ago of 
the first PD-causing mutation in the SNCA gene. Since then at least six genes, PARK2, PINK1, 
DJ-1, SNCA, LRRK2 and ATP13A2, have been conclusively implicated in PD pathogenesis. 
However, these genes have been shown to account for < 10% of all PD cases which highlights 
the need to identify additional PD candidate genes. Identification of these genes and the 
pathways that they are involved in may ultimately result in the development of new therapeutic 
modalities.  
 
The present study is the first to investigate the genetic basis of PD in South Africa and it was 
hypothesized that, due to the unique ancestry of this country’s populations, these patients may 
harbor novel mutations. The mixed ancestry sub-population, in particular, has a complex 
ancestry, being an admixture of at least five different population groups (African, European, 
Madagascan, Malaysian and Indian). The Afrikaner population is also unique to South Africa. 
They are known to have undergone a genetic bottleneck at the end of the 19th century, and 
founder effects for a number of disorders including variegate porphyria and familial 
hypercholesterolemia have been identified in this group (Jenkins 1990). It could be speculated 
that a founder effect for PD may also exist in this group. In addition, the South African Black PD 
population is of interest since Black individuals with PD have been reported to present with 
atypical clinical features, and a late-onset akinetic-rigid variant (Chaudhuri et al. 2000). PD is 
also thought to be uncommon in the Black population worldwide.  
 
During our investigation of the genetic etiology of PD in South Africa, we found the following 
disease-causing mutations: parkin (exonic duplications and deletions in five probands; 40bp 
homozygous deletion in one proband); PINK1 (homozygous Y258X in one proband); LRRK2 
(G2019S in five probands and R1441C in one proband) and SNCA (whole-gene triplication in 
one proband). These findings have important implications for these individuals and their family 
members. Identification of pre-symptomatic mutation carriers in these families provides a unique 
opportunity for recruitment of these individuals for neuroprotective clinical trials and 
longitudinal studies in order to identify biomarkers of neurodegeneration. 
 
These mutations were mainly found in Caucasian individuals as indicated in Figure 9.1. The 
parkin gene is predominantly involved in early-onset forms of PD and the higher prevalence of 
parkin mutations found in the present study might be attributed to the fact that the study group 
consisted mostly of individuals with early-onset PD. Higher mutation frequencies in the known 
PD genes have been reported for other populations and we concluded that these genes are not a 
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common cause of the disease in the South African population. Due to this finding, a 
bioinformatic approach was employed in order to identify novel PD candidate genes for mutation 
screening. The MAPT and SNCAIP genes were selected by this approach and a number of novel 
sequence variants of unknown pathogenic significance were found in these genes. The known 
and putative mutations identified in the present study are shown in Table 9.1.  
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Figure 9.1 Number of individuals from the different South African sub-population groups in 
which pathogenic mutations were found.  
 
 
Table 9.1 Known and putative mutations identified in the present study 
Gene Variant a 
Number of 
patients/ 
Ethnicity b 
AAO 
(yrs) 
Family 
history 
Frequency in 
control 
chromosomes 
Previously reported/ 
reference 
Autosomal recessive genes 
Parkin 
Duplication exon 2 + 
deletion exon 9 
1/ Black  
(37.12) 45 + ND 
(Madegowda et al. 2005; 
Simon-Sanchez et al. 
2008)  
Duplication exon 2 1/ Afrikaner  (55.54) 56 - ND 
(Simon-Sanchez et al. 
2008) 
Duplication exons 2+3 1/ Mixed ancestry (68.22) 50 - ND (Periquet et al. 2003) 
Deletion exons 3+4 
(homozygous) 
1/ Mixed 
ancestry (53.44) 27 - ND (Hattori et al. 1998)) 
Deletion exon 4 
(homozygous) 
1/ Afrikaner  
(56.45) 27 + ND (Kitada et al. 1998) 
40bp deletion in exon 3 
(T113fsX163) 
(homozygous) 
1/ Caucasian 
(77.60) 25 + ND (Farrer et al. 2001) 
H200Q 1/ Caucasian (65.79) 55 + 0/106 novel 
D280N 1/ Indian (68.10) 37 + 0/118 (Lucking et al. 2000; Oliveira et al. 2003) 
E310D 1/ Afrikaner  (51.70) 42 - 0/110 novel 
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R402C 1/ Afrikaner  (42.06) 37 - 0/100 (Kay et al. 2007) 
PINK1 
Y258X 
(homozygous) 
1/ Indian  
(68.10) 37 + 0/130 (Tan et al. 2006)  
P305A 1/ Black  (42.03) 30 + 
2/108  
(1.9%) novel 
E476K 1/ Mixed ancestry (63.69) 48 - 
2/144 
(1.4%) (Valente et al. 2004) 
DJ-1 g.-6_+10del 1/ Mixed ancestry (50.31) 38 - 
2/148 
(0.7%) novel 
Autosomal dominant genes 
LRRK2 
R1441C 1/ Mixed ancestry (85.57) 62 - ND (Mata et al. 2005) 
G2019S 
1/ Mixed 
ancestry (60.47) 47 + 
0/158 
(Kachergus et al. 2005; 
Lesage et al. 2009)   
1/ Caucasian 
(Russian-
Ashkenazi 
Jewish) (68.06) 
42 + 
1/ Caucasian 
(Polish Jewish) 
(81.64) 
70 - 
1/ Caucasian 
(Jewish) (82.47) 63 - 
G2019S 
(homozygous) 
1/ Caucasian 
(Russian) (84.25) 58 + 
E899D 1/ Black  (43.59) 51 + ND novel 
R924H 1/ Afrikaner  (38.36) 44 - ND novel 
I997N 1/ Caucasian  (67.66) 65 - ND novel 
S1228T 1/ Caucasian (67.31) 50 + ND (Berg et al. 2005) 
SNCA Triplication of whole gene 
1/ Caucasian 
(French-Italian) 
(42.35) 
46 + ND (Singleton et al. 2003; Farrer et al. 2004)) 
Bioinformatically selected genes 
MAPT 
A91V 
1/ mixed 
ancestry 
(51.30) 
32 - 0/124 novel 
V635I 1/ Black  (60.43) 60 - 
1/140 
(0.7%) novel 
SNCAIP 
T383N 1/ Black  (52.23) 50 + 0/124 novel 
R606Q 1/ Caucasian (67.92) 70 - 0/124 novel 
E709Q 1/ Caucasian (83.15) 64 - 
2/124 
(1.6%)  (Marx et al. 2003) 
N906H 1/ Caucasian (82.92) 64 - 0/124 novel 
 
a all variants are heterozygous unless stated otherwise.  
b patient sample numbers are shown in brackets. 
AAO: age at onset; ND: not determined. 
Mutations with known pathogenic significance are shown in bold and shaded boxes indicate novel 
sequence variants. 
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9.1 Summary of main research findings 
 
9.1.1 HRM screening of the parkin gene 
 
More PD-causing mutations have been found in the parkin gene than in any other gene 
(Parkinson’s disease Mutation Database, http://grenada.lumc.nl/LOVD2/TPI/home.php). For this 
reason mutation screening of all 12 exons of parkin was conducted in South African PD patients. 
The HRM technique was used and we showed that this method was effective in detecting 
sequence variants and that it was less time- and labor-intensive than the single strand 
conformation polymorphism (SSCP) technique. In our study, four missense sequence variants 
were identified (H200Q, D280N, E310D and R402C) but currently it is not known whether these 
are rare non-pathogenic polymorphisms. Two genomic rearrangement mutations (a homozygous 
deletion of exon 4 and a homozygous deletion of exons 3 and 4) were found. In addition, parkin 
was found to be highly polymorphic in the South African population. Our study revealed that the 
S167N, M192L and R334C variants, which had previously been reported to be mutations, were 
in fact polymorphisms due to their high prevalence in control chromosomes.  
 
The low frequency of parkin mutations found were unexpected given that our patients had 
predominantly early-onset PD. Parkin mutations were also not found in one patient with juvenile 
onset PD, with an AAO of 17 years. From our investigation it became clear that point mutations 
or homozygous exon deletions in parkin are not a major cause of PD in the South African 
population.  
 
 9.1.2 Analysis of the LRRK2 gene 
 
The initial part of this study on the LRRK2 gene focused on the G2019S mutation since this is 
the most commonly occurring mutation worldwide for PD (Wider et al. 2010). The HRM 
method was used to screen 205 patients and proved efficient in detecting the mutation. The 
frequency of G2019S was found to be low in this population compared to findings from other 
countries. It was detected at a frequency of 2.8% in patients with familial PD and 1.5% in 
apparently sporadic patients, and was absent in Afrikaner and Black patients. These low 
frequencies may indicate that genetic screening for this mutation is possibly less important in the 
South African population. Two of the G2019S-positive patients have late AAO PD with no 
apparent family history which concurs with other studies, and indicates that the familial and 
idiopathic late-onset forms of PD may share a common genetic basis.  
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The G2019S mutation has previously been shown to be present on only three haplotypes, 
referred to as haplotypes 1, 2 and 3 (Lesage et al. 2010). Haplotype studies revealed that the five 
South African G2019S-positive patients (four are Caucasian and one is of mixed ancestry)  have 
the same disease-associated haplotype (haplotype 1) which has been found in a number of 
families worldwide of diverse origins including Ashkenazi Jews, North African Arabs, 
Caucasian Europeans and North Americans (Lesage et al. 2010). The one individual who had a 
homozygous G2019S was found to be homozygous for haplotype-1. 
 
The second part of this study on LRRK2 involved direct sequencing of nine exons in 195 
patients, which had been selected according to AAO >40 years and autosomal dominant 
inheritance patterns. Using this approach, another one of the known pathogenic mutations, 
R1441C, was identified in only one patient. In addition, a previously identified putative 
pathogenic mutation, S1228T (Berg et al. 2005; Gandhi et al. 2009), was found in a patient. 
PolyPhen analysis however predicts this variant to be benign. Also, three novel missense 
sequence variants were found (E899D, R924H, I997N) which occur in evolutionary conserved 
regions of the gene. PolyPhen analysis predicts the E899D variant to be benign and the R924H 
variant to be possibly damaging. Both these variants occur in between the ANK (ankyrin) and 
LRR (leucine rich repeat) domains. The I997N variant, located in the LRR domain, is predicted 
by PolyPhen analysis to be probably damaging. A number of synonymous and intronic variants 
were also identified. Future work will be to assess the prevalence of the missense variants in 
ethnic matched control individuals and to determine their significance by means of functional 
studies.   
 
9.1.3 HRM screening of the PINK1 gene 
 
After parkin, mutations in PINK1 have been shown to be the second most common cause of PD 
(Klein & Lohmann-Hedrich 2007). For this reason all 8 exons of the PINK1 gene were screened 
for pathogenic mutations. Only one mutation, homozygous Y258X, was found in three affected 
members of an Indian family. This mutation causes a significant truncation of the protein, which 
results in loss of the functional serine/threonine kinase domain. 
 
Two missense variants (P305A and E476K) were also identified in PINK1 as well as 13 
polymorphisms. The P305A variant was present in a Black Xhosa individual who had typical 
clinical features of PD, which is in contrast to the atypical features that have been reported for 
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Black PD patients. Upon further investigation of the frequency of the P305A and E476K variants 
in ethnic matched control chromosomes, their location in evolutionary conserved regions and 
PolyPhen analysis, the two variants were found to be most likely non-pathogenic 
polymorphisms.  
 
PINK1 was found to be polymorphic in the South African population, and the IVS1-7A>G 
variant was found at a frequency of 30%. Our preliminary findings suggest that IVS1-7A>G 
might be associated with a decreased AAO in our study participants (P < 0.001; t-test). This 
variant has been shown to decrease the AAO in patients exposed to various environmental risk 
factors (Godeiro, Jr. et al. 2010); however, their finding could not be verified in the present study 
due to the lack of comprehensive data on environmental exposures for all our study participants.  
 
The very low frequency of mutations detected in the present study correlates with recent studies 
in which no mutations were detected (Bras et al. 2008; Godeiro-Junior et al. 2009; Zhang et al. 
2010) or only a few heterozygous variants of unknown pathogenic significance were found 
(Mellick et al. 2009; Biswas et al. 2010). Earlier studies however reported higher frequencies 
which might indicate that the contribution of this gene varies according to ethnicity or that the 
frequency of mutations is not as common as was previously thought.   
 
9.1.4 HRM screening of the SNCA gene  
 
SNCA has been found to be a relatively rare cause of PD worldwide (Wider et al. 2010). To date, 
only three missense mutations (A30P, E46K and A53T) have been identified. As these mutations 
are found in exons 2 and 3, these two exons were subjected to mutation screening in the present 
study. No pathogenic missense mutations or novel sequence variants were identified. 
 
9.1.5 Analysis of exon dosage/genomic rearrangements 
 
Exon dosage/genomic rearrangements are a common type of mutation found in PD patients 
(Hedrich et al. 2001; Hedrich et al. 2002). This type of mutation can not be detected by 
traditional mutation screening methods such as DNA sequencing. The MLPA method was used 
in the present study and was found to be effective in detecting a variety of genomic 
rearrangements as well as a specific point mutation (Y258X in PINK1). These findings revealed 
the importance of including exon dosage studies as part of a PD mutation screening strategy.  
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The parkin gene presented with the highest proportion of genomic rearrangements compared to 
the other known PD genes (Table 9.1). As our study group was mostly early- onset PD patients, 
it was proposed that the higher frequency of parkin mutations detected was due to the fact that 
this gene is predominantly involved in early-onset forms of the disease. The frequency of parkin 
mutations (6.8%) detected in the present study was however much lower than that reported in 
many previous studies in which up to 50% of patients were found to have exonic rearrangements 
(Hattori et al. 1998; Hedrich et al. 2004). Notably, no parkin exonic rearrangements were found 
in the patient with an AAO of 17 years. 
 
Our study reported a family with a SNCA triplication mutation, which is the 4th family worldwide 
to have this specific mutation. SNCA triplication mutations are thought to lead to a more severe 
form of early-onset PD with autonomic dysfunction and subsequent dementia (Singleton et al. 
2003; Farrer et al. 2004). Our study identified mutation-positive presymptomatic members of the 
family who can now be offered the option of genetic testing with appropriate genetic counseling. 
 
Another important finding from this study was that a common polymorphism in the South 
African population (M192L in parkin; frequency of 6.7% in controls) disrupts the ligation of the 
probes in kit P051 resulting in false positives (deletions) in exon 5. This highlights the 
importance of verifying all MLPA positive results with an independent method.  
 
No genomic rearrangements were found in four of the major PD genes (LRRK2, PINK1, DJ-1, 
and ATP13A2) or in the UCHL1, LPA, TNFRSF9, CAV2, CAV1, GCH1 genes in our study 
participants. 
 
 9.1.6 HRM screening of the MAPT and SNCAIP genes  
 
Since we have shown that the known PD genes are not a common cause of the disease in the 
South African population we speculated that novel genes might be involved. A bioinformatics 
approach was used to select novel PD candidate genes for further study. The CAESAR 
bioinformatic program (Gaulton et al. 2007) was used and it produced a ranked list of hundreds 
of genes containing known PD-causing genes as well as novel candidates. The MAPT and 
SNCAIP genes, which encode tau and synphilin-1, respectively, were selected from the list of ten 
highest scoring genes for mutation screening based on current literature showing potential 
involvement in PD pathogenesis; GWAS have recently revealed MAPT to be a risk factor for 
idiopathic PD (Simon-Sanchez et al. 2009; Edwards et al. 2010) and synphilin-1 has been shown 
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to interact with α-synuclein, parkin and LRRK2 (Engelender et al. 1999; Chung et al. 2001). 
Mutation screening identified novel sequence variants in both genes that may have potential 
functional implications. Further functional studies are needed to determine the possible 
pathogenic significance of these sequence variants. 
 
In the present study, the ATP13A2 gene was not included in our mutation screening experiments 
since the phenotype of ATP13A2-linked individuals is juvenile-onset atypical parkinsonism with 
pyramidal tract dysfunction, supranuclear gaze paresis, dementia, and cognitive dysfunction (Di 
Fonzo et al. 2007) and our study participants did not exhibit these features. 
 
9.1.7 Functional study of the DJ-1 5’UTR variant 
 
For all novel sequence variants identified, functional studies are needed to assess their functional 
significance. For variants found in the 5’UTR regions of genes, luciferase reporter assays can be 
used to determine if they have an affect on the transcription or translation efficiency. In the 
present study, SSCP analysis of the DJ-1 gene in 30 study participants had revealed a novel 16bp 
deletion variant (g.-6_+10del) in the promoter region and the functional significance of this 
variant was investigated by means of a Dual-luciferase reporter assay. The variant was found to 
span the transcription start site and was situated 93bp downstream of a Sp1 transcription 
regulatory sequence which is essential for DJ-1 promoter activity (Taira et al. 2001). It was 
hypothesized that the variant might influence the level of DJ-1 expression, the transcript stability 
or the translation efficiency. The variant was found to reduce luciferase activity in both HEK293 
and neuroblastoma M17 cells, with the M17 cells exhibiting a higher reduction in activity. 
Induced oxidative stress conditions led to a dose-dependent moderate up-regulation in the 
promoter activity with the variant retaining its lower activity compared to the wild-type DJ-1. It 
was therefore proposed that the 16bp sequence might be important in transcriptional regulation 
of the DJ-1 gene.  
 
In addition, bioinformatic analysis found putative binding sites for three transcription factors 
(AhR, ARNT and HIF-1) within the 16bp deletion sequence and we suggested that the binding 
of these factors might be influenced by the variant. These findings are important since AhR and 
ARNT control a variety of developmental and physiological events including metabolism of 
toxins and responses to hypoxia (Wilson & Safe 1998; Pocar et al. 2005). AhR and ARNT are 
known to dimerize to form an active transcription factor complex that binds to Xenobiotic 
Response Elements (XRE) in promoter regions and alters expression of genes involved in 
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metabolism of endogenous substances, environmental chemicals and various drugs, such as the 
genes belonging to the Cytochrome P450 family (Rivera et al. 2007). Further studies are needed 
to verify that DJ-1’s expression is regulated by the AhR, ARNT and HIF-1 transcription factors. 
Furthermore, the possible importance of the 16bp sequence in higher order mammals, and 
therefore an evolutionary retained functionality, was suggested due to our finding that the 
deletion sequence is present in a highly conserved region between man and other primates.  
 
9.2 Limitations of the study 
A limitation of the experimental strategy used in the present study is not using direct sequencing 
to screen for pathogenic mutations in all study participants. However, due to cost-constraints in a 
low-resource setting like ours, sequencing was not feasible and therefore HRM was used instead. 
 
9.2.1 Limitations of HRM 
 
HRM has limitations which could results in both false positive and false negatives results. For 
this technique, the template DNA has to be of high purity and the PCR products should not 
contain contaminants such as primer dimers. Poor quality template DNA can result in spurious 
melt curves which are difficult to analyze. Primer dimers produce an additional melt curve which 
interferes with curve normalization and analysis of results. The efficacy of HRM also depends on 
the instruments and the type of intercalating dye used (Wittwer 2009). Different dyes are 
available (LCGreen® Plus, SYTO®9, EvaGreen® and SYBR Green I) and the type of analysis 
conducted determines which one should be used. PCR products should typically not exceed 250 
base pairs and should not contain more than one melting domain as this will lead to poor quality 
melt curves. In our experience, HRM has been found to be less effective in detecting small 
insertions and deletions, and homozygous substitutions. Furthermore, samples with similar melt 
curves do not necessarily indicate the presence of the same variant and the results always need to 
be verified by sequencing.  
 
9.2.2 Limitations of MLPA 
 
A limitation of the MLPA technique is that it is very sensitive to contaminants such as high salt 
concentrations, which results in aberrant peak profiles. The initial template DNA has to be at the 
same concentration for all samples, must be of good quality and the same DNA isolation method 
needs to be used across all samples screened. The MLPA method can also detect point mutations 
which occur at the ligation site of two adjacent probes. Therefore, polymorphisms that occur at 
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this position, e.g. M192L in parkin, as shown in the present study (Chapter 3) will produce false 
positive results. Due to this problem all MLPA positive results need to be verified by sequencing 
and an alternative exon dosage detection method, thereby introducing additional reagent and 
labor costs.  
 
9.2.3 Limitations of the study group and controls 
 
A limitation of the study group was the lack of information regarding family history of the 
disorder for all the study participants. The inheritance pattern of PD was therefore not known for 
a large proportion of the study group which made it difficult to subdivide the patients into 
autosomal recessive and dominant categories for mutation screening purposes. Another 
limitation was the fact that the study group consisted predominantly of families with one or two 
affected members. For larger families with more affected individuals it would have been possible 
to determine whether sequence variants cosegregated with the disease in a family, in order to 
establish the pathogenicity of novel variants. Also, it would have been possible to conduct 
haplotype analysis studies. Furthermore, a major short-coming was the limited number of Black 
PD patients. Despite intensive efforts, no additional patients could be recruited due to a variety 
of reasons including the lack of contact details, death of patients and lack of willingness of 
family members to participate in the research. Ascertainment problems are also a factor as Black 
PD patients who live in rural areas often do not present to clinicians or neurologists. A limitation 
of the control individuals was that they had not been clinically assessed for signs of PD.  
 
9.3 Future work 
 
The present study identified a number of novel sequence variants in our study participants (Table 
9.1) which should be investigated using functional studies in order to determine their possible 
involvement in PD pathogenesis. For these studies, mammalian expression constructs encoding 
wild-type and specific sequence variants for the parkin, PINK1, LRRK2, MAPT, and SNCAIP 
genes could be generated for the following functional experiments.  
 
parkin 
In vitro ubiquitylation assays and immunobloting are techniques which could be used in order to 
assess whether the parkin sequence variants negatively affect the ubiquitylation function of the 
protein. In addition, the possibility of the sequence variants to cause spontaneous aggregation of 
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the protein, as has been shown for some parkin mutations (Gu et al. 2003) could be assessed by 
means of immunohistochemistry and pulse-chase experiments.   
 
LRRK2 
LRRK2 mutations have been shown to result in reduced GTPase activity as well as an increase in 
kinase activity and autophosphorylation (Aasly et al. 2010). In order to investigate the enzymatic 
properties of the novel sequence variants identified in LRRK2, in vitro kinase and GTP-binding 
assays could be conducted. LRRK2 mutations have also been associated with greater rate of 
apoptosis under oxidative stress conditions (Tan et al. 2007). Whether the novel variants 
identified in the study leads to the same consequences could be determined by performing an 
apoptosis assay and confocal microscopy. 
 
PINK1 
The fluorescence-activated cell sorting mitochondrial membrane potential assay could be used to 
determine whether the PINK1 sequence variants leads to increased susceptibility of cells to 
cellular stress as has been shown for other mutations in PINK1 (Abou-Sleiman et al. 2006). 
Also, the effect of the P305A variant on mitochondrial morphology could be assessed by 
fluorescence microscopy. 
 
MAPT 
Immunofluorescence confocal microscopy could be employed in order to determine whether the 
MAPT variants result in abnormalities such as failure of microtubules to assemble, reduced 
length of microtubules, and whether the microtubules occur as fragments in the cytoplasm. 
Western blotting analysis could be performed to assess the biochemical profiles of the mutant 
proteins (Sahara et al. 2000). Quantitative PCR could be used in order to assess the ratio of tau 
containing either four or three repeats of the microtubule binding domains as this has been 
shown by other studies to be increased in PD patients (Tobin et al. 2008).  
 
SNCAIP 
In order to determine the effect of SNCAIP variants, cells could be treated with specific toxins 
such as proteasome inhibitors, in order to assess the formation of inclusion bodies. It has been 
suggested that mutations in SNCAIP that reduce the ability of cells to form intracellular 
inclusions may sensitize neurons to cellular stress (Marx et al. 2003). In addition, the ability of a 
mutant synphilin-1 protein to interact with α-synuclein, parkin and LRRK2 could be assessed by 
means of a co-immunoprecipitation assay.  
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9.3.1 Bioinformatic analysis to predict functionality of novel variants 
 
Bioinformatic analysis in collaboration with researchers at the South African National 
Bioinformatics Institute (SANBI) could be conducted to investigate whether the sequence 
variants found in the present study result in significant protein changes (such as alterations in 
structure, charge, absence/presence of disulphide bridges and position of hydrogen-bonds in side 
chains), which could negatively affect the molecular pathways in which the proteins are 
involved.  
 
SIFT (Sorting Intolerant From Tolerant, http://sift.jcvi.org/), PolyPhen (Polymorphism 
Phenotyping, http://genetics.bwh.harvard.edu/pph/), SNPs3D (Single Nucleotide Polymorphisms 
3D, http://www.snps3d.org/) and SNPeffect (Single Nucleotide Polymorphism effect, 
http://snpeffect.vib.be/) are some of the computational tools that can be used for this analysis. 
 
9.3.2 Mutation screening of PD candidate genes 
 
The study participants that had not been screened for mutations in the parkin, PINK1, LRRK2 
and SNCA genes in the present study should be investigated (this work is currently ongoing in 
our laboratory). Furthermore, other PD candidate genes identified by the CAESAR program, 
namely BCL2L1 (bcl-2-like protein 1), SNCB (β-synuclein) and TH (tyrosine hydroxylase), 
should also be screened for mutations in the South African PD population. Other suitable 
candidates are the genes involved in spinocerebellar ataxia types 2, 3, 6 and 17 that have been 
found to be implicated in PD patients (Klein et al. 2009). Another exciting prospect would be to 
investigate genes involved in maintenance and function of mitochondria, and this would include 
both mitochondrial-encoded and nuclear-encoded genes.   
 
9.4 PD research in sub-Saharan Africa  
 
There is a paucity of data on PD in African populations. A literature search conducted by 
Okubadejo and colleagues using search terms ‘Parkinson’s disease and Africa’ and related terms 
revealed that there were publications from 13 countries over the period 1944 to 2004 (Okubadejo 
et al. 2006). The bulk of this literature was based on clinical descriptions of patients and genetic 
studies had only been conducted on populations from the Northern African countries, Tunisia 
and Algeria. The lack of genetic studies in sub-Saharan African countries was thought to be due 
to the scarcity of resources including finances, manpower and equipment. 
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A literature search conducted a few years later in 2007, this time focusing specifically on genetic 
studies using search terms ‘Parkinson’s disease and genetics and Africa’ and related terms found 
a very limited number (12) of publications (Okubadejo et al. 2008). Eleven of the 12 studies 
were on Northern African populations (Morocco, Algeria and Tunisia) and only one study was 
on a sub-Saharan African country. This study examined the autosomal dominant and recessive 
inheritance patterns of seven Zambian families with familial PD (Atadzhanov et al. 2005). 
 
An interesting finding from the North African populations is that the LRRK2 G2019S mutation 
appears to be a common cause of PD (41%) in these populations compared to Europe and North 
America (Lesage et al. 2006). The only molecular genetic studies conducted on a sub-Saharan 
population are the work reported in this dissertation. Further genetic studies into the diverse 
populations of sub-Saharan Africa are warranted as they may reveal insights into novel 
mechanisms, causes and patho-physiology of PD. 
 
9.5 Next-generation sequencing technologies 
 
Exome sequencing is a new technology that is currently being employed to identify disease-
causing genes and rare variants. This approach was first used to successfully identify the genetic 
cause of Miller syndrome, a rare Mendelian disorder (Ng et al. 2010). It involves sequencing the 
complete exome (all protein-coding sequences in the genome) as well as splice donor and 
acceptor sites in disease affected individuals. Bioinformatics approaches are used to exclude 
known and likely benign variants by screening dbSNP or HapMap databases and mutation 
databases. Also the possible effect of the variants on the normal function of the protein is 
investigated (Ng et al. 2010; Kobelka 2010). This results in a list of possible pathogenic variants 
based on gene function, evolutionary conservation and likely mutational impact. Exome 
sequencing requires only 5% as much sequencing as whole-genome sequencing and is therefore 
more cost effective (Ng et al. 2010). The probability of finding the disease causing gene and 
variant is higher when sequencing the exome than when sequencing the genome. A limitation of 
this method is that it is not able to detect cytogenetic abnormalities, genomic copy number 
variants, exon rearrangements, non-coding sequence variants, and inherited epigenetic 
modifications (Kobelka 2010).    
 
Whole-genome sequencing is currently still too expensive to be used as a routine mutation 
screening technique in most laboratories. However, next-generation sequencing technologies 
which involves various platforms including that of Illumina Genome Analyzer and Applied 
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Biosystem’s SOLiD has revolutionized the field. It is anticipated that this will eventually lead to 
a dramatic reduction of costs to only ~$1,000 per genome (Service 2006). Next-generation 
sequencing technologies comprise different approaches for template preparation, sequencing and 
imaging, genome alignment and assembly methods.  
 
According to a recent survey conducted in 2010, the Illumina platform is the most popular 
amongst laboratories worldwide (http://www.genomeweb.com/sequencing/survey-illumina-
solid-and-454-gain-ground-research-labs-most-users-mull-addition). It produces 18 gigabases of 
sequence data per run. The average read length is about 72 base pairs for single reads and 80 
base pairs for paired reads. The SOLiD platform produces 30 gigabases of sequence data per run. 
The average read length is 50 base pairs for single reads and 25, 35, or 50 base pairs for paired 
reads (Hong & Oh 2010). Problems that users of the Illumina and SOLiD platforms have 
reported include sample and complex library preparations, software and mechanical 
complications. According to the survey, most of the users of next-generation sequencing 
technologies are universities or non-profit research institutes based in North America and 
Europe, and the top three applications include mRNA sequencing, whole-genome de novo 
sequencing and small RNA sequencing.   
  
These exciting new technologies could be used to make important discoveries about genetic 
causes of PD in South African populations. Given that Black African populations have been 
under-studied, whole- genome or exome sequencing data from these populations would be of 
interest for comparison with that of Caucasian and Asian genomes. Ultimately, genome 
sequencing of South African PD patients would facilitate the ‘holy grail’ of personalized 
medicine (Hong & Oh 2010) but would also be beneficial for the generation of new hypotheses 
and development of novel therapeutics for PD.  
 
9.6 Concluding remarks  
 
Investigating the genetic basis of predominantly early-onset PD in the South African population 
has revealed that the parkin, PINK1, LRRK2 and SNCA genes are not major causes of PD in this 
particular population. Pathogenic mutations were found in only 14 patients and of these, the 
majority (six) are Caucasian. It is important that the PD-causing mutations in diverse populations 
worldwide are identified, and it is speculated that these mutations may occur in as yet 
unidentified PD genes (Okubadejo et al. 2008; Bardien et al. 2009). In this regard, bioinformatic 
in-silico approaches are an important tool for the identification of disease-causing genes, 
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especially in complex diseases such as PD, as they can be used to systematically and 
methodically search through vast amounts of information and are cost effective. Also 
bioinformatic approaches are not prone to many of the inherent biases invariably introduced by 
researchers.  
 
There is currently very limited data available on the genetic basis of PD in sub-Saharan Africa. 
The usefulness for these populations of the therapeutic modalities or predictive genetic tests, 
developed by the first world countries, will only become apparent once we know the genetic 
basis of PD in Africa’s populations (Okubadejo et al. 2008). This knowledge may also have an 
impact on our understanding of disease pathogenesis and may provide important insights into the 
interactions between genetic and lifestyle factors. 
 
From the functions of the known PD-causing genes it has become clear that there is considerable 
cross-talk between the different pathways proposed to be involved in the pathogenesis. These 
processes include abnormal handling of misfolded proteins by the ubiquitin proteasome and 
autophagy-lysosomal systems (parkin, ATP13A2, SNCA), mitochondrial dysfunction (PINK1, 
DJ-1, parkin), and aberrant kinase signaling (PINK1, LRRK2). It has also recently been shown 
that some of the apparently unrelated neurodegenerative disorders may share overlapping genetic 
causes. Recent GWAS studies have found that in the European population, multiple 
polymorphisms within and near MAPT are associated with idiopathic late onset PD (Simon-
Sanchez et al. 2009). MAPT has also been implicated in Alzheimer’s disease in which β-amyloid 
aggregates to form plaques and the neurotoxicity is thought to be mediated, in part by tau 
(encoded by MAPT) which can also aggregate to form neurofibrillary tangles (Shulman & De 
Jager 2009). In addition, patients with pathogenic triplet expansions in the genes involved in 
spinocerebellar ataxia types 2, 3, 6 and 17 have been found in patients that present with clinical 
features of PD (Klein et al. 2009). Taken together, these findings imply that understanding the 
biological pathways or mechanisms in PD will shed light on the disease mechanisms underlying 
other neurodegenerative disorders. 
 
Recently, mitochondrial dysfunction has been conclusively implicated as a major role player in 
PD (Zheng et al. 2010). Zheng and colleagues (2010) performed gene expression profiling on 
322 brain and 88 blood samples, and found that the expression of genes involved in 
mitochondrial electron transport, mitochondrial biogenesis, glucose utilization, and glucose 
sensing are reduced in PD patients. Specifically, genes that are expressed in response to the 
transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor-gamma 
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coactivator -1, alpha) were under-expressed. PGC-1α over-expression resulted in increased 
transcription of subunits of the mitochondrial respiratory chain and importantly, could block 
dopaminergic neuron loss in cell culture models of PD. PGC-1α is necessary for induction of 
numerous ROS-detoxifying enzymes thereby serving as a ‘master regulator’ of ROS metabolism 
in the cell (St-Pierre et al. 2006). The findings by Zheng and colleagues are a major 
breakthrough in PD research as it reveals that PGC-1α-activating drugs may be potential 
therapeutic targets for early intervention. It is still unclear though whether the PGC-1α- pathway 
is specifically suppressed in PD or if the suppression is a consequence of more widespread 
mitochondrial damage.  
 
An improved understanding of the complex mechanisms and role players involved in 
neurodegeneration in PD, such as PGC-1α  and other agents that block mitochondrial 
dysfunction including co-enzyme Q and creatine (Thomas & Beal 2010), brings us one step 
closer to more effective therapy and possibly a cure, which will offer a beacon of hope for the 
thousands of patients suffering from this debilitating disorder. 
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Table 1 List of all SNPs and pathogenic variants found in 250 South African patients screened 
 Nr. 
Lab 
Nr. 
AAO  PARK2 (parkin)   PARK7 (DJ‐1)  PARK8 (LRRK2) 
PARK1/4 
(SNCA) 
PARK 6 (PINK1)  SNCAIP  MAPT 
1  37.12  45  ex2 het DUP & ex9 het DEL    
2  37.45  38  het V380L, het D394N       het N521T  het P605P 
3  38.37  40  hom 5'UTR ‐227 A>G       
4  38.36  44  het 5'UTR ‐258 T>G     het R924H  
5  38.23  40       
6  42.19  38  hom 5'UTR ‐258 T>G    
7  42.26  39       het N521T 
8  42.03  30  het C238C     het P305A, het A340T, het N521T  
9  42.04  64  het V380L     het N521T 
10  42.05  41    
11  42.06  37  het R402C,het 5'UTR ‐258 T>G, het V380L       het IVS4+9A>G, het A562A,  
              het N590N, hom IVS11+40C>T 
12  42.30  39    
13  42.35  40  het 5'UTR ‐258 T>G, het V380L       Triplication  ND ND 
14  42.56  43  het 5'UTR ‐258 T>G, het R402R    
15  43.59  51     het E899D  
16  56.45  27  ex4 hom DEL       het IVS4+9A>G 
17  50.31  38  het 5'UTR ‐258 T>G; het Q34R' het IVS2 +10C>T;  
g.‐6_+10 het 
DEL     
         het IVS2 +25T>C, het S167N       
18  51.30  32  het V380L       het A91V  
19  50.86  41  het 5'UTR ‐258 T>G, het V380L    
20  50.03  17       hom IVS1‐7A>G 
21  51.70  42  het E310D, het 5'UTR ‐227 A>G     hom IVS1‐7A>G 
22  52.23  50     het T383N,  
            het G390G  
23  53.44  27  ex3 & 4 hom DEL, het 5'UTR ‐227 A>G;       hom IVS1‐7A>G 
          het P34P; het IVS2 +25T>C         
24  54.73  69  het IVS7 ‐35 G>A, het IVS7 ‐68C>G    
25  54.74  63     het L638L 
26  55.41  77  het M192L, het R402R    
27  55.45  52  het IVS8 ‐21_‐17del, het R334C     het 3'UTR+37A>T 
28  55.50  55    
29  54.89  26    
30  55.52  42  het L261L    
het IVS6‐23 
T>C 
31  55.54  56  ex2 het DUP   ND hom IVS1‐7A>G, hom 3'UTR+37A>T 
32  55.65  40  het IVS2 +25T>C, hom IVS7 ‐35 G>A  ND 
het IVS26‐
89T>A;  
           het E1224E 
33  55.77  47  ND 
het IVS26‐
89T>A 
34  55.81  72  ND het P1542S 
35  59.91  29  ND het A562A, het N590N 
36  60.38  47  het 5'UTR ‐227 A>G; het S167N, het V380L  ND hom IVS1‐7A>G, het N521T, 
           hom 3'UTR+37A>T 
37  60.39  55  het P34P; het IVS2 +25T>C;   ND 
het IVS26‐
89T>A;  
         hom IVS3 ‐20 T>C, het V380L    
het IVS26‐
33T>C 
38  60.43  60  het IVS7 ‐35 G>A, het IVS8 +43A>G, het IVS8 +48C>T,  ND 
het IVS20‐
65A>T  het V635I  
          het D394N, het 3'UTR *103C>T         
39  60.45  71     ND 
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 Nr. 
Lab 
Nr. 
AAO  PARK2 (parkin)   PARK7 (DJ‐1)  PARK8 (LRRK2) 
PARK1/4 
(SNCA) 
PARK 6 (PINK1)  SNCAIP  MAPT 
40  60.47  47  ND het G2019S  
41  60.48  60  ND 
42  60.92  52  ND 
43  61.37  44  ND 
44  61.79  74  hom M192L, het C238C, het 3'UTR repeat  ND het S1721S 
          expansion: WT 6CAs, 6CGs; variant 5CAs, 8CGs      
45  61.80  50  het 3'UTR *16G>A  ND 
het IVS26‐
89T>A  het S406S 
46  61.81  55  het M192L   ND 
het IVS26‐
33T>C 
47  63.40  48  ND het IVS3+18C>T 
48  63.42  74  ND 
het IVS26‐
89T>A 
49  63.43  35  ND   het A340T 
50  63.52  71  ND 
51  63.68  60  het D394N  ND hom IVS1‐7A>G 
52  63.69  48  ND het E1224E  het E476K  
53  63.73  59  het P34P; het IVS2 +25T>C  ND 
54  64.85  38  hom IVS2 +25T>C  ND   
55  64.88  56  ND 
56  64.89  58  hom IVS3 ‐20 T>C, hom V380L  ND   
hom IVS4+9A>G,hom A562A, hom 
N590N 
57  65.25  59  ND 
58  65.26  50  het IVS2 +35G>A, , het D394N  ND 
59  65.65  69  ND 
60  65.68  50  het R334C  ND 
61  65.79  55  het H200Q, het D394N  ND 
62  67.31  50  ND het S1228T  
63  67.32  67  hom IVS8 +48C>T  ND 
64  67.34  63  ND 
65  67.52  57  ND 
66  67.61  70  ND 
67  67.63  65  ND hom IVS3+18C>T,hom IVS4+9A>G, 
           hom A562A, hom N590N 
68  67.64  49  het IVS8 +48C>T  ND 
69  67.65  61  ND 
70  67.66  65  het 3'UTR *94A>G  ND het I997N  
71  67.67  64  het V380L  ND het IVS11+40C>T 
72  67.68  68  ND 
73  67.69  52  ND het A340T 
74  67.70  58  ND 
75  67.71  71  ND 
hom IVS3+18C>T,hom A562A, hom 
N590N 
76  67.72  65  ND hom IVS1‐7A>G 
77  67.80  57  het IVS2 +35G>A; hom IVS3 ‐20 T>C  ND 
78  67.82  54  ND het P1542S 
79  67.92  70  ND het R606Q  
80  67.93  70  ND het 3'UTR+37A>T 
81  67.97  68  het L63L  ND hom L63L 
82  67.98  52  ND 
83  67.99  58  ND 
84  68.00  65  ND 
85  68.06  42  ND het G2019S 
86  68.07  50  ND het Q2089R   het L504L 
87  68.08  62     ND 
171 
 
 Nr. 
Lab 
Nr. 
AAO  PARK2 (parkin)   PARK7 (DJ‐1)  PARK8 (LRRK2) 
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88  68.10  37  het D280N  ND   hom Y258X  hom P605P 
89  68.16  47  ND 
het IVS6‐23 
T>C 
90  68.17  50  ND 
91  68.22  50  ex2 & 3 het DUP   ND het IVS1‐7A>G,het 3'UTR+37A>T 
92  68.27  55  ND 
93  68.37  60  ND 
94  69.33  74  ND het A340T 
95  69.24  55  ND 
96  69.54  51  ND hom IVS1‐7A>G 
97  70.01  68  ND het A340T, hom N521T 
98  70.03  55  ND 
99  70.05  45  ND het R1514Q 
100  70.32  40  ND   
101  70.77  74  ND 
102  76.92  76  ND ND ND 
103  72.68  41  het IVS2   +25T>C  ND het A340T 
104  73.65  75  ND 
105  77.60  25  c.337‐376 hom DEL  ND   
106  78.67  49  ND   
107  78.74  56  het G430D   ND 
het IVS20‐
65A>T 
108  78.76  27  PARK2 ex4 het DEL, het G430D, het IVS8  +48C>T  ND   
109  78.82  55  ND 
110  78.84  50  ND 
111  78.95  58  ND 
112  78.97  53  het IVS2 +35G>A  ND het L504L 
113  79.04  34  ND het IVS1‐7A>G,het 3'UTR+37A>T 
114  79.16     ND 
115  79.17  38  het M192L   ND   
116  79.29  40  ND   
117  79.35  48  ND 
118  79.91  46  ND 
119  79.99  39  het IVS8  +48C>T; het V380L  ND het IVS27+7C>T  hom IVS1‐7A>G  hom P605P 
120  80.59  33  het IVS2 +25T>C; IVS2  +62G>A  ND   ND 
121  81.03  48  PARK2 ex2‐6 het DUP + ex5 het DUP,  ND ND 
          het IVS8  +48C>T; het D394N      
122  81.04  54  ND ND 
123  81.05  62  het  S167N  ND ND 
124  81.06  42  het R334C, het S167N  ND ND 
125  81.23  55  ND ND 
126  81.27  49  PARK2 ex4 het DEL, het IVS8  +43A>G;   ND ND 
         het 3'UTR *16G>A       
127  81.28  51  ND ND 
128  81.58  38  ND ND 
129  81.60  49  het IVS8 +43A>G  ND 
het IVS26‐
29G>A  ND 
130  81.61  42  ND ND 
131  81.62  53  ND   ND het IVS1‐7A>G 
132  81.63  65  ND ND 
het IVS6‐23 
T>C 
133  81.64  70  het P437L  ND het G2019S   ND 
134  81.65  62  ND ND het A340T 
135  81.66  70  ND het R1514Q  ND 
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 Nr. 
Lab 
Nr. 
AAO  PARK2 (parkin)   PARK7 (DJ‐1)  PARK8 (LRRK2) 
PARK1/4 
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136  81.67  63  het IVS8 +48C>T  ND ND het A340T 
137  81.68  54  het IVS1 +42C>T; het IVS2 +20del(C);   ND 
het IVS26‐
33T>C  ND ND 
         het IVS2   +25T>C ; het M192L            
138  81.69  53  ND ND ND 
139  81.70  55  het M192L; het 3'UTR *16G>A  ND ND ND 
140  81.74  48  het D394N  ND ND het Q115L, het IVS1‐65C>G,het IVS1‐7A>G,  
             het IVS7‐8T>G, het 3'UTR+40A>T 
141  81.81  40  ND ND het IVS1‐7A>G, het IVS7‐8T>G, het 3'UTR+40A>T 
142  81.90  50  ND ND het L63L,het IVS1‐7A>G,  
             het IVS7‐8T>G, het 3'UTR+40A>T 
143  82.18  37  ND ND het IVS6+43C>T,het IVS1‐7A>G,   het IVS3+18C>T,het A562A, het N590N 
             het IVS7‐8T>G, het 3'UTR+40A>T    
144  82.32  59  ND ND ND 
145  82.33  70  ND ND ND hom IVS3+18C>T,hom IVS4+9A>G, 
               hom A562A, hom N590N 
146  82.34  75  ND ND ND 
147  82.35  62  ND ND ND 
148  82.36  55  ND ND ND 
149  82.38  68  het D394N  ND ND ND het A562A, het N590N 
150  82.39  50  ND ND het A340T, hom N521T,het IVS1‐7A>G,  
             het IVS7‐8T>G, het 3'UTR+40A>T 
151  82.44  56  ND ND ND 
152  82.45  80  het D394N  ND ND ND 
153  82.46  42  ND ND het IVS1‐7A>G, het IVS7‐8T>G, het 3'UTR+40A>T 
154  82.47  63  het A82E, het  S167N; het D394N  ND het G2019S   ND ND 
155  82.48  68  ND ND ND 
156  82.49  53  ND ND ND 
157  82.50  38  A397A  ND ND het L63L,het IVS1‐7A>G,   het A90A 
             het IVS7‐8T>G, het 3'UTR+40A>T    
158  82.53  65  ND ND ND 
159  82.85  77  het V380L  ND ND ND 
160  82.68  64  het IVS2  +25T>C; IVS2  +35T>C  ND ND ND hom IVS4+9A>G 
161  82.74  55  ND ND ND 
162  82.75  56  ND ND ND 
163  82.82  51  ND ND ND 
164  82.89  56  ND ND ND 
165  82.90  55  het IVS8  +48C>T  ND ND ND 
166  82.91  53  ND ND ND 
167  82.92  64  het A82E  ND ND ND het N906H  
168  82.93  60  ND het R1514Q  ND ND 
169  82.94  66  ND ND ND 
170  82.95  56  ND het S1721S  ND ND 
171  82.96  60  het IVS8  +48C>T  ND ND ND 
172  82.97  60  ND 
het 
IVS23+78C>T  ND ND 
173  82.99  46  het  S167N  ND ND het IVS6+43C>T,het IVS1‐7A>G,  
             het IVS7‐8T>G, het 3'UTR+40A>T 
174  83.00  62  hom IVS2 +25T>C  ND ND ND 
175  83.01  55  het 5'UTR ‐89C>T  ND ND ND 
176  83.02  72  ND ND ND 
177  83.03  66  ND ND ND 
178  83.04  65  ND ND ND 
179  83.05  75  ND ND ND 
180  83.06  52  ND ND ND 
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Nr. 
AAO  PARK2 (parkin)   PARK7 (DJ‐1)  PARK8 (LRRK2) 
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PARK 6 (PINK1)  SNCAIP  MAPT 
181  83.07  67  het IVS2 +25T>C; het P37P  ND ND ND 
182  83.08  68  ND ND ND 
183  83.09  75  ND ND ND 
184  83.10  72  ND ND ND 
185  83.11  34  ND ND het L63L,het IVS1‐7A>G,  
             het IVS7‐8T>G, het 3'UTR+40A>T 
186  83.12  60  ND ND ND 
187  83.13  51  ND ND ND 
188  83.14  65  ND ND ND 
189  83.15  64  ND ND ND het E709Q  
190  83.16  47  ND het R1514Q  ND hom IVS6+43C>T,het IVS1‐7A>G,  
                het IVS7‐8T>G, het 3'UTR+40A>T 
191  83.17  62  ND het P1542S  ND ND 
192  83.18  56  ND het P1542S  ND ND 
193  83.19  62  ND ND ND 
194  83.38  55  het IVS2 +25T>C  ND het P1542S  ND ND 
195  83.39  63  ND ND ND 
196  83.40  53  ND ND ND 
197  83.41  63  het V380L  ND ND ND 
198  83.42  68  ND ND ND 
199  83.43  73  ND ND ND 
200  83.44  52  ND ND ND het IVS3+18C>T 
201  83.45  52  ND ND ND 
202  83.46  56  ND ND ND 
203  83.47  57  ND ND ND 
204  83.48  76  ND ND ND 
205  83.49  58  ND ND ND ND ND 
206  84.25  58  het  S167N  ND hom G2019S   ND ND ND ND 
207  83.88  52  ND ND ND ND ND 
208  83.91  60  ND ND ND ND ND 
209  83.93  45  ND ND het N521T,het IVS1‐7A>G,   ND ND 
             het IVS7‐8T>G, het 3'UTR+40A>T      
210  84.02  75  het D394N  ND ND ND ND ND 
211  84.04  57  het D394N  ND ND ND ND ND 
212  84.14  56  ND ND ND ND ND 
213  84.15  73  ND ND ND ND ND 
214  84.18  59  ND ND ND ND ND 
215  84.21  60  ND ND ND ND ND 
216  84.30  34  ND ND het 5'UTR‐35C>T, het L63L,het IVS1‐7A>G,   ND ND 
             het IVS7‐8T>G, het 3'UTR+40A>T      
217  84.47  61  PARK2 ex3 & 4 het DEL  ND ND ND ND ND 
218  84.52  57  ND ND het IVS4+56G>T,het N521T,het IVS1‐7A>G,   ND ND 
             het IVS7‐8T>G, het 3'UTR+40A>T      
219  84.66  57  het IVS8 +43A>G; het S167N  ND ND ND ND ND 
220  84.67  55  ND ND ND ND ND 
221  84.68  48  het IVS2  +35G>A  ND ND het IVS1‐7A>G, het IVS7‐8T>G, het 3'UTR+40A>T  ND ND 
222  85.40  46  ND ND het IVS1‐7A>G, het IVS7‐8T>G, het 3'UTR+40A>T  ND ND 
223  85.56  58  ND 
het IVS26‐
29G>A  ND ND ND ND 
224  85.57  62  ND het R1441C   ND ND ND ND 
225  85.58  45  ND ND het IVS6+43C>T,het IVS1‐7A>G,   ND ND 
             het IVS7‐8T>G, het 3'UTR+40A>T      
226  86.48  35  het R334C  ND   ND het L63L, het IVS4+72G>C, 3'UTR+43G>A,  ND ND 
               het IVS1‐7A>G, het IVS7‐8T>G, het 3'UTR+40A>T      
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227  86.86  54  het S167N, het M192L  ND ND ND ND ND 
228  88.28  40  ND ND het A340T, het N521T, 3'UTR+43G>A,  ND ND 
             het IVS1‐7A>G, het IVS7‐8T>G, het 3'UTR+40A>T      
229  88.29  57  ND ND ND ND ND 
230  88.40  70  ND ND ND ND ND ND 
231  88.52  65  ND ND ND ND ND ND 
232  88.53  66  ND ND   ND ND ND ND 
233  88.74  37  ND ND   ND ND ND ND 
234  88.98  58  ND ND   ND ND ND ND 
235  88.99  23  ND ND   ND ND ND ND 
236  89.01  66  ND ND   ND ND ND ND 
237  89.02  56  ND ND   ND ND ND ND 
238  89.03  57  ND ND   ND ND ND ND 
239  90.03  57  ND ND   ND ND ND ND 
240  90.86  70  ND ND ND ND ND ND ND 
241  90.87  37  ND ND ND ND ND ND ND 
242  90.88  80  ND ND ND ND ND ND ND 
243  90.91  59  ND ND ND ND ND ND ND 
244  90.92  75  ND ND ND ND ND ND ND 
245  90.94  40  ND ND ND ND ND ND ND 
246  90.95  27  ND ND ND ND ND ND ND 
247  91.84  43  ND ND ND ND ND ND ND 
248  91.85  65  ND ND ND ND ND ND ND 
249  91.86  59  ND ND ND ND ND ND ND 
250  91.87  44  ND ND ND ND ND ND ND 
 
AAO: age at onset, DUP: duplication, DEL: deletion, het: heterozygous, hom: homozygous, ND: not determined 
Proven mutations are shown in red 
Possible mutations are shown in blue 
Polymorphisms are shown in black 
 
